var title_f41_49_42768="Neuroblastoma in marrow";
var content_f41_49_42768=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F73187&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F73187&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Neuroblastoma cells within the bone marrow",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 433px; height: 288px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Bone marrow aspirate from a patient with metastatic neuroblastoma shows a clump of cells forming a rosette. Note the indistinct borders between cells in this clump of tumor cells.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of David S Rosenthal, MD and William C Moloney, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f41_49_42768=[""].join("\n");
var outline_f41_49_42768=null;
var title_f41_49_42769="Retained surgical sponge of the liver on computed tomography";
var content_f41_49_42769=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F61325&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F61325&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Retained surgical sponge of the liver on computed tomography",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 339px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Unenhanced computed tomography of the abdomen at level of liver shows a mass containing mixed areas of high and low attenuation (arrow).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Manoel de Souza Rocha. Originally published in Manzella A, Filho PB, Albuquerque E, et al. Imaging of gossypibomas: Pictorial review. AJR Am J Roentgenol 2009; 193:S94.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f41_49_42769=[""].join("\n");
var outline_f41_49_42769=null;
var title_f41_49_42770="Breech3";
var content_f41_49_42770=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F59678&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F59678&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 561px\">",
"   <div class=\"ttl\">",
"    Delivery of the upper limbs",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 541px; height: 209px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A towel is wrapped around the fetus for better traction. When the scapulae appears under the symphysis, the operator reaches over the left shoulder, sweeps the arm across the chest (A), and delivers the arm (B).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Gabbe, SG, Niebyl, JR, Simpson, JL (Eds). Obstetrics: Normal and Problem Pregnancies, 4th ed, Churchill Livingstone New York 2003. Copyright &copy; 2003 Elsevier.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f41_49_42770=[""].join("\n");
var outline_f41_49_42770=null;
var title_f41_49_42771="MALDI TOF methodology";
var content_f41_49_42771=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F70974&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F70974&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 534px\">",
"   <div class=\"ttl\">",
"    Methodology developed for the spatial analysis of tissue by MALDI mass spectrometry",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 514px; height: 358px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Frozen sections are mounted on a metal plate, coated wtih a UV-absorbing matrix and placed in the mass spectrometer. A pulsed UV laser desorbs and ionizes analytes from the tissue and their m/z values are determined using a time-of-flight (TOF) analyzer. From a raster over the tissue and measurement of the peak intensities over thousands of spots, mass spectrometric images are generated at specific molecular weight values.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Stoeckli M, Chaurans P, Hallahan D, Caprioli R. Imaging mass spectrometry: A new technology for the analysis of protein expression in mammalian tissues. Nature Med 2001; 7:493. Copyright &copy; 2001 Nature Publishing Group.",
"    </div>",
"    <div class=\"contractual\">",
"     <br/>",
"     <a href=\"file://www.nature.com\">",
"      file://www.nature.com",
"     </a>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f41_49_42771=[""].join("\n");
var outline_f41_49_42771=null;
var title_f41_49_42772="Insulin lispro: Patient drug information";
var content_f41_49_42772=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Insulin lispro: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/48/17160?source=see_link\">",
"     see \"Insulin lispro: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?14/40/14982?source=see_link\">",
"     see \"Insulin lispro: Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F2127784\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      HumaLOG&reg;;",
"     </li>",
"     <li>",
"      HumaLOG&reg; KwikPen&trade;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F2127785\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Humalog&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10018669\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691404",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to lower blood sugar in patients with high blood sugar (diabetes).",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10018668\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702304",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to insulin or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10018673\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697780",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Wear disease medical alert ID (identification).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697009",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are 80 or older, use this drug with care. You could be more sensitive to low blood sugar.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696750",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not drive if your blood sugar has been low. There is a greater chance of you having a crash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697282",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have kidney disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698422",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check your blood sugar as you have been told by your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698463",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your blood work checked often. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698495",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have an eye exam and visit the foot doctor every year.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697562",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Limit your drinking of wine, beer, or mixed drinks.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696704",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep workouts the same. More workouts may lower your insulin needs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10018674\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698210",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Low blood sugar may occur. Signs may be dizziness, headache, feeling sleepy, feeling weak, shaking, a fast heartbeat, confusion, hunger, or sweating. Keep hard candies, glucose tablets, liquid glucose, or juice on hand for low blood sugar.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698392",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Weight gain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698189",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Irritation where the shot is given.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10018676\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699077",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of infection. These include a fever of 100.5&deg;F (38&deg;C) or higher, chills, very bad sore throat, ear or sinus pain, cough, more sputum or change in color of sputum, pain with passing urine, mouth sores, wound that will not heal, or anal itching or pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699111",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very low blood sugar or very high blood sugar.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10018671\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696185",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use as you have been told, even if you are feeling better.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699163",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not use out dated insulin.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696001",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is given as a shot into the fatty part of the skin.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695819",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take 15 minutes before or right after a meal.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696118",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Throw away needles in a needle/sharp disposal box and take the box back to your doctor when it is full.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694865",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Follow the diet and workout plan that your doctor told you about.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10018672\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3629482",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Give a missed shot as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3629483",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next shot, skip the missed shot and go back to your normal time.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10018677\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699566",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store unopened containers in a refrigerator. Do not freeze.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699214",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       You may store opened vials at room temperature or in a refrigerator. If stored at room temperature, throw away any part not used after 1 month.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699509",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store opened cartridges and pens at room temperature. Throw away any part not used after 1 month.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699284",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Protect opened containers from heat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699285",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Protect opened containers from light.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10018678\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11770 Version 31.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-61.234.146.186-4FB60DB4AC-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f41_49_42772=[""].join("\n");
var outline_f41_49_42772=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2127784\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2127785\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10018669\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10018668\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10018673\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10018674\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10018676\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10018671\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10018672\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10018677\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10018678\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?16/48/17160?source=related_link\">",
"      Insulin lispro: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?14/40/14982?source=related_link\">",
"      Insulin lispro: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f41_49_42773="Definition of acute kidney injury (acute renal failure)";
var content_f41_49_42773=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Definition of acute kidney injury (acute renal failure)",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?41/49/42773/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?41/49/42773/contributors\">",
"     Paul M Palevsky, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?41/49/42773/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?41/49/42773/contributors\">",
"     Gary C Curhan, MD, ScD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?41/49/42773/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?41/49/42773/contributors\">",
"     Alice M Sheridan, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?41/49/42773/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 11, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acute renal failure (ARF) has traditionally been defined as the abrupt loss of kidney function that results in the retention of urea and other nitrogenous waste products and in the dysregulation of extracellular volume and electrolytes. The loss of kidney function is most easily detected by measurement of the serum creatinine which is used to estimate the glomerular filtration rate (GFR).",
"   </p>",
"   <p>",
"    Three problems are associated with the use of the serum creatinine to quantitatively define ARF:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Serum creatinine does not accurately reflect the GFR in a patient who is not in steady state. In the early stages of severe acute renal failure, the serum creatinine may be low even though the actual (not estimated) GFR is markedly reduced since there may not have been sufficient time for the creatinine to accumulate. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?35/45/36570?source=see_link\">",
"       \"Assessment of kidney function\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Creatinine is removed by dialysis. As a result, it is usually not possible to assess kidney function by measuring the serum creatinine once dialysis is initiated. One exception is when the serum creatinine continues to fall on days when hemodialysis is not performed, indicating recovery of renal function.",
"     </li>",
"     <li>",
"      Numerous epidemiologic studies and clinical trials have used different cut-off values for serum creatinine to quantitatively define ARF [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/49/42773/abstract/1\">",
"       1",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The lack of consensus in the quantitative definition of ARF, in particular, has hindered clinical research since it confounds comparisons between studies. Some definitions employed in clinical studies have been extremely complex with graded increments in serum creatinine for different baseline serum creatinine values [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/49/42773/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. As an example, in a classic study of the epidemiology of hospital-acquired acute renal failure, ARF was defined as a 0.5",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    increase in serum creatinine if the baseline serum creatinine was &le;1.9",
"    <span class=\"nowrap\">",
"     mg/dL,",
"    </span>",
"    an 1.0",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    increase in serum creatinine if the baseline serum creatinine was 2.0 to 4.9",
"    <span class=\"nowrap\">",
"     mg/dL,",
"    </span>",
"    and a 1.5",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    increase in serum creatinine if the baseline serum creatinine was &ge;5.0",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/49/42773/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The Acute Dialysis Quality Initiative (ADQI) was created by a group of expert intensivists and nephrologists to develop consensus and evidence based guidelines for the treatment and prevention of acute renal failure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/49/42773/abstract/3\">",
"     3",
"    </a>",
"    ]. Recognizing the need for a uniform definition for ARF, the ADQI group proposed a consensus graded definition, called the RIFLE criteria [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/49/42773/abstract/4\">",
"     4",
"    </a>",
"    ]. A modification of the RIFLE criteria was subsequently proposed by the Acute Kidney Injury Network, which included the ADQI group as well as representatives from other nephrology and intensive care societies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/49/42773/abstract/5-7\">",
"     5-7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Because of these initiatives, the term acute kidney injury (AKI) was proposed to represent the entire spectrum of acute renal failure. This topic review will address the current definitions of acute renal failure, particularly the RIFLE criteria and the AKIN modifications.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     RIFLE CRITERIA",
"    </span>",
"    &nbsp;&mdash;&nbsp;The RIFLE criteria consists of three graded levels of injury (Risk, Injury, and Failure) based upon either the magnitude of elevation in serum creatinine or urine output, and two outcome measures (Loss and End-stage renal disease). The RIFLE strata are as follows [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/49/42773/abstract/4\">",
"     4",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Risk &mdash; 1.5-fold increase in the serum creatinine or GFR decrease by 25 percent or urine output &lt;0.5",
"      <span class=\"nowrap\">",
"       mL/kg",
"      </span>",
"      per hour for six hours",
"     </li>",
"     <li>",
"      Injury &mdash; Twofold increase in the serum creatinine or GFR decrease by 50 percent or urine output &lt;0.5",
"      <span class=\"nowrap\">",
"       mL/kg",
"      </span>",
"      per hour for 12 hours",
"     </li>",
"     <li>",
"      Failure &mdash; Threefold increase in the serum creatinine or GFR decrease by 75 percent or urine output of &lt;0.3",
"      <span class=\"nowrap\">",
"       mL/kg",
"      </span>",
"      per hour for 24 hours, or anuria for 12 hours",
"     </li>",
"     <li>",
"      Loss &mdash; Complete loss of kidney function (eg, need for renal replacement therapy) for more than four weeks",
"     </li>",
"     <li>",
"      ESRD &mdash; Complete loss of kidney function (eg, need for renal replacement therapy) for more than three months",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The RIFLE criteria correlated with prognosis in a number of studies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/49/42773/abstract/8-14\">",
"     8-14",
"    </a>",
"    ]. As an example, a systematic review of 13 studies demonstrated a stepwise increase in the relative risk of death in patients who met the RIFLE criteria for various stages of AKI [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/49/42773/abstract/14\">",
"     14",
"    </a>",
"    ]. Compared to patients who did not have AKI, patients in the RIFLE stages of \"risk,\" \"injury,\" and \"failure\" had increased relative mortality risks of 2.4 (CI 1.94-2.97), 4.15 (CI 3.14-5.48), and 6.37 (CI 5.14-7.9). Despite significant heterogeneity among studies, results from most individual reports were qualitatively similar.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Limitations",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are several important shortcomings to the RIFLE criteria:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The \"risk,\" \"injury,\" and \"failure\" strata are defined by either changes in serum creatinine or urine output. The assignment of the corresponding changes in serum creatinine and changes in urine output to the same strata are NOT based on evidence. In the one assessment of the RIFLE classification that compared the serum creatinine and urine output criteria, the serum creatinine criteria were strong predictors of ICU mortality, whereas the urine output criteria did not independently predict mortality [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/49/42773/abstract/12\">",
"       12",
"      </a>",
"      ]. Thus, if the RIFLE classification is used to stratify risk, it is important that the criteria that result in the least favorable RIFLE strata be used [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/49/42773/abstract/4\">",
"       4",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      As mentioned above, the change in serum creatinine during acute renal failure does not directly correlate with the actual change in glomerular filtration rate, which alters the assignment of that patient to a particular RIFLE level. As an example, in a patient with an abrupt decline in renal function in the setting of severe ARF, the serum creatinine might rise from 1.0 to 1.5",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (88.4 to 133",
"      <span class=\"nowrap\">",
"       micromol/L)",
"      </span>",
"      on day one, 2.5",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (221",
"      <span class=\"nowrap\">",
"       micromol/L)",
"      </span>",
"      on day two, and 3.5",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (309",
"      <span class=\"nowrap\">",
"       micromol/L)",
"      </span>",
"      on day three. According to the RIFLE criteria, the patient would progress from \"risk\" on day one to \"injury\" on day two and \"failure\" on day three, even though the actual GFR has been &lt;10",
"      <span class=\"nowrap\">",
"       mL/min",
"      </span>",
"      over the entire period. This issue is intrinsic to any assessment of acute renal failure based upon the serum creatinine level.",
"     </li>",
"     <li>",
"      Even among patients in steady state, the change in serum creatinine concentrations do not correlate with the percent decrease in GFR that is cited in the RIFLE classification; a 1.5-fold increase in serum creatinine corresponds to a 33 rather than 25 percent decrease in GFR [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/49/42773/abstract/15\">",
"       15",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      It is impossible to calculate the change in serum creatinine in patients who present with ARF but without a baseline measurement of serum creatinine. The authors of the RIFLE criteria suggest back-calculating an estimated baseline serum creatinine concentration using the four-variable MDRD equation, assuming a baseline GFR of 75",
"      <span class=\"nowrap\">",
"       mL/min",
"      </span>",
"      per 1.73 m2 [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/49/42773/abstract/4\">",
"       4",
"      </a>",
"      ]. However, this approach has been demonstrated to result in significant misclassification and is not recommended.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Most investigators and clinicians who use the RIFLE criteria to stratify patients with AKI do NOT use the GFR, because of the reasons cited above; the reference to change in GFR is not included in the more recent Acute Kidney Injury Network (AKIN) classification system (See",
"    <a class=\"local\" href=\"#H4\">",
"     'AKIN criteria'",
"    </a>",
"    below.) and in Kidney Disease: Improving Global Outcomes (KDIGO) AKI classification system, except for the classification of children under the age of 18 years. (See",
"    <a class=\"local\" href=\"#H277795488\">",
"     'KDIGO modifications to RIFLE and AKIN'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     AKIN CRITERIA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Given these limitations, a modification of the RIFLE criteria has been proposed by the Acute Kidney Injury Network. The AKIN proposed both diagnostic criteria for ARF and a staging system that was based on the RIFLE criteria [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/49/42773/abstract/5-7\">",
"     5-7",
"    </a>",
"    ]. In addition, the term acute kidney injury (AKI) was proposed to represent the entire spectrum of acute renal failure.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Diagnostic criteria",
"    </span>",
"    &nbsp;&mdash;&nbsp;The proposed diagnostic criteria for ARF are an abrupt (within 48 hours) absolute increase in the serum creatinine concentration of &ge;0.3",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (26.4",
"    <span class=\"nowrap\">",
"     micromol/L)",
"    </span>",
"    from baseline, a percentage increase in the serum creatinine concentration of &ge;50 percent, or oliguria of less than 0.5",
"    <span class=\"nowrap\">",
"     mL/kg",
"    </span>",
"    per hour for more than six hours (",
"    <a class=\"graphic graphic_table graphicRef83168 \" href=\"mobipreview.htm?10/4/10316\">",
"     table 1",
"    </a>",
"    ).",
"    <br/>",
"   </p>",
"   <p>",
"    The latter two of these criteria are identical to the RIFLE \"risk\" criteria. The addition of an absolute change in serum creatinine of &ge;0.3",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    is based on epidemiologic data that have demonstrated an 80 percent increase in mortality risk associated with changes in serum creatinine concentration of as little as 0.3 to 0.5",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/49/42773/abstract/16\">",
"     16",
"    </a>",
"    ]. Including a time constraint of 48 hours is based upon data that showed that poorer outcomes were associated with small changes in the creatinine when the rise in creatinine was observed within 24 to 48 hours [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/49/42773/abstract/17,18\">",
"     17,18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Two additional caveats were proposed by the AKIN group:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The diagnostic criteria should be applied only after volume status had been optimized.",
"     </li>",
"     <li>",
"      Urinary tract obstruction needed to be excluded if oliguria was used as the sole diagnostic criterion.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A flaw with the last caveat is that, according to the current definition, AKI would still be used to describe the patient with acute urinary tract obstruction and an acute increase in serum creatinine. It is not clear whether the AKIN modifications to RIFLE have substantively changed the classification of patients with AKI or improved its ability to predict hospital mortality [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/49/42773/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Staging system",
"    </span>",
"    &nbsp;&mdash;&nbsp;The classification or staging system for ARF is comprised of three stages of increasing severity, which correspond to risk (stage 1), injury (stage 2), and failure (stage 3) of the RIFLE criteria. Loss and ESRD are removed from the staging system and defined as outcomes.",
"   </p>",
"   <p>",
"    The clinical applicability of these staging systems is uncertain. However, they will likely have some utility in standardizing the definitions for epidemiologic studies and for establishing inclusion criteria and endpoints for clinical trials.",
"   </p>",
"   <p>",
"    Ultimately these definitions are likely to be replaced by more sensitive and specific biomarkers of renal injury.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H277795488\">",
"    <span class=\"h1\">",
"     KDIGO MODIFICATIONS TO RIFLE AND AKIN",
"    </span>",
"    &nbsp;&mdash;&nbsp;The KDIGO clinical practice guidelines included a revised definition of AKI while retaining the AKIN staging criteria [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/49/42773/abstract/20\">",
"     20",
"    </a>",
"    ]. In the KDIGO definition, the time frame for an absolute increase in serum creatinine of 0.3",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    is retained from the AKIN definition (48 hours) while the time frame for a 50 percent increase in serum creatinine is the seven days, as originally suggested by the RIFLE criteria. The KDIGO criteria only utilize changes in serum creatinine and urine output ,and not changes in GFR for staging, with the exception of children under the age of 18 years, for whom an acute decrease in estimated GFR to &lt;35",
"    <span class=\"nowrap\">",
"     ml/min",
"    </span>",
"    per 1.73m2 is included in the criteria for stage 3 AKI. As with the RIFLE and AKIN staging systems, patients should be classified according to criteria that result in the highest (ie, most severe) stage of injury. Using the KDIGO criteria, AKI is staged as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Stage 1&mdash; 1.5-1.9 times baseline OR &ge;0.3",
"      <span class=\"nowrap\">",
"       mg/dl",
"      </span>",
"      (&ge;26.5",
"      <span class=\"nowrap\">",
"       micromol/l)",
"      </span>",
"      increase in the serum creatinine, OR urine output &lt;0.5",
"      <span class=\"nowrap\">",
"       ml/kg",
"      </span>",
"      per hour for 6 to 12 hours.",
"     </li>",
"     <li>",
"      Stage 2 &mdash; 2.0-2.9 times baseline increase in the serum creatinine OR urine output &lt;0.5",
"      <span class=\"nowrap\">",
"       ml/kg",
"      </span>",
"      per hour for &ge;12 hours.",
"     </li>",
"     <li>",
"      Stage 3 &mdash; 3.0 times baseline increase in the serum creatinine OR increase in serum creatinine to &ge;4.0",
"      <span class=\"nowrap\">",
"       mg/dl",
"      </span>",
"      (&ge;353.6",
"      <span class=\"nowrap\">",
"       micromol/l)",
"      </span>",
"      OR urine output of &lt;0.3",
"      <span class=\"nowrap\">",
"       ml/kg",
"      </span>",
"      per hour for &ge;24 hours, OR anuria for &ge;12 hours OR the initiation of renal replacement therapy OR, in patients &lt;18 years, decrease in estimated GFR to &lt;35",
"      <span class=\"nowrap\">",
"       ml/min",
"      </span>",
"      per 1.73m2.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     CLINICAL UTILITY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The RIFLE and AKIN criteria have helped to focus attention that decrements in renal function that result in small changes in serum creatinine concentration are associated with significant clinical consequences. However, the precise clinical utility of these criteria is uncertain. There is also an inherent confusion within these criteria as to whether prerenal and obstructive etiologies of ARF are subsumed in or are external to the definition of AKI.",
"   </p>",
"   <p>",
"    We believe that these criteria have greatest utility in epidemiologic studies and in defining consistent inclusion criteria",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    endpoints for clinical studies. Their utility at the bedside is less clear and it seems likely that they will eventually be replaced at least in part by sensitive and specific biomarkers of renal tubular injury. The use of such biomarkers, analogous to troponin as a marker of myocardial injury, will permit development of a new paradigm for classifying acute kidney injury that is not solely dependent upon serum creatinine or other functional markers.",
"   </p>",
"   <p>",
"    We do believe that adoption of the term acute kidney injury (AKI) to replace the older terminology of acute renal failure is highly appropriate. Just as acute lung injury is used to describe acute pulmonary injury that has not progressed to overt organ failure, we believe that AKI is more representative of the full spectrum of acute kidney dysfunction.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?5/46/5859?source=see_link\">",
"       \"Patient information: Acute kidney failure (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Acute renal failure (ARF) has traditionally been defined as the abrupt loss of kidney function resulting in the retention of urea and other nitrogenous waste products and in the dysregulation of extracellular volume and electrolytes. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Although the loss of kidney function is most easily detected by measurement of the serum creatinine, several problems are associated with the use of this measure to quantitatively define ARF, particularly the lack of consensus in the quantitative definition. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The Acute Dialysis Quality Initiative (ADQI) has proposed a graded definition of ARF called the RIFLE criteria. The Acute Kidney Injury Network (AKIN) modified the RIFLE criteria in order to include less severe ARF, to impose a time constraint of 48 hours, and to allow for correction of volume status and obstructive causes of ARF prior to classification. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Rifle criteria'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H4\">",
"       'AKIN criteria'",
"      </a>",
"      above.) These criteria have their greatest utility in epidemiologic studies.",
"     </li>",
"     <li>",
"      The AKIN proposed the term acute kidney injury (AKI) to represent the entire spectrum of acute renal failure. The proposed diagnostic criteria are an abrupt (within 48 hours) absolute increase in the serum creatinine concentration of &ge;0.3",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (26.4",
"      <span class=\"nowrap\">",
"       micromol/L)",
"      </span>",
"      from baseline, a percentage increase in the serum creatinine concentration of &ge;50 percent, or oliguria of less than 0.5",
"      <span class=\"nowrap\">",
"       mL/kg",
"      </span>",
"      per hour for more than six hours. These criteria will likely be revised, and possibly replaced, as biomarkers of tubular injury are developed. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Diagnostic criteria'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      More recently, KDIGO proposed a consensus definition utilizing the 48 hour time frame from AKIN for a 0.3",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      change in serum creatinine while using a seven day time frame for the 50 percent change in serum creatinine originally applied by the RIFLE criteria, while retaining the tripartite staging of both systems. (See",
"      <a class=\"local\" href=\"#H277795488\">",
"       'KDIGO modifications to RIFLE and AKIN'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We agree that adoption of the term acute kidney injury to replace the older terminology of acute renal failure is highly appropriate. AKI better represents the full spectrum of acute kidney dysfunction. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Clinical utility'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/49/42773/abstract/1\">",
"      Mehta RL, Chertow GM. Acute renal failure definitions and classification: time for change? J Am Soc Nephrol 2003; 14:2178.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/49/42773/abstract/2\">",
"      Hou SH, Bushinsky DA, Wish JB, et al. Hospital-acquired renal insufficiency: a prospective study. Am J Med 1983; 74:243.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/49/42773/abstract/3\">",
"      Ronco C, Kellum JA, Mehta R. Acute dialysis quality initiative (ADQI). Nephrol Dial Transplant 2001; 16:1555.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/49/42773/abstract/4\">",
"      Bellomo R, Ronco C, Kellum JA, et al. Acute renal failure - definition, outcome measures, animal models, fluid therapy and information technology needs: the Second International Consensus Conference of the Acute Dialysis Quality Initiative (ADQI) Group. Crit Care 2004; 8:R204.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/49/42773/abstract/5\">",
"      Mehta RL, Kellum JA, Shah SV, et al. Acute Kidney Injury Network: report of an initiative to improve outcomes in acute kidney injury. Crit Care 2007; 11:R31.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/49/42773/abstract/6\">",
"      Levin A, Warnock DG, Mehta RL, et al. Improving outcomes from acute kidney injury: report of an initiative. Am J Kidney Dis 2007; 50:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/49/42773/abstract/7\">",
"      Molitoris BA, Levin A, Warnock DG, et al. Improving outcomes from acute kidney injury. J Am Soc Nephrol 2007; 18:1992.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/49/42773/abstract/8\">",
"      Ali T, Khan I, Simpson W, et al. Incidence and outcomes in acute kidney injury: a comprehensive population-based study. J Am Soc Nephrol 2007; 18:1292.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/49/42773/abstract/9\">",
"      Uchino S, Bellomo R, Goldsmith D, et al. An assessment of the RIFLE criteria for acute renal failure in hospitalized patients. Crit Care Med 2006; 34:1913.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/49/42773/abstract/10\">",
"      Hoste EA, Clermont G, Kersten A, et al. RIFLE criteria for acute kidney injury are associated with hospital mortality in critically ill patients: a cohort analysis. Crit Care 2006; 10:R73.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/49/42773/abstract/11\">",
"      Kuitunen A, Vento A, Suojaranta-Ylinen R, Pettil&auml; V. Acute renal failure after cardiac surgery: evaluation of the RIFLE classification. Ann Thorac Surg 2006; 81:542.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/49/42773/abstract/12\">",
"      Cruz DN, Bolgan I, Perazella MA, et al. North East Italian Prospective Hospital Renal Outcome Survey on Acute Kidney Injury (NEiPHROS-AKI): targeting the problem with the RIFLE Criteria. Clin J Am Soc Nephrol 2007; 2:418.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/49/42773/abstract/13\">",
"      Ostermann M, Chang RW. Acute kidney injury in the intensive care unit according to RIFLE. Crit Care Med 2007; 35:1837.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/49/42773/abstract/14\">",
"      Ricci Z, Cruz D, Ronco C. The RIFLE criteria and mortality in acute kidney injury: A systematic review. Kidney Int 2008; 73:538.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/49/42773/abstract/15\">",
"      Pickering JW, Endre ZH. GFR shot by RIFLE: errors in staging acute kidney injury. Lancet 2009; 373:1318.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/49/42773/abstract/16\">",
"      Chertow GM, Burdick E, Honour M, et al. Acute kidney injury, mortality, length of stay, and costs in hospitalized patients. J Am Soc Nephrol 2005; 16:3365.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/49/42773/abstract/17\">",
"      Lassnigg A, Schmidlin D, Mouhieddine M, et al. Minimal changes of serum creatinine predict prognosis in patients after cardiothoracic surgery: a prospective cohort study. J Am Soc Nephrol 2004; 15:1597.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/49/42773/abstract/18\">",
"      Levy MM, Macias WL, Vincent JL, et al. Early changes in organ function predict eventual survival in severe sepsis. Crit Care Med 2005; 33:2194.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/49/42773/abstract/19\">",
"      Bagshaw SM, George C, Bellomo R, ANZICS Database Management Committe. A comparison of the RIFLE and AKIN criteria for acute kidney injury in critically ill patients. Nephrol Dial Transplant 2008; 23:1569.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/49/42773/abstract/20\">",
"      Kidney Int Suppl 2012; 2:8.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7238 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0505-217.117.136.88-29CCF0041E-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f41_49_42773=[""].join("\n");
var outline_f41_49_42773=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H8\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      RIFLE CRITERIA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Limitations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      AKIN CRITERIA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Diagnostic criteria",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Staging system",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H277795488\">",
"      KDIGO MODIFICATIONS TO RIFLE AND AKIN",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      CLINICAL UTILITY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"NEPH/7238\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEPH/7238|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?10/4/10316\" title=\"table 1\">",
"      Criteria for acute kidney injury",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/45/36570?source=related_link\">",
"      Assessment of kidney function",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?5/46/5859?source=related_link\">",
"      Patient information: Acute kidney failure (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f41_49_42774="Tolbutamide: Drug information";
var content_f41_49_42774=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Tolbutamide: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?33/22/34148?source=see_link\">",
"    see \"Tolbutamide: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F228919\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Apo-Tolbutamide&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F228955\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antidiabetic Agent, Sulfonylurea",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F228923\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     <b>",
"      Type 2 diabetes:",
"     </b>",
"     Oral: Initial: 1-2 g/day as a single dose in the morning or in divided doses throughout the day. Maintenance dose: 0.25-3 g/day; however, a maintenance dose &gt;2 g/day is seldom required.",
"     <b>",
"      Note:",
"     </b>",
"     Divided doses may improve gastrointestinal tolerance",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F228924\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Initial: 250 mg 1-3 times/day; usual: 500-2000 mg; maximum: 3 g/day",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F228925\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adjustment is not necessary.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hemodialysis: Not dialyzable (0% to 5%)",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F228926\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Reduced dose may be necessary.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F228893\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral: 500 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F228878\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F228898\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral: Entire dose can be administered in AM, divided doses may improve GI tolerance.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F228897\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adjunct to diet for the management of type 2 diabetes mellitus (noninsulin dependent, NIDDM)",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F228962\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       TOLBUTamide may be confused with terbutaline, TOLAZamide",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Orinase may be confused with Orabase&reg;, Ornex&reg;, Tolinase&reg;",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      High alert medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       The Institute for Safe Medication Practices (ISMP) includes this medication among its list of drugs which have a heightened risk of causing significant patient harm when used in error.",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F228953\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Frequency not defined.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Headache",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Erythema, maculopapular rash, morbilliform rash, pruritus, urticaria, photosensitivity",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Disulfiram-like reactions, hypoglycemia, hyponatremia, SIADH",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Epigastric fullness, heartburn, nausea, taste alteration",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hematologic: Agranulocytosis, aplastic anemia, hemolytic anemia, leukopenia, pancytopenia, thrombocytopenia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hepatic: Cholestatic jaundice, hepatic porphyria, porphyria cutanea tarda",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Hypersensitivity reaction",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F228901\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to tolbutamide, sulfonylureas, or any component of the formulation; treatment of type 1 diabetes; diabetic ketoacidosis",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F228882\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse reactions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cardiovascular mortality: Product labeling states oral hypoglycemic drugs may be associated with an increased cardiovascular mortality as compared to treatment with diet alone or diet plus insulin. Data to support this association are limited, and several studies, including a large prospective trial (UKPDS) have not supported an association.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypoglycemia: All sulfonylurea drugs are capable of producing severe hypoglycemia. Hypoglycemia is more likely to occur when caloric intake is deficient, after severe or prolonged exercise, when ethanol is ingested, or when more than one glucose-lowering drug is used. It is also more likely in elderly patients, malnourished patients and in patients with impaired renal or hepatic function; use with caution.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Sulfonamide allergy: Chemical similarities are present among sulfonamides, sulfonylureas, carbonic anhydrase inhibitors, thiazides, and loop diuretics (except ethacrynic acid). Use in patients with sulfonylurea allergy is specifically contraindicated in product labeling, however, a risk of cross-reaction exists in patients with allergy to any of these compounds; avoid use when previous reaction has been severe.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Glucose-6-phosphate dehydrogenase (G6PD) deficiency: Patients with G6PD deficiency may be at an increased risk of sulfonylurea-induced hemolytic anemia; however, cases have also been described in patients without G6PD deficiency during postmarketing surveillance. Use with caution and consider a nonsulfonylurea alternative in patients with G6PD deficiency.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Stress-related states: It may be necessary to discontinue therapy and administer insulin if the patient is exposed to stress (fever, trauma, infection, surgery).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Secondary failure: Loss of efficacy may be observed following prolonged use as a result of the progression of type 2 diabetes mellitus which results in continued beta cell destruction. In patients who were previously responding to sulfonylurea therapy, consider additional factors which may be contributing to decreased efficacy (eg, inappropriate dose, nonadherence to diet and exercise regimen). If no contributing factors can be identified, consider discontinuing use of the sulfonylurea due to secondary failure of treatment.  Additional antidiabetic therapy (eg, insulin) will be required.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F228951\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP2C19 (minor), CYP2C9 (major);",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential;",
"     <b>",
"      Inhibits",
"     </b>",
"     CYP2C8 (weak), CYP2C9 (strong)",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F228887\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alcohol (Ethyl): Sulfonylureas may enhance the adverse/toxic effect of Alcohol (Ethyl). A flushing reaction may occur.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aprepitant: May decrease the serum concentration of TOLBUTamide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Beta-Blockers: May enhance the hypoglycemic effect of Sulfonylureas. Cardioselective beta-blockers (eg, acebutolol, atenolol, metoprolol, and penbutolol) may be safer than nonselective beta-blockers. All beta-blockers appear to mask tachycardia as an initial symptom of hypoglycemia. Ophthalmic beta-blockers are probably associated with lower risk than systemic agents.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levobunolol; Metipranolol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Chloramphenicol: May decrease the metabolism of Sulfonylureas.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cimetidine: May increase the serum concentration of Sulfonylureas.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Corticosteroids (Orally Inhaled): May diminish the hypoglycemic effect of Antidiabetic Agents. In some instances, corticosteroid-mediated HPA axis suppression has led to episodes of acute adrenal crisis, which may manifest as enhanced hypoglycemia, particularly in the setting of insulin or other antidiabetic agent use.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Corticosteroids (Systemic): May diminish the hypoglycemic effect of Antidiabetic Agents. In some instances, corticosteroid-mediated HPA axis suppression has led to episodes of acute adrenal crisis, which may manifest as enhanced hypoglycemia, particularly in the setting of insulin or other antidiabetic agent use.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cyclic Antidepressants: May enhance the hypoglycemic effect of Sulfonylureas.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2C9 Inducers (Strong): May increase the metabolism of CYP2C9 Substrates. Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2C9 Inhibitors (Moderate): May decrease the metabolism of CYP2C9 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2C9 Inhibitors (Strong): May decrease the metabolism of CYP2C9 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2C9 Substrates: CYP2C9 Inhibitors (Strong) may decrease the metabolism of CYP2C9 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Diclofenac (Systemic): CYP2C9 Inhibitors (Strong) may increase the serum concentration of Diclofenac (Systemic).  Management: Consider using a lower dose of diclofenac when used together with a strong CYP2C9 inhibitor.  Arthrotec (diclofenac and misoprostol) labeling specifically recommends limiting the total daily dose to a maximum of 50 mg twice/day.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fibric Acid Derivatives: May enhance the hypoglycemic effect of Sulfonylureas.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fluconazole: May increase the serum concentration of Sulfonylureas.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fosaprepitant: May decrease the serum concentration of TOLBUTamide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     GLP-1 Agonists: May enhance the hypoglycemic effect of Sulfonylureas. Management: Consider sulfonylurea dose reductions when used in combination with GLP-1 agonists.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Hypoglycemic Properties): May enhance the hypoglycemic effect of Hypoglycemic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hypoglycemic Agents: May enhance the adverse/toxic effect of other Hypoglycemic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Leflunomide: May increase the serum concentration of TOLBUTamide. Specifically, the active metabolite of leflunomide (M1) may both increase total tolbutamide concentrations and increase the free fraction (i.e., non-protein bound) of tolbutamide. TOLBUTamide may increase the serum concentration of Leflunomide. Specifically, tolbutamide may increase the proportion of non-protein-bound (i.e., free fraction) M1, which is the active metabolite of leflunomide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Loop Diuretics: May diminish the hypoglycemic effect of Hypoglycemic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Luteinizing Hormone-Releasing Hormone Analogs: May diminish the therapeutic effect of Antidiabetic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MAO Inhibitors: May enhance the hypoglycemic effect of Hypoglycemic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: May increase the serum concentration of CYP2C9 Substrates. Management: Use CYP2C9 substrates at the lowest recommended dose, and monitor closely for adverse effects, during and in the 2 weeks following mifepristone treatment.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ospemifene: CYP2C9 Inhibitors (Strong) may increase the serum concentration of Ospemifene.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Peginterferon Alfa-2b: May decrease the serum concentration of CYP2C9 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pegvisomant: May enhance the hypoglycemic effect of Antidiabetic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Porfimer: Photosensitizing Agents may enhance the photosensitizing effect of Porfimer.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Probenecid: May decrease the protein binding of Sulfonylureas. Probenecid may increase the serum concentration of Sulfonylureas.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Quinolone Antibiotics: May enhance the hypoglycemic effect of Sulfonylureas. This appears to be particularly concerning early in the course of combination therapy. Quinolone Antibiotics may diminish the hypoglycemic effect of Sulfonylureas. With longer-term combination, there is a greater risk of hyperglycemia.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ranitidine: May increase the serum concentration of Sulfonylureas.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rifampin: May increase the metabolism of Sulfonylureas.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Salicylates: May enhance the hypoglycemic effect of Hypoglycemic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Selective Serotonin Reuptake Inhibitors: May enhance the hypoglycemic effect of Hypoglycemic Agents. Selective Serotonin Reuptake Inhibitors may increase the serum concentration of Hypoglycemic Agents. Management: Consider increased monitoring of glycemic control with concomitant use of a hypoglycemic agent and an SSRI. Dosage adjustments of the hypoglycemic agent may be necessary upon SSRI initiation or discontinuation.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Somatropin: May diminish the hypoglycemic effect of Antidiabetic Agents.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sulfonamide Derivatives: May enhance the hypoglycemic effect of Sulfonylureas.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thiazide Diuretics: May diminish the therapeutic effect of Antidiabetic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin K Antagonists (eg, warfarin): Sulfonylureas may enhance the anticoagulant effect of Vitamin K Antagonists. Vitamin K Antagonists may enhance the hypoglycemic effect of Sulfonylureas.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Voriconazole: May increase the serum concentration of Sulfonylureas.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F228915\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ethanol: Avoid ethanol (possible disulfiram-like reaction).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herb/Nutraceutical: Herbs with hypoglycemic properties may enhance the hypoglycemic effect of tolbutamide. This includes alfalfa, aloe, bilberry, bitter melon, burdock, celery, damiana, fenugreek, garcinia, garlic, ginger, ginseng (American), gymnema, marshmallow, stinging nettle.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F228888\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F228903\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse events have been observed in animal studies; therefore, tolbutamide is classified as pregnancy category C. Tolbutamide crosses the placenta and levels can be measured in the serum of newborn infants following maternal use during pregnancy. Teratogenic effects have been noted in some case reports. Prolonged hyperinsulinemic hypoglycemia has been reported in an infant following maternal use of tolbutamide and severe hypoglycemia lasting 4-10 days has been noted in infants born to mothers taking a sulfonylurea at the time of delivery. Maternal hyperglycemia can be associated with adverse effects in the fetus, including macrosomia, neonatal hyperglycemia, and hyperbilirubinemia; the risk of congenital malformations is increased when the Hb A",
"     <sub>",
"      1c",
"     </sub>",
"     is above the normal range. Diabetes can also be associated with adverse effects in the mother. Poorly-treated diabetes may cause end-organ damage that may in turn negatively affect obstetric outcomes. Physiologic glucose levels should be maintained prior to and during pregnancy to decrease the risk of adverse events in the mother and the fetus. Until additional safety and efficacy data are obtained, the use of oral agents is generally not recommended as routine management of GDM or type 2 diabetes mellitus during pregnancy. The manufacturer recommends if tolbutamide is used during pregnancy, it should be discontinued at least 2 weeks before the expected delivery date. Insulin is the drug of choice for the control of diabetes mellitus during pregnancy.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F228930\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Enters breast milk/not recommended (AAP rates \"compatible\"; AAP 2001 update pending)",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F228904\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Tolbutamide is excreted in breast milk. Breast-feeding is not recommended by the manufacturer. Potentially, hypoglycemia may occur in a nursing infant exposed to a sulfonylurea via breast milk.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F2524728\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (TOLBUTamide Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     500 mg (100): $111.22",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F228891\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Blood glucose, hemoglobin A",
"     <sub>",
"      1c",
"     </sub>",
"     ; signs and symptoms of hypoglycemia",
"    </p>",
"   </div>",
"   <div class=\"block rer drugH1Div\" id=\"F228894\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Reference Range",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Recommendations for glycemic control in nonpregnant adults with diabetes (ADA, 2012):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hb A",
"     <sub>",
"      1c",
"     </sub>",
"     : &lt;7% (a more aggressive [&lt;6.5%] or less aggressive [&lt;8%] Hb A",
"     <sub>",
"      1c",
"     </sub>",
"     goal may be targeted based on patient-specific characteristics)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Preprandial capillary plasma glucose: 70-130 mg/dL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Peak postprandial capillary blood glucose: &lt;180 mg/dL",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F228905\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Aglicem (ES);",
"     </li>",
"     <li>",
"      Aglycid (IT);",
"     </li>",
"     <li>",
"      Arcosal (DK);",
"     </li>",
"     <li>",
"      Artison (AE, BH, CY, EG, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SY, YE);",
"     </li>",
"     <li>",
"      Artosin (DE, JP, MX, NL);",
"     </li>",
"     <li>",
"      Asto (JP);",
"     </li>",
"     <li>",
"      Butamide (JP);",
"     </li>",
"     <li>",
"      Diaben (JP);",
"     </li>",
"     <li>",
"      Diabetol (PL);",
"     </li>",
"     <li>",
"      Diabeton Metilato (IT);",
"     </li>",
"     <li>",
"      Diabetose (JP);",
"     </li>",
"     <li>",
"      Diatol (HK, NZ);",
"     </li>",
"     <li>",
"      Dirastan (CZ);",
"     </li>",
"     <li>",
"      Dolipol (FR);",
"     </li>",
"     <li>",
"      Mellitos D (JP);",
"     </li>",
"     <li>",
"      Neobezeta (UY);",
"     </li>",
"     <li>",
"      Orabet (DE);",
"     </li>",
"     <li>",
"      Orsinon (IL);",
"     </li>",
"     <li>",
"      Rastinon (AE, AT, AU, BE, BH, CH, CY, EG, ES, GR, IE, IN, IQ, IR, IT, JO, KW, LB, LU, LY, MX, OM, QA, SA, SY, YE);",
"     </li>",
"     <li>",
"      Tobumide (SG);",
"     </li>",
"     <li>",
"      Tolbutamid R.A.N. (DE);",
"     </li>",
"     <li>",
"      Tolmide (SG);",
"     </li>",
"     <li>",
"      Tolsiran (JP);",
"     </li>",
"     <li>",
"      Tolumide (JP);",
"     </li>",
"     <li>",
"      Tydadex (ZA)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F228881\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Stimulates insulin release from the pancreatic beta cells; reduces glucose output from the liver; insulin sensitivity is increased at peripheral target sites, suppression of glucagon may also contribute",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F228900\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset of action:  1 hour",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Duration: Oral: 6-24 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Oral: Rapid",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: V",
"     <sub>",
"      d",
"     </sub>",
"     : 0.15 L/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: ~95% (concentration dependent)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Hepatic via CYP2C9 to hydroxymethyltolbutamide (mildly active) and carboxytolbutamide (inactive); metabolism does not appear to be affected by age",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: 4.5-6.5  hours (range: 4-25 hours)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak, serum: 3-4 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Urine (75% to 85% primarily as metabolites); feces",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      American Academy of Pediatrics Committee on Drugs, \"Transfer of Drugs and Other Chemicals Into Human Milk,\"",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2001, 108(3):776-89.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?41/49/42774/abstract-text/11533352/pubmed\" id=\"11533352\" target=\"_blank\">",
"        11533352",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      American Diabetes Association, &ldquo;Standards of Medical Care in Diabetes Mellitus -- 2012,&rdquo;",
"      <i>",
"       Diabetes Care",
"      </i>",
"      , 2012, 35(Suppl 1):11-63.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?41/49/42774/abstract-text/22187469/pubmed\" id=\"22187469\" target=\"_blank\">",
"        22187469",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      &ldquo;A Study of the Effects of Hypoglycemia Agents on Vascular Complications in Patients With Adult-Onset Diabetes. VI. Supplementary Report on Nonfatal Events in Patients Treated With Tolbutamide. The University Group Diabetes Program,&rdquo;",
"      <i>",
"       Diabetes",
"      </i>",
"      , 1976, 25(12):1129-53.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?41/49/42774/abstract-text/992232/pubmed\" id=\"992232\" target=\"_blank\">",
"        992232",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Canadian Diabetes Association Clinical Practice Guidelines Expert Committee, \"Canadian Diabetes Association 2008 Clinical Practice Guidelines for the Prevention and Management of Diabetes in Canada,\"",
"      <i>",
"       Can J Diabetes",
"      </i>",
"      , 20078, 32(suppl 1):1-201.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      &ldquo;Effect of Intensive Blood-Glucose Control With Metformin on Complications in Overweight Patients With Type 2 Diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group,&rdquo;",
"      <i>",
"       Lancet",
"      </i>",
"      , 1998, 352(9131):854-65.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?41/49/42774/abstract-text/9742977/pubmed\" id=\"9742977\" target=\"_blank\">",
"        9742977",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Garratt KN, Brady PA, Hassinger NL, et al, &ldquo;Sulfonylurea Drugs Increase Early Mortality in Patients With Diabetes Mellitus After Direct Angioplasty for Acute Myocardial Infarction,&rdquo;",
"      <i>",
"       J Am Coll Cardiol",
"      </i>",
"      , 1999, 33(1):119-24.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?41/49/42774/abstract-text/9935017/pubmed\" id=\"9935017\" target=\"_blank\">",
"        9935017",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Huupponen R, &ldquo;Adverse Cardiovascular Effects of Sulphonylurea Drugs. Clinical Significance,&rdquo;",
"      <i>",
"       Med Toxicol",
"      </i>",
"      , 1987, 2(3):190-209.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?41/49/42774/abstract-text/3298923/pubmed\" id=\"3298923\" target=\"_blank\">",
"        3298923",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      &ldquo;Intensive Blood-Glucose Control With Sulphonylureas or Insulin Compared With Conventional Treatment and Risk of Complications in Patients With Type 2 Diabetes (UKPDS 33) UK Prospective Diabetes Study (UKPDS) Group,&rdquo;",
"      <i>",
"       Lancet",
"      </i>",
"      , 1998, 352(9131):837-53.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?41/49/42774/abstract-text/9742976/pubmed\" id=\"9742976\" target=\"_blank\">",
"        9742976",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kirkman M, Briscoe VJ, Clark N, et al, \"Diabetes in Older Adults: A Consensus Report,\"",
"      <i>",
"       J Am Geriatr Soc",
"      </i>",
"      , 2012; doi: 10.1111/jgs.12035.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?41/49/42774/abstract-text/23106132/pubmed\" id=\"23106132\" target=\"_blank\">",
"        23106132",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Klamann A, Sarfert P, Launhardt V, et al, &ldquo;Myocardial Infarction in Diabetic vs Nondiabetic Subjects. Survival and Infarct Size Following Therapy With Sulfonylureas (Glibenclamide),&rdquo;",
"      <i>",
"       Eur Heart J",
"      </i>",
"      , 2000, 21(3):220-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?41/49/42774/abstract-text/10639304/pubmed\" id=\"10639304\" target=\"_blank\">",
"        10639304",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lazner J, &ldquo;Fatal Hypoglycaemia From Tolbutamide in a Nondiabetic Patient,&rdquo;",
"      <i>",
"       Med J Aust",
"      </i>",
"      , 1970, 1:327-8.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Meinert CL, Knatterud GL, Prout TE, et al, &ldquo;A Study of the Effects of Hypoglycemic Agents on Vascular Complications in Patients With Adult-Onset Diabetes. II. Mortality Results,&rdquo;",
"      <i>",
"       Diabetes",
"      </i>",
"      , 1970, 19:789-830.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?41/49/42774/abstract-text/4926376/pubmed\" id=\"4926376\" target=\"_blank\">",
"        4926376",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Miller AK, Adir J, and Vestal RE, &ldquo;Effect of Age on the Pharmacokinetics of Tolbutamide in Man,&rdquo;",
"      <i>",
"       Pharmacologist",
"      </i>",
"      , 1977, 19:128.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Miller AK, Adir J, and Vestal RE, &ldquo;Tolbutamide Binding to Plasma Proteins of Young and Old Human Subjects,&rdquo;",
"      <i>",
"       J Pharm Sci",
"      </i>",
"      , 1978, 67(8):1192-3.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?41/49/42774/abstract-text/671270/pubmed\" id=\"671270\" target=\"_blank\">",
"        671270",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      O'Keefe JH, Blackstone EH, Sergeant P, et al, &ldquo;The Optimal Mode of Coronary Revascularization for Diabetics. A Risk-Adjusted Long-Term Study Comparing Coronary Angioplasty and Coronary Bypass Surgery,&rdquo;",
"      <i>",
"       Eur Heart J",
"      </i>",
"      , 1998, 19(11):1696-703.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?41/49/42774/abstract-text/9857923/pubmed\" id=\"9857923\" target=\"_blank\">",
"        9857923",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Qaseem A, Humphrey LL, Sweet DE, et al,&ldquo;Oral Pharmacologic Treatment of Type 2 Diabetes Mellitus: A Clinical Practice Guideline from the American College of Physicians,&rdquo;",
"      <i>",
"       Ann Intern Med",
"      </i>",
"      , 2012, 156(3):218-31.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?41/49/42774/abstract-text/22312141/pubmed\" id=\"22312141\" target=\"_blank\">",
"        22312141",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Seger D, &ldquo;Toxic Emergencies of Endocrine and Metabolic Therapeutic Agents,&rdquo;",
"      <i>",
"       J Emerg Med",
"      </i>",
"      , 1988, 6(6):527-37.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?41/49/42774/abstract-text/3065405/pubmed\" id=\"3065405\" target=\"_blank\">",
"        3065405",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Seltzer HS, &ldquo;Drug-Induced Hypoglycemia: A Review Based on 473 Cases,&rdquo;",
"      <i>",
"       Diabetes",
"      </i>",
"      , 1972, 21(9):955-66.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?41/49/42774/abstract-text/4626706/pubmed\" id=\"4626706\" target=\"_blank\">",
"        4626706",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10003 Version 39.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-197.136.42.3-E93FDBD5C8-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f41_49_42774=[""].join("\n");
var outline_f41_49_42774=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F228919\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F228955\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F228923\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F228924\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F228925\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F228926\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F228893\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F228878\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F228898\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F228897\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F228962\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F228953\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F228901\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F228882\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F228951\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F228887\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F228915\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F228888\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F228903\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F228930\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F228904\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2524728\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F228891\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F228894\">",
"      Reference Range",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F228905\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F228881\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F228900\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/10003\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/10003|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?33/22/34148?source=related_link\">",
"      Tolbutamide: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f41_49_42775="Hydroxychloroquine-induced cardiomyopathy 400X";
var content_f41_49_42775=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RADIOL%2F87854&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RADIOL%2F87854&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 522px\">",
"   <div class=\"ttl\">",
"    Hydroxychloroquine-induced cardiomyopathy showing cardiomyocytes with Luxol stain",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 502px; height: 376px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The histopathology using Luxol fast blue stain with 400x magnification highlights the vacuolated myocardial cells which contain blue intracytoplasmic granules (arrow), characteristic of abundant lysosomes.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Aleksandr Perepletchikov, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f41_49_42775=[""].join("\n");
var outline_f41_49_42775=null;
var title_f41_49_42776="Overview of breast masses in children and adolescents";
var content_f41_49_42776=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Overview of breast masses in children and adolescents",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?41/49/42776/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?41/49/42776/contributors\">",
"     Chantay Banikarim, MD, MPH",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?41/49/42776/contributors\">",
"     Nirupama K De Silva, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?41/49/42776/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?41/49/42776/contributors\">",
"     Jan E Drutz, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?41/49/42776/contributors\">",
"     Amy B Middleman, MD, MPH, MS Ed",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?41/49/42776/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?41/49/42776/contributors\">",
"     Mary M Torchia, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?41/49/42776/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 2, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The overwhelming majority of breast masses in children and adolescents are benign and self-limited. Nonetheless, the finding of a breast mass can be disconcerting to the patient and her family [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/49/42776/abstract/1,2\">",
"     1,2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The common causes of breast masses in children and adolescents and the approach to the evaluation of an adolescent with a breast mass will be discussed below. An overview of other breast disorders and breast infections in children and adolescents, and the evaluation of breast lumps in adult women, are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/36/4680?source=see_link\">",
"     \"Mastitis and breast abscess in infants, children, and adolescents\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/37/3673?source=see_link\">",
"     \"Overview of breast disorders in children and adolescents\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/15/24825?source=see_link\">",
"     \"Breast masses and other common breast problems\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     BREAST EXAMINATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Assessment of breast masses in young females can be challenging due to normal glandular variance. Initial steps in evaluation of breast masses are obtaining a detailed history and physical examination [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/49/42776/abstract/3\">",
"     3",
"    </a>",
"    ]. The breast examination in children and adolescents and self-breast examination in adolescents are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/37/3673?source=see_link&amp;anchor=H3#H3\">",
"     \"Overview of breast disorders in children and adolescents\", section on 'Breast examination'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     CAUSES OF BREAST ENLARGEMENT IN CHILDREN",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Neonates and infants",
"    </span>",
"    &nbsp;&mdash;&nbsp;Breast hypertrophy related to stimulation from maternal hormones can occur in both male and female neonates during the first few weeks of life; it is sometimes associated with a thin milky nipple discharge (\"witch's' milk\") [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/49/42776/abstract/1\">",
"     1",
"    </a>",
"    ]. Neonatal breast hypertrophy usually resolves spontaneously within two weeks in boys and several months in girls. However, it may persist if the breast tissue is stimulated (eg, by attempting to express the milky discharge).",
"   </p>",
"   <p>",
"    Mastitis",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    breast abscess is another cause of breast enlargement in neonates. It is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/36/4680?source=see_link\">",
"     \"Mastitis and breast abscess in infants, children, and adolescents\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Prepubertal and pubertal children",
"    </span>",
"    &nbsp;&mdash;&nbsp;Breast enlargement",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    the development of a breast bud in prepubertal children may be related to thelarche or premature thelarche [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/49/42776/abstract/4\">",
"     4",
"    </a>",
"    ]. Unilateral thelarche, a firm, disc-like area of tissue under the areolar complex, typically heralds the onset of puberty (",
"    <a class=\"graphic graphic_picture graphicRef72038 \" href=\"mobipreview.htm?10/43/10932\">",
"     picture 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/49/42776/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Premature thelarche (ie, the development of breast buds before eight years of age in girls) must be distinguished from normal puberty, which usually has onset after age eight years for girls. At the onset of puberty, breast buds may be mistaken for a \"mass\", particularly if they develop on one side before the other [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/49/42776/abstract/4\">",
"     4",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/5/19546?source=see_link&amp;anchor=H3#H3\">",
"     \"Definition, etiology, and evaluation of precocious puberty\", section on 'Definition'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/25/1434?source=see_link&amp;anchor=H4#H4\">",
"     \"Normal puberty\", section on 'Sexual maturity rating (Tanner stages)'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Premature unilateral thelarche is generally benign. It has been described as a side effect of",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?42/58/43943?source=see_link\">",
"     cimetidine",
"    </a>",
"    and was reversible upon discontinuation of the drug [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/49/42776/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Bilateral premature thelarche is often an isolated finding but has been associated with hypothyroidism and also may be the first symptom of precocious puberty, particularly in girls older than two years of age [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/49/42776/abstract/1,4,7,8\">",
"     1,4,7,8",
"    </a>",
"    ]. Precocious puberty is reported in up to 18 percent of girls with premature thelarche who are followed over time [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/49/42776/abstract/9\">",
"     9",
"    </a>",
"    ]. Girls with bilateral premature thelarche should have serial examination for signs of precocious puberty [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/49/42776/abstract/9\">",
"     9",
"    </a>",
"    ]. Ultrasonography of the uterus and pelvis also may be indicated [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/49/42776/abstract/10\">",
"     10",
"    </a>",
"    ]. Young girls with bilateral premature thelarche and signs of adrenarche (eg, axillary or pubic hair) and young boys with breast buds (prepubertal gynecomastia) require evaluation to determine a specific cause (eg, adrenal, ovarian, or hypothalamic pathology, including tumors) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/49/42776/abstract/4,7\">",
"     4,7",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/5/19546?source=see_link&amp;anchor=H21089789#H21089789\">",
"     \"Definition, etiology, and evaluation of precocious puberty\", section on 'Premature thelarche'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Breast enlargement in prepubertal children also may be caused by hemangiomas or lymphangiomas [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/49/42776/abstract/2\">",
"     2",
"    </a>",
"    ]. The diagnosis of hemangioma or lymphangioma is usually made clinically but can be confirmed with ultrasonography or magnetic resonance imaging (MRI) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/49/42776/abstract/2\">",
"     2",
"    </a>",
"    ]. If there is doubt about the diagnosis, a fine needle aspiration may be necessary [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/49/42776/abstract/2\">",
"     2",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/23/5495?source=see_link\">",
"     \"Evaluation and diagnosis of infantile hemangiomas\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     CAUSES OF BREAST MASS IN FEMALE ADOLESCENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are a number of causes of breast mass in adolescents, most of which are self-limited and benign. Common benign breast lesions in adolescents include fibrocystic disease, fibroadenoma, breast trauma, and breast infection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/49/42776/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Less common benign breast lesions include mammary duct ectasia and cysts of Montgomery. Intraductal papilloma and phyllodes tumor also are usually benign, but may be malignant.",
"   </p>",
"   <p>",
"    Malignant breast lesions, which are extremely uncommon in adolescents, include primary breast cancer, metastatic cancer, and secondary cancer.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Fibrocystic change",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fibrocystic changes of the breast are common in adolescents. Although the prevalence of fibrocystic changes in adolescents is not known, more than 50 percent of women of reproductive age have fibrocystic changes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/49/42776/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The etiology is unknown, but fibrocystic changes are thought to result from an imbalance between estrogen and progesterone. Some studies have suggested that caffeine worsens the symptoms, but others have failed to demonstrate this association [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/49/42776/abstract/9,12-14\">",
"     9,12-14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients with fibrocystic change present with painful breast tissue before menses and report improvement during menstruation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/49/42776/abstract/15\">",
"     15",
"    </a>",
"    ]. On examination, fibrotic tissue may be palpated and is generally found in the upper outer quadrants of the breast; cysts are more frequent in women in their 30s and 40s. A nonbloody, serosanguineous discharge may be present [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/49/42776/abstract/15\">",
"     15",
"    </a>",
"    ]. Ultrasonography may be helpful in the diagnosis; mammography is not indicated for adolescents [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/49/42776/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The treatment of fibrocystic change in adolescents may include [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/49/42776/abstract/1,2,9\">",
"     1,2,9",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Mild analgesia (eg, nonsteroidal antiinflammatory agents, NSAIDS). In adults,",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?5/11/5301?source=see_link\">",
"       danazol",
"      </a>",
"      and",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?42/6/43111?source=see_link\">",
"       tamoxifen",
"      </a>",
"      have been effective, but these drugs have not been studied in adolescents [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/49/42776/abstract/16-18\">",
"       16-18",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?8/33/8728?source=see_link\">",
"       \"Breast pain\"",
"      </a>",
"      .) We suggest treatment with",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?7/48/7946?source=see_link\">",
"       ibuprofen",
"      </a>",
"      for adolescents.",
"     </li>",
"     <li>",
"      Oral contraceptives. Oral contraceptives improve symptoms in 70 to 90 percent of women; pills with 20 mcg of ethinyl estradiol may be better tolerated than higher doses of estrogen [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/49/42776/abstract/9,15\">",
"       9,15",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Elimination of caffeine. Although controlled studies have failed to demonstrate an association between caffeine and breast pain, limiting caffeine intake may provide relief for some patients [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/49/42776/abstract/9,12-14\">",
"       9,12-14",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Fibroadenoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fibroadenomas (also called juvenile fibroadenomas) are the most common breast lesions in adolescents [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/49/42776/abstract/1,9,15\">",
"     1,9,15",
"    </a>",
"    ]. Fibroadenomas typically are asymptomatic but may cause discomfort for a few days before the onset of menses.",
"   </p>",
"   <p>",
"    On examination, fibroadenomas are rubbery, well circumscribed, and mobile [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/49/42776/abstract/1\">",
"     1",
"    </a>",
"    ]. The average size is 2 to 3 cm (range 1 to 10 cm) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/49/42776/abstract/9\">",
"     9",
"    </a>",
"    ]. They are most frequently found in the upper, outer quadrants but may occur in any quadrant [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/49/42776/abstract/1\">",
"     1",
"    </a>",
"    ]. They have been reported to be recurrent or multiple in 10 to 25 percent of cases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/49/42776/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Fibroadenomas can be diagnosed clinically; in equivocal cases, ultrasonography",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    needle aspiration are helpful [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/49/42776/abstract/2,19\">",
"     2,19",
"    </a>",
"    ]. Ultrasonographic evaluation reveals a solid avascular mass that is well circumscribed. Mammography is not indicated to evaluate masses in the adolescent, because the large amount of glandular tissue present in adolescents makes mammography difficult to interpret [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/49/42776/abstract/2\">",
"     2",
"    </a>",
"    ]. Histologically, fibroadenomas consist of proliferating stroma.",
"   </p>",
"   <p>",
"    Management of fibroadenomas entails careful follow-up and reassurance [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/49/42776/abstract/2\">",
"     2",
"    </a>",
"    ], as most fibroadenomas in adolescents decrease in size, and some completely disappear with time [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/49/42776/abstract/11\">",
"     11",
"    </a>",
"    ]. Fibroadenomas less than 5 cm without concerning features can be observed at one to two month intervals for growth or regression. When the mass regresses, observation at three to four month intervals (with increasingly longer intervals each time) are appropriate for up to two years while the mass is regressing [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/49/42776/abstract/20\">",
"     20",
"    </a>",
"    ]. If there is persistence of the lesion, an ultrasound can be obtained. If the ultrasound characteristics are entirely consistent with a fibroadenoma, the mass need not be biopsied or excised unless there is overriding clinical concern [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/49/42776/abstract/21\">",
"     21",
"    </a>",
"    ]. The decision to proceed with excision is based on family anxiety, history of breast cancer, and the patient&rsquo;s age. As girls approach adulthood, and the risk of breast cancer therefore increases, most physicians recommend excision of persistent masses [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/49/42776/abstract/5\">",
"     5",
"    </a>",
"    ]. Reports of malignancy associated with a preexisting fibroadenoma in adolescents are rare [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/49/42776/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, if there is growth of the lesion, the lesion is greater than 5 cm, or the lesion persists to adulthood, excisional biopsy is warranted [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/49/42776/abstract/2\">",
"     2",
"    </a>",
"    ]. Disadvantages of excisional surgery include scarring at the incision site, dimpling of the breast from the removal of the tumor, damage to the breast's duct system, and mammographic changes (eg, architectural distortion, skin thickening, increased focal density).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Giant fibroadenoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Giant fibroadenomas grow rapidly to greater than 5 cm and may compress or replace normal breast tissue [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/49/42776/abstract/1\">",
"     1",
"    </a>",
"    ]. Giant fibroadenomas should be excised because they cannot be easily distinguished from phyllodes tumors by physical examination, ultrasonography, or mammography [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/49/42776/abstract/2,23\">",
"     2,23",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Phyllodes tumor",
"    </span>",
"    &nbsp;&mdash;&nbsp;Phyllodes tumor (previously called cystosarcoma phyllodes) is a rare primary tumor that typically occurs in older women but has been reported in girls as young as 10 years of age [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/49/42776/abstract/24-26\">",
"     24-26",
"    </a>",
"    ]. Although phyllodes tumors are capable of a diverse range of biologic behavior, most are benign [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/49/42776/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients present with a large breast mass that is usually painless [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/49/42776/abstract/27\">",
"     27",
"    </a>",
"    ]; the overlying skin may be shiny and stretched from rapid growth. A bloody discharge may be present if the nipple is involved. Ultrasonographic findings that are suggestive, but not diagnostic, of phyllodes tumors include lobulations, a heterogeneous echo pattern, and an absence of microcalcifications [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/49/42776/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The recommended treatment is excision; more radical measures may be indicated for malignant lesions.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Intraductal papilloma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intraductal papilloma is a rare benign breast tumor arising from proliferation of mammary duct epithelium.",
"   </p>",
"   <p>",
"    It typically presents in women between 20 and 40 years of age [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/49/42776/abstract/28\">",
"     28",
"    </a>",
"    ]. In a review of breast biopsies in adolescents, intraductal papilloma accounted for only 1.2 percent of lesions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/49/42776/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The mass arises from mammary duct cells. The clinical presentation varies from bloody nipple discharge to breast enlargement. It is bilateral in approximately one-fourth of patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/49/42776/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    On examination, well-circumscribed nodules may be palpated under the areola or in the ducts at the periphery of the breast [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/49/42776/abstract/15\">",
"     15",
"    </a>",
"    ]. Cytology of the nipple discharge demonstrates ductal cells, which differentiates it from fibrocystic disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/49/42776/abstract/1\">",
"     1",
"    </a>",
"    ]. Excision may be indicated to confirm the diagnosis and is curative.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Mammary duct ectasia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mammary duct ectasia is characterized by distention of subareolar ducts with fibrosis and inflammation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/49/42776/abstract/30\">",
"     30",
"    </a>",
"    ]. A nipple discharge (multicolored, sticky) may be present [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/49/42776/abstract/1\">",
"     1",
"    </a>",
"    ]. If the fluid in the cyst is dark, it may appear as a blue mass under the nipple (sometimes referred to as \"blue breast\") [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/49/42776/abstract/15\">",
"     15",
"    </a>",
"    ]. Ultrasonography can be helpful in making the diagnosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/49/42776/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The blocked ducts can predispose to infection, leading to mastitis or breast abscess. In addition, penetration of the duct wall by lipid material may be associated with fever and acute local pain and tenderness.",
"   </p>",
"   <p>",
"    Mammary duct ectasia often resolves spontaneously, sometimes with a residual subareolar nodule [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/49/42776/abstract/5\">",
"     5",
"    </a>",
"    ]. Surgical excision may be warranted for persistent or recurrent symptoms or an associated persistent cyst [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/49/42776/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Montgomery tubercles",
"    </span>",
"    &nbsp;&mdash;&nbsp;The periareolar glands of Montgomery (Montgomery tubercles, also called Morgagni tubercles) (",
"    <a class=\"graphic graphic_figure graphicRef76928 \" href=\"mobipreview.htm?26/62/27621\">",
"     figure 1",
"    </a>",
"    ) are small papular projections at the edge of the areola that may play a role in lactation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/49/42776/abstract/2\">",
"     2",
"    </a>",
"    ]. Obstruction of these glands may result in acute inflammation, an asymptomatic subareolar mass (cyst of Montgomery),",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    drainage of clear to brownish fluid [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/49/42776/abstract/15,32,33\">",
"     15,32,33",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The diagnosis of a cyst of Montgomery (also called a retroareolar cyst) can be made clinically. However, it may be confirmed with ultrasonography, which most commonly demonstrates a single cystic lesion located in the retroareolar area [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/49/42776/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Management depends upon associated symptoms. If there are signs of infection (eg, erythema, warmth, tenderness), treatment for mastitis should be initiated. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/36/4680?source=see_link&amp;anchor=H16#H16\">",
"     \"Mastitis and breast abscess in infants, children, and adolescents\", section on 'Management'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In the absence of acute infection or other complications, cysts of Montgomery are observed with serial examination and repeat ultrasonography, if necessary [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/49/42776/abstract/2\">",
"     2",
"    </a>",
"    ]. More than 80 percent resolve spontaneously over weeks to months, but resolution may take up to two years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/49/42776/abstract/2,32\">",
"     2,32",
"    </a>",
"    ]. In rare cases, drainage is necessary. Resection may be warranted if the cyst persists or the diagnosis is in question [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/49/42776/abstract/9,15\">",
"     9,15",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Breast trauma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Trauma to the breast (eg, direct blows to the breast, seatbelt injury) may result in fat necrosis, which can resemble a solid mass [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/49/42776/abstract/1,15,34\">",
"     1,15,34",
"    </a>",
"    ]. The radiographic and clinical significance of fat necrosis of the breast is that it can mimic a breast malignancy. Though rare in adolescents, if malignancy is suspected based on symptoms, physical findings, and imaging, biopsy may be warranted.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Breast infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Breast infection in adolescents is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/36/4680?source=see_link\">",
"     \"Mastitis and breast abscess in infants, children, and adolescents\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Primary breast cancer",
"    </span>",
"    &nbsp;&mdash;&nbsp;Primary breast cancer is exceedingly rare in children and adolescents [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/49/42776/abstract/2,11,22,28,35-39\">",
"     2,11,22,28,35-39",
"    </a>",
"    ]. Surveillance Epidemiology and End Results (SEER) data from 1975 to 2006 lists no incident cases of breast cancer in situ in females less than 20 years and publishes an incidence of invasive breast cancer of",
"    <span class=\"nowrap\">",
"     0.2/100,000",
"    </span>",
"    for females between 15 and 19 years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/49/42776/abstract/40\">",
"     40",
"    </a>",
"    ]. Juvenile secretory carcinoma was most common (more than 80 percent of cases), followed by intraductal carcinoma. Rhabdomyosarcoma and lymphoma also may occur as a primary tumor of the breast [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/49/42776/abstract/41\">",
"     41",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/63/16377?source=see_link\">",
"     \"Rhabdomyosarcoma and undifferentiated sarcoma in childhood and adolescence: Epidemiology, pathology, and molecular pathogenesis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The most common examination finding of breast cancer in adolescents is a hard, irregular mass [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/49/42776/abstract/1,7,28,37\">",
"     1,7,28,37",
"    </a>",
"    ]. The mass may or may not be fixed to the underlying tissue. Additional findings may include skin or nipple retraction, skin edema (peau d'orange), nipple involvement, nipple discharge, and axillary or supraclavicular lymphadenopathy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/49/42776/abstract/7,42,43\">",
"     7,42,43",
"    </a>",
"    ]. Metastatic breast cancer may cause dyspnea, generalized skin rash, limb swelling, back pain, and hepatomegaly.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Risk factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Effective and accurate counseling for adolescents and their parents regarding breast cancer prevention should be a routine component of preventive health services for adolescents. Risk factors for breast cancer that may affect adolescent patients include a family history of breast cancer and exposure to radiation. Smoking, alcohol consumption, and limited physical activity have also been associated with breast cancer. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/17/28954?source=see_link\">",
"     \"Factors that modify breast cancer risk in women\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Family history &ndash; A positive family history on either the maternal or paternal side is one of the most significant risk factors for breast cancer. Between 20 to 30 percent of women with breast cancer have at least one relative with the disease [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/49/42776/abstract/44-46\">",
"       44-46",
"      </a>",
"      ]. However, only 5 to 10 percent have a true hereditary predisposition [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/49/42776/abstract/46,47\">",
"       46,47",
"      </a>",
"      ]. Most hereditary breast cancers arise from mutations in the genes",
"      <em>",
"       BRCA1",
"      </em>",
"      on chromosome 17 and",
"      <em>",
"       BRCA2",
"      </em>",
"      on chromosome 13, which are thought to function as tumor suppressor genes. Mutations in these genes are inherited in an autosomal dominant fashion. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?42/63/44025?source=see_link\">",
"       \"Characteristics of hereditary breast and ovarian cancer syndromes\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?31/31/32249?source=see_link\">",
"       \"Genetic testing for hereditary breast and ovarian cancer syndrome\"",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      Surveillance for breast cancer in adolescents with",
"      <em>",
"       BRCA1",
"      </em>",
"      or",
"      <em>",
"       BRCA2",
"      </em>",
"      mutations, including frequency of self-breast examination, clinical breast examination, and imaging, is discussed separately. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?17/0/17418?source=see_link&amp;anchor=H779411428#H779411428\">",
"       \"Management of hereditary breast and ovarian cancer syndrome and patients with BRCA mutations\", section on 'Cancer surveillance'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Radiation exposure &ndash; Exposure to ionizing radiation (eg, radiation therapy to the chest) is a risk factor for secondary breast cancer in adolescents. Women exposed to ionizing radiation should have biannual breast examination by a healthcare provider [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/49/42776/abstract/48\">",
"       48",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Metastatic cancer",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the adolescent age group, most malignant breast masses are metastatic from other cancers such as Hodgkin, non-Hodgkin, or neuroblastomas, hepatocellular carcinoma, and rhabdomyosarcoma [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/49/42776/abstract/5,28,35,49-51\">",
"     5,28,35,49-51",
"    </a>",
"    ]. (See appropriate topic reviews).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Secondary cancer",
"    </span>",
"    &nbsp;&mdash;&nbsp;Secondary cancers, including carcinomas, are another category of tumors of the breast that may occur in adolescents [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/49/42776/abstract/52\">",
"     52",
"    </a>",
"    ]. Secondary cancers typically occur after radiation therapy to the chest to treat another illness (eg, for Hodgkin lymphoma) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/49/42776/abstract/51,53\">",
"     51,53",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     APPROACH TO BREAST MASS IN THE FEMALE ADOLESCENT PATIENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The majority of adolescent patients who present with a breast mass have normal physiologic breast tissue or fibrocystic changes; breast cancer is extremely rare [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/49/42776/abstract/15\">",
"     15",
"    </a>",
"    ]. For most adolescent patients who present with a breast mass, after a careful history and examination to rule out life-threatening disease, it is reasonable to observe the mass through one or two menstrual cycles [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/49/42776/abstract/9,28,54\">",
"     9,28,54",
"    </a>",
"    ]. This approach is based on the observations that most adolescents who present to their primary care clinician with breast lumps have normal nodularity or fibrocystic change, and that most breast masses that are surgically excised are fibroadenomas [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/49/42776/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     History",
"    </span>",
"    &nbsp;&mdash;&nbsp;Important aspects of the history for the adolescent patient with a breast mass include [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/49/42776/abstract/7,15\">",
"     7,15",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Duration and size of mass",
"     </li>",
"     <li>",
"      Associated symptoms, including nipple discharge (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?3/37/3673?source=see_link&amp;anchor=H19#H19\">",
"       \"Overview of breast disorders in children and adolescents\", section on 'Nipple discharge'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Previous breast disease",
"     </li>",
"     <li>",
"      Previous or intercurrent malignancy or chest irradiation",
"     </li>",
"     <li>",
"      Chronology of the development of secondary sexual characteristics",
"     </li>",
"     <li>",
"      Menstrual history",
"     </li>",
"     <li>",
"      Pregnancy history",
"     </li>",
"     <li>",
"      Medication history (oral contraceptive pills,",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?42/58/43943?source=see_link\">",
"       cimetidine",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Family history of breast disease and breast cancer",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;Important aspects of the examination include [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/49/42776/abstract/7,15\">",
"     7,15",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Location of the mass &ndash; Fibrocystic change and fibroadenoma are usually located in the upper outer breast quadrants. The well-circumscribed nodules of intraductal papilloma may be located under the areola or in the ducts at the breast periphery. Mammary duct ectasia and cysts of Montgomery are subareolar.",
"     </li>",
"     <li>",
"      Consistency of the mass (cystic versus solid) &ndash; Mammary duct ectasia and cysts of Montgomery are cystic, whereas fibroadenoma, phyllodes tumors, fat necrosis, and malignant breast tumors are usually solid.",
"     </li>",
"     <li>",
"      Size of the mass &ndash; Fibroadenomas are usually smaller than phyllodes tumors (average of 2 to 3 cm versus 7 cm) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/49/42776/abstract/9,27\">",
"       9,27",
"      </a>",
"      ]. The size of the mass can be monitored through the menstrual cycle.",
"     </li>",
"     <li>",
"      Mobility of the mass &ndash; Fibroadenomas are usually mobile, whereas malignant breast tumors are usually (but not always) fixed to the underlying tissue.",
"     </li>",
"     <li>",
"      Tenderness &ndash; Tenderness may be present before the onset of menses in adolescents with fibrocystic change and fibroadenoma. Tenderness also may occur in patients with infection or trauma.",
"     </li>",
"     <li>",
"      Overlying skin changes &ndash; Overlying skin changes may occur in large fibroadenomas, phyllodes tumors (the skin is shiny and stretched from rapid growth), and in breast cancer (peau d'orange, retraction).",
"     </li>",
"     <li>",
"      Nipple discharge &ndash; Nipple discharge may occur in fibrocystic disease (nonbloody green or brown), cysts of Montgomery (clear to brown), intraductal papilloma (bloody), mammary duct ectasia (multicolored, sticky), phyllodes tumor (bloody), infection (purulent) and breast cancer (bloody).",
"     </li>",
"     <li>",
"      Appearance of the nipple &ndash; The nipple may appear to be blue or to have a blue mass under it in patients with mammary duct ectasia. Nipple retraction may occur in patients with breast cancer.",
"     </li>",
"     <li>",
"      Lymphadenopathy &ndash; Lymphadenopathy may be present in patients with breast infection or cancer.",
"     </li>",
"     <li>",
"      Hepatosplenomegaly &ndash; Hepatosplenomegaly may be an indication of metastatic cancer.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Imaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;Imaging may be necessary to differentiate cystic from solid masses or if the mass persists for more than one or two menstrual cycles (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef82129 \" href=\"mobipreview.htm?38/22/39266\">",
"     image 1",
"    </a>",
"    ). Ultrasonography is the preferred imaging modality for breast masses in adolescents because of the increased density of the adolescent breast; the large amount of fibroglandular tissue makes mammography difficult to interpret [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/49/42776/abstract/5,31,50,55\">",
"     5,31,50,55",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The accuracy of ultrasonography in differentiating solid from cystic lesions is 96 to 100 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/49/42776/abstract/56-59\">",
"     56-59",
"    </a>",
"    ]. Ultrasonography also can be helpful in differentiating a fibroadenoma from a simple cyst or galactocele and in determining the extent of a breast abscess [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/49/42776/abstract/15,55\">",
"     15,55",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Subsequent management",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Asymptomatic solid breast masses that are &lt;5 cm and consistent with a fibroadenoma can be observed [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/49/42776/abstract/15\">",
"       15",
"      </a>",
"      ]. Cystic lesions (eg, related to fibrocystic changes, mammary duct ectasia, Montgomery tubercles) typically resolve spontaneously over weeks to months.",
"     </li>",
"     <li>",
"      Persistent cystic breast lesions can be evaluated",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      treated with needle aspiration, although this technique is rarely necessary in children and adolescents [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/49/42776/abstract/15\">",
"       15",
"      </a>",
"      ]. Aspirated fluid that is clear may be discarded [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/49/42776/abstract/2\">",
"       2",
"      </a>",
"      ]. Bloody fluid and other aspirated material should be sent for cytology [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/49/42776/abstract/2,15,60\">",
"       2,15,60",
"      </a>",
"      ]. Cystic lesions that resolve with aspiration should be reevaluated with ultrasonography three months after aspiration [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/49/42776/abstract/15\">",
"       15",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Surgical resection (excisional biopsy) may be warranted for cystic lesions that do not resolve with aspiration, when aspiration is not productive or not feasible, and for suspicious solid lesions [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/49/42776/abstract/15\">",
"       15",
"      </a>",
"      ]. Suspicious solid lesions include those that are nonmobile, hard, enlarging, associated with skin changes, hepatosplenomegaly, or adenopathy, or are a source of considerable anxiety for the patient and caregivers.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Breast masses in neonates may be caused by stimulation from maternal hormones or infection. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Neonates and infants'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?4/36/4680?source=see_link\">",
"       \"Mastitis and breast abscess in infants, children, and adolescents\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The development of breast buds in pubertal children is usually the first sign of puberty. The development of breast buds in prepubertal children may indicate premature thelarche or precocious puberty. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Prepubertal and pubertal children'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?1/25/1434?source=see_link\">",
"       \"Normal puberty\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?19/5/19546?source=see_link\">",
"       \"Definition, etiology, and evaluation of precocious puberty\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      There are a number of causes of breast mass in adolescents, most of which are self-limited and benign. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Causes of breast mass in female adolescents'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Fibroadenoma is the most common breast lesion in adolescents. Fibroadenomas are rubbery, well-circumscribed, mobile masses with an average of size of 2 to 3 cm. They may cause discomfort for a few days before the onset of menses. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Fibroadenoma'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Breast cancer is exceedingly rare in children and adolescents. Predisposing factors include a family history of hereditary breast cancer and exposure to ionizing radiation. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Primary breast cancer'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The initial approach to the adolescent patient with a breast mass includes a careful history and physical examination. (See",
"      <a class=\"local\" href=\"#H21\">",
"       'History'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H22\">",
"       'Examination'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Imaging may be necessary to differentiate cystic from solid masses or if the mass persists through more than one menstrual cycle. Ultrasonography is the preferred imaging modality for breast masses in adolescents. (See",
"      <a class=\"local\" href=\"#H23\">",
"       'Imaging'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The subsequent management of the adolescent with a breast mass depends upon the type of mass that is present. (See",
"      <a class=\"local\" href=\"#H24\">",
"       'Subsequent management'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Aspiration may be warranted for persistent cystic lesions.",
"     </li>",
"     <li>",
"      Excisional biopsy may be warranted for cystic lesions that do not resolve with aspiration, when aspiration is not productive or not feasible, and for suspicious solid lesions (eg, those that are nonmobile, hard, enlarging, associated with skin changes, hepatosplenomegaly, or adenopathy).",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/49/42776/abstract/1\">",
"      Greydanus DE, Matytsina L, Gains M. Breast disorders in children and adolescents. Prim Care 2006; 33:455.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/49/42776/abstract/2\">",
"      De Silva NK, Brandt ML. Disorders of the breast in children and adolescents, Part 2: breast masses. J Pediatr Adolesc Gynecol 2006; 19:415.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/49/42776/abstract/3\">",
"      Vargas HI, Vargas MP, Eldrageely K, et al. Outcomes of surgical and sonographic assessment of breast masses in women younger than 30. Am Surg 2005; 71:716.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/49/42776/abstract/4\">",
"      De Silva NK, Brandt ML. Disorders of the breast in children and adolescents, Part 1: Disorders of growth and infections of the breast. J Pediatr Adolesc Gynecol 2006; 19:345.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/49/42776/abstract/5\">",
"      West KW, Rescorla FJ, Scherer LR 3rd, Grosfeld JL. Diagnosis and treatment of symptomatic breast masses in the pediatric population. J Pediatr Surg 1995; 30:182.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/49/42776/abstract/6\">",
"      Bosman JM, Bax NM, Wit JM. Premature thelarche: a possible adverse effect of cimetidine treatment. Eur J Pediatr 1990; 149:534.",
"     </a>",
"    </li>",
"    <li>",
"     Baren JM. Breast lesions. In: Textbook of Pediatric Emergency Medicine, 5th, Fleisher GR, Ludwig S, Henretig FM (Eds), Lippincott Williams and Wilkins, Philadelphia 2006. p.193.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/49/42776/abstract/8\">",
"      Verrotti A, Ferrari M, Morgese G, Chiarelli F. Premature thelarche: a long-term follow-up. Gynecol Endocrinol 1996; 10:241.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/49/42776/abstract/9\">",
"      Templeman C, Hertweck SP. Breast disorders in the pediatric and adolescent patient. Obstet Gynecol Clin North Am 2000; 27:19.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/49/42776/abstract/10\">",
"      Bock K, Duda VF, Hadji P, et al. Pathologic breast conditions in childhood and adolescence: evaluation by sonographic diagnosis. J Ultrasound Med 2005; 24:1347.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/49/42776/abstract/11\">",
"      ACOG Committee on Adolescent Health Care. ACOG Committee Opinion No. 350, November 2006: Breast concerns in the adolescent. Obstet Gynecol 2006; 108:1329.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/49/42776/abstract/12\">",
"      Schairer C, Brinton LA, Hoover RN. Methylxanthines and benign breast disease. Am J Epidemiol 1986; 124:603.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/49/42776/abstract/13\">",
"      Levinson W, Dunn PM. Nonassociation of caffeine and fibrocystic breast disease. Arch Intern Med 1986; 146:1773.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/49/42776/abstract/14\">",
"      Jacobson MF, Liebman BF. Caffeine and benign breast disease. JAMA 1986; 255:1438.",
"     </a>",
"    </li>",
"    <li>",
"     DiVasta AD, Weldon C, Labow BI. The breast: Examination and lesions. In: Emans, Laufer, Goldstein's Pediatric &amp; Adolescent Gynecology, 6th, Emans SJ, Laufer MR.  (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2012. p.405.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/49/42776/abstract/16\">",
"      Gumm R, Cunnick GH, Mokbel K. Evidence for the management of mastalgia. Curr Med Res Opin 2004; 20:681.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/49/42776/abstract/17\">",
"      Pye JK, Mansel RE, Hughes LE. Clinical experience of drug treatments for mastalgia. Lancet 1985; 2:373.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/49/42776/abstract/18\">",
"      Faiz O, Fentiman IS. Management of breast pain. Int J Clin Pract 2000; 54:228.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/49/42776/abstract/19\">",
"      Fornage BD, Lorigan JG, Andry E. Fibroadenoma of the breast: sonographic appearance. Radiology 1989; 172:671.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/49/42776/abstract/20\">",
"      Jayasinghe Y, Simmons PS. Fibroadenomas in adolescence. Curr Opin Obstet Gynecol 2009; 21:402.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/49/42776/abstract/21\">",
"      Smith GE, Burrows P. Ultrasound diagnosis of fibroadenoma - is biopsy always necessary? Clin Radiol 2008; 63:511.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/49/42776/abstract/22\">",
"      Tea MK, Asseryanis E, Kroiss R, et al. Surgical breast lesions in adolescent females. Pediatr Surg Int 2009; 25:73.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/49/42776/abstract/23\">",
"      Chao TC, Lo YF, Chen SC, Chen MF. Sonographic features of phyllodes tumors of the breast. Ultrasound Obstet Gynecol 2002; 20:64.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/49/42776/abstract/24\">",
"      Parker SJ, Harries SA. Phyllodes tumours. Postgrad Med J 2001; 77:428.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/49/42776/abstract/25\">",
"      Alabassi A, Fentiman IS. Sarcomas of the breast. Int J Clin Pract 2003; 57:886.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/49/42776/abstract/26\">",
"      Pistolese CA, Tanga I, Cossu E, et al. A phyllodes tumor in a child. J Pediatr Adolesc Gynecol 2009; 22:e21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/49/42776/abstract/27\">",
"      Reinfuss M, Mitu J, Duda K, et al. The treatment and prognosis of patients with phyllodes tumor of the breast: an analysis of 170 cases. Cancer 1996; 77:910.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/49/42776/abstract/28\">",
"      Oberman HA, Stephens PJ. Carcinoma of the breast in childhood. Cancer 1972; 30:470.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/49/42776/abstract/29\">",
"      Neinstein LS. Review of breast masses in adolescents. Adolesc Pediatr Gynecol 1994; 7:119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/49/42776/abstract/30\">",
"      Schwartz GF. Benign neoplasms and \"inflammations\" of the breast. Clin Obstet Gynecol 1982; 25:373.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/49/42776/abstract/31\">",
"      Garc&iacute;a CJ, Espinoza A, Dinamarca V, et al. Breast US in children and adolescents. Radiographics 2000; 20:1605.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/49/42776/abstract/32\">",
"      Huneeus A, Schilling A, Horvath E, et al. Retroareolar cysts in the adolescent. J Pediatr Adolesc Gynecol 2003; 16:45.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/49/42776/abstract/33\">",
"      Watkins F, Giacomantonio M, Salisbury S. Nipple discharge and breast lump related to Montgomery's tubercles in adolescent females. J Pediatr Surg 1988; 23:718.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/49/42776/abstract/34\">",
"      Williams HJ, Hejmadi RK, England DW, Bradley SA. Imaging features of breast trauma: a pictorial review. Breast 2002; 11:107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/49/42776/abstract/35\">",
"      Corpron CA, Black CT, Singletary SE, Andrassy RJ. Breast cancer in adolescent females. J Pediatr Surg 1995; 30:322.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/49/42776/abstract/36\">",
"      Bhatia S, Robison LL, Oberlin O, et al. Breast cancer and other second neoplasms after childhood Hodgkin's disease. N Engl J Med 1996; 334:745.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/49/42776/abstract/37\">",
"      Dixon JM, Mansel RE. ABC of breast diseases. Congenital problems and aberrations of normal breast development and involution. BMJ 1994; 309:797.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/49/42776/abstract/38\">",
"      Ravichandran D, Naz S. A study of children and adolescents referred to a rapid diagnosis breast clinic. Eur J Pediatr Surg 2006; 16:303.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/49/42776/abstract/39\">",
"      Longo OA, Mosto A, Moran JC, et al. Breast Carcinoma in Childhood and Adolescence: Case Report and Review of the Literature. Breast J 1999; 5:65.",
"     </a>",
"    </li>",
"    <li>",
"     Ries, LAG, Melbert, D, Krapcho, M, et al (Eds). SEER Cancer Statistics Review, 1975-2005, National Cancer Institute. Bethesda, MD. Available at: seer.cancer.gov/csr/1975_2005/. Accessed on December 10, 2009.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/49/42776/abstract/41\">",
"      Binokay F, Soyupak SK, Inal M, et al. Primary and metastatic rhabdomyosarcoma in the breast: report of two pediatric cases. Eur J Radiol 2003; 48:282.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/49/42776/abstract/42\">",
"      Marchant DJ. History, physical examination, and breast self-examination. Clin Obstet Gynecol 1982; 25:359.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/49/42776/abstract/43\">",
"      Wile AG, Kollin M. Office management of the breast mass. Postgrad Med 1987; 81:137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/49/42776/abstract/44\">",
"      Slattery ML, Kerber RA. A comprehensive evaluation of family history and breast cancer risk. The Utah Population Database. JAMA 1993; 270:1563.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/49/42776/abstract/45\">",
"      Claus EB, Risch NJ, Thompson WD. Age at onset as an indicator of familial risk of breast cancer. Am J Epidemiol 1990; 131:961.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/49/42776/abstract/46\">",
"      Collaborative Group on Hormonal Factors in Breast Cancer. Familial breast cancer: collaborative reanalysis of individual data from 52 epidemiological studies including 58,209 women with breast cancer and 101,986 women without the disease. Lancet 2001; 358:1389.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/49/42776/abstract/47\">",
"      Claus EB, Schildkraut JM, Thompson WD, Risch NJ. The genetic attributable risk of breast and ovarian cancer. Cancer 1996; 77:2318.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/49/42776/abstract/48\">",
"      Hammar B. Childhood breast carcinoma: report of a case. J Pediatr Surg 1981; 16:77.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/49/42776/abstract/49\">",
"      Rogers DA, Lobe TE, Rao BN, et al. Breast malignancy in children. J Pediatr Surg 1994; 29:48.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/49/42776/abstract/50\">",
"      Chateil JF, Arboucalot F, P&eacute;rel Y, et al. Breast metastases in adolescent girls: US findings. Pediatr Radiol 1998; 28:832.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/49/42776/abstract/51\">",
"      Howarth CB, Caces JN, Pratt CB. Breast metastases in children with rhabdomyosarcoma. Cancer 1980; 46:2520.",
"     </a>",
"    </li>",
"    <li>",
"     Pappo AS, Rodriguez-Galindo C, Furman WL. Management of infrequent cancers of childhood. In: Principles and Practice of Pediatric Oncology, 6th ed, Pizzo PA, Poplack DG (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2011. p.1098.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/49/42776/abstract/53\">",
"      Raj KA, Marks LB, Prosnitz RG. Late effects of breast radiotherapy in young women. Breast Dis 2005; 23:53.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/49/42776/abstract/54\">",
"      Carty NJ, Carter C, Rubin C, et al. Management of fibroadenoma of the breast. Ann R Coll Surg Engl 1995; 77:127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/49/42776/abstract/55\">",
"      Kaneda HJ, Mack J, Kasales CJ, Schetter S. Pediatric and adolescent breast masses: a review of pathophysiology, imaging, diagnosis, and treatment. AJR Am J Roentgenol 2013; 200:W204.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/49/42776/abstract/56\">",
"      Sickles EA, Filly RA, Callen PW. Benign breast lesions: ultrasound detection and diagnosis. Radiology 1984; 151:467.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/49/42776/abstract/57\">",
"      Egan RL, Egan KL. Automated water-path full-breast sonography: correlation with histology of 176 solid lesions. AJR Am J Roentgenol 1984; 143:499.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/49/42776/abstract/58\">",
"      Hilton SV, Leopold GR, Olson LK, Willson SA. Real-time breast sonography: application in 300 consecutive patients. AJR Am J Roentgenol 1986; 147:479.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/49/42776/abstract/59\">",
"      Jellins J, Kossoff G, Reeve TS. Detection and classification of liquid-filled masses in the breast by gray scale echography. Radiology 1977; 125:205.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/49/42776/abstract/60\">",
"      Hindle WH, Arias RD, Florentine B, Whang J. Lack of utility in clinical practice of cytologic examination of nonbloody cyst fluid from palpable breast cysts. Am J Obstet Gynecol 2000; 182:1300.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 104 Version 12.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0505-122.72.76.133-D6C6C51ACA-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f41_49_42776=[""].join("\n");
var outline_f41_49_42776=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H25\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      BREAST EXAMINATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      CAUSES OF BREAST ENLARGEMENT IN CHILDREN",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Neonates and infants",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Prepubertal and pubertal children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      CAUSES OF BREAST MASS IN FEMALE ADOLESCENTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Fibrocystic change",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Fibroadenoma",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Giant fibroadenoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Phyllodes tumor",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Intraductal papilloma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Mammary duct ectasia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Montgomery tubercles",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Breast trauma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Breast infection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Primary breast cancer",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Risk factors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Metastatic cancer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Secondary cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      APPROACH TO BREAST MASS IN THE FEMALE ADOLESCENT PATIENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      History",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Examination",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Imaging",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Subsequent management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PEDS/104\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/104|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?38/22/39266\" title=\"diagnostic image 1\">",
"      Cystic breast mass US",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/104|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?26/62/27621\" title=\"figure 1\">",
"      Nipple and breast anatomy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/104|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?10/43/10932\" title=\"picture 1\">",
"      Sexual maturity rating of breast development in girls",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/15/24825?source=related_link\">",
"      Breast masses and other common breast problems",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?8/33/8728?source=related_link\">",
"      Breast pain",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/63/44025?source=related_link\">",
"      Characteristics of hereditary breast and ovarian cancer syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/5/19546?source=related_link\">",
"      Definition, etiology, and evaluation of precocious puberty",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?5/23/5495?source=related_link\">",
"      Evaluation and diagnosis of infantile hemangiomas",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/17/28954?source=related_link\">",
"      Factors that modify breast cancer risk in women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/31/32249?source=related_link\">",
"      Genetic testing for hereditary breast and ovarian cancer syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?17/0/17418?source=related_link\">",
"      Management of hereditary breast and ovarian cancer syndrome and patients with BRCA mutations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?4/36/4680?source=related_link\">",
"      Mastitis and breast abscess in infants, children, and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?1/25/1434?source=related_link\">",
"      Normal puberty",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?3/37/3673?source=related_link\">",
"      Overview of breast disorders in children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/63/16377?source=related_link\">",
"      Rhabdomyosarcoma and undifferentiated sarcoma in childhood and adolescence: Epidemiology, pathology, and molecular pathogenesis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f41_49_42777="Microalbuminuria in type 1 diabetes mellitus";
var content_f41_49_42777=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Microalbuminuria in type 1 diabetes mellitus",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?41/49/42777/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?41/49/42777/contributors\">",
"     David K McCulloch, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?41/49/42777/contributors\">",
"     George L Bakris, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?41/49/42777/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?41/49/42777/contributors\">",
"     Richard J Glassock, MD, MACP",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?41/49/42777/contributors\">",
"     David M Nathan, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?41/49/42777/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?41/49/42777/contributors\">",
"     John P Forman, MD, MSc",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?41/49/42777/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 29, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION AND DEFINITIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Increased urinary protein excretion is the earliest clinical manifestation of diabetic nephropathy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/49/42777/abstract/1-5\">",
"     1-5",
"    </a>",
"    ]. However, when assessing protein excretion, the urine dipstick is a relatively insensitive marker for initial increases in protein excretion, not becoming positive until protein excretion exceeds 300 to 500",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    (upper limit of normal less than 150",
"    <span class=\"nowrap\">",
"     mg/day,",
"    </span>",
"    with most individuals excreting less than 100",
"    <span class=\"nowrap\">",
"     mg/day).",
"    </span>",
"   </p>",
"   <p>",
"    Using",
"    a specific assay for albumin is a more sensitive technique. The normal rate of albumin excretion is less than 20",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    (15",
"    <span class=\"nowrap\">",
"     &micro;g/min);",
"    </span>",
"    persistent albumin excretion between 30 and 300",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    (20 to 200",
"    <span class=\"nowrap\">",
"     &micro;g/min)",
"    </span>",
"    is called microalbuminuria and, in patients with diabetes (particularly type 1 diabetes), persistent microalbuminuria may be indicative of early diabetic nephropathy unless there is some coexistent renal disease. Albumin excretion above 300",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    (200",
"    <span class=\"nowrap\">",
"     &micro;g/min)",
"    </span>",
"    is considered to represent macroalbuminuria (also called overt proteinuria, clinical renal disease, or dipstick positive proteinuria) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/49/42777/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although these cut-offs defining normoalbuminuria, microalbuminuria, and macroalbuminuria facilitate determining the risk for subsequent progression of nephropathy, the later risk of developing overt diabetic nephropathy is probably directly associated with albumin excretion rates at all levels above the normal excretion rate.",
"   </p>",
"   <p>",
"    The clinical significance, screening, and management of microalbuminuria in patients with type 1 diabetes will be reviewed here. In addition to being a possible marker of early diabetic nephropathy in both type 1 and type 2 diabetes, microalbuminuria is also associated with cardiovascular disease in both diabetic and nondiabetic patients.",
"   </p>",
"   <p>",
"    The significance of microalbuminuria in patients with type 2 diabetes, the association of microalbuminuria with cardiovascular risk, and the treatment of overt diabetic nephropathy are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/33/39449?source=see_link\">",
"     \"Microalbuminuria in type 2 diabetes mellitus\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/16/20745?source=see_link\">",
"     \"High albuminuria (microalbuminuria) and cardiovascular disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/48/40714?source=see_link\">",
"     \"Treatment of diabetic nephropathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     DETECTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Establishing the diagnosis of microalbuminuria requires the demonstration of an elevation in albumin excretion that persists over a three- to six-month period. Fever, exercise, heart failure, and poor glycemic control are among the factors that can cause transient microalbuminuria [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/49/42777/abstract/7\">",
"     7",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/37/13914?source=see_link\">",
"     \"Assessment of urinary protein excretion and evaluation of isolated non-nephrotic proteinuria in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Urine albumin concentration",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although the 24-hour urine collection was the initial gold standard for the detection of microalbuminuria [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/49/42777/abstract/7,8\">",
"     7,8",
"    </a>",
"    ], it has been suggested that screening can be more simply achieved by a timed urine collection or measurement of the urine albumin concentration on an early morning specimen to minimize changes in urine volume that occur during the day [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/49/42777/abstract/7,9\">",
"     7,9",
"    </a>",
"    ]. Microalbuminuria is unlikely if the albumin excretion rate is below 20",
"    <span class=\"nowrap\">",
"     &micro;g/min",
"    </span>",
"    in a timed collection or the urine albumin concentration is less than 20 to 30",
"    <span class=\"nowrap\">",
"     mg/L",
"    </span>",
"    in a random specimen. Higher values (particularly those just above this range) may represent false positive results, and should be confirmed by repeated measurements [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/49/42777/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There are also a variety of semiquantitative dipsticks, such as Clinitek Microalbumin Dipsticks and Micral-Test II test strips, which can be used to test for microalbuminuria if urine albumin excretion cannot be directly measured [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/49/42777/abstract/2\">",
"     2",
"    </a>",
"    ]. The reported sensitivity and specificity of these tests range from 80 to 97 percent and 33 to 80 percent, respectively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/49/42777/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    One problem with measuring the urine albumin concentration or estimating it with a sensitive dipstick is that false negative and false positive results can occur, since the urine albumin concentration is determined by the urine volume and the amount of albuminuria [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/49/42777/abstract/11\">",
"     11",
"    </a>",
"    ]. Thus, at a particular rate of albumin excretion, a substantial increase or decrease in urine volume will respectively lower and raise the urine albumin concentration. The confounding effect of the urine volume can be minimized by repeated measurements on early morning specimens [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/49/42777/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Urine albumin-to-creatinine ratio",
"    </span>",
"    &nbsp;&mdash;&nbsp;The confounding effect of variations in urine volume on the urine albumin concentration can be avoided by calculation of the urine albumin-to-creatinine ratio in an untimed urine specimen. A value of 30 to 300",
"    <span class=\"nowrap\">",
"     mg/g",
"    </span>",
"    of creatinine (or, using standard [SI] units, 3.4 to 34",
"    <span class=\"nowrap\">",
"     mg/mmol",
"    </span>",
"    of creatinine) suggests that albumin excretion is between 30 and 300",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    and, therefore, that microalbuminuria is probably present [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/49/42777/abstract/1\">",
"     1",
"    </a>",
"    ]. Values above 300",
"    <span class=\"nowrap\">",
"     mg/g",
"    </span>",
"    (or 34",
"    <span class=\"nowrap\">",
"     mg/mmol)",
"    </span>",
"    are indicative of macroalbuminuria. This classification system requires that at least two of three specimens fall within the microalbuminuric or macroalbuminuric range obtained over a three- to six-month period [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/49/42777/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In one report, 24-hour urine collections and random, single-void urine specimens for albumin and creatinine were obtained in 14 normal subjects, 13 with type 1 diabetes, and 12 with type 2 diabetes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/49/42777/abstract/12\">",
"     12",
"    </a>",
"    ]. A close correlation was noted between the two measurements and the within-patient variability was very small. A random albumin-to-creatinine ratio above 30",
"    <span class=\"nowrap\">",
"     mg/g",
"    </span>",
"    had a sensitivity of 100 percent for the detection of microalbuminuria. Similar findings have been noted by others [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/49/42777/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Limitations",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are three important caveats that must be considered to maximize the reliability of the urine albumin-to-creatinine ratio.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The optimal time to measure the urine albumin-to-creatinine ratio is uncertain. The best data come from reports that primarily evaluated patients without diabetes. In a 1983 study, the best correlation with a 24-hour urine collection occurred with samples obtained after the first morning void and before bedtime [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/49/42777/abstract/13\">",
"       13",
"      </a>",
"      ]. In contrast, a later and larger study found the best correlation with the first morning void, although the difference compared to spot urine samples at other times was not significant [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/49/42777/abstract/14\">",
"       14",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Given the uncertainty, we have a slight preference for first morning void specimens. If this is inconvenient, specimens can be obtained at other times during the day. There are no data about the timing of repeat measurements as the patient's course is being monitored. If possible, it seems preferable to obtain the samples at approximately the same time of day.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Vigorous exercise can cause a transient increase in albumin excretion [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/49/42777/abstract/15\">",
"       15",
"      </a>",
"      ]. As a result, patients should refrain from vigorous exercise in the 24 hours prior to the test.",
"     </li>",
"     <li>",
"      The accuracy of the urine albumin-to-creatinine ratio will be diminished if creatinine excretion is substantially different from the expected value; this is particularly important in patients with borderline values. Albumin excretion will be underestimated in a muscular man with a high rate of creatinine excretion and overestimated in a cachectic patient in whom muscle mass and creatinine excretion are markedly reduced. The ratio also varies with",
"      <span class=\"nowrap\">",
"       race/ethnicity",
"      </span>",
"      in the United States, as creatinine excretion is significantly higher among non-Hispanic blacks and Mexican Americans than among non-Hispanic whites [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/49/42777/abstract/16\">",
"       16",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Detection recommendation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Measurement of the urine albumin-to-creatinine ratio in an untimed urinary sample is the preferred screening strategy for microalbuminuria in all diabetic patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/49/42777/abstract/1,2,6,7\">",
"     1,2,6,7",
"    </a>",
"    ]. This test has the following advantages: it gives a quantitative result that correlates with the 24-hour urine values over a wide range of protein excretion, it is simple to perform and inexpensive, and repeat values can be easily obtained to ascertain that microalbuminuria, if present, is persistent. (See",
"    <a class=\"local\" href=\"#H20\">",
"     'Screening'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     MECHANISMS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The glomerular capillary wall limits the filtration of anionic macromolecules such as albumin by size- and charge-selective properties. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/37/13914?source=see_link&amp;anchor=H3#H3\">",
"     \"Assessment of urinary protein excretion and evaluation of isolated non-nephrotic proteinuria in adults\", section on 'Glomerular proteinuria'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/5/9304?source=see_link\">",
"     \"Biology of glomerular podocytes\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Studies in diabetic subjects with microalbuminuria demonstrate both an increase in the number of large pores (limiting size-selectivity) and decreased staining for heparan sulfate (the major component of the charge barrier) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/49/42777/abstract/17-19\">",
"     17-19",
"    </a>",
"    ]. These defects become more prominent with progression to overt proteinuria [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/49/42777/abstract/18\">",
"     18",
"    </a>",
"    ]. However, changes in charge selectivity may not be an important factor in the genesis of proteinuria [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/49/42777/abstract/20,21\">",
"     20,21",
"    </a>",
"    ]. Another possible mechanism of albuminuria, at least in type 1 diabetes mellitus, is decreased degradation of filtered albumin within the tubules [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/49/42777/abstract/22\">",
"     22",
"    </a>",
"    ] or impaired tubular uptake of filtered albumin [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/49/42777/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     NATURAL HISTORY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following data might be considered to represent the \"natural history\" of microalbuminuria in patients with type 1 diabetes, since they were mostly obtained before the current era of recommended strict glycemic control, aggressive blood pressure control, and therapy with angiotensin converting enzyme inhibitors or angiotensin II receptor blockers. (See",
"    <a class=\"local\" href=\"#H16\">",
"     'Treatment'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Long-term follow-up of patients with type 1 diabetes who have microalbuminuria has shown that the likelihood of progression to overt nephropathy (defined as a positive urine dipstick for protein, also called macroalbuminuria or overt or clinical proteinuria) varies with the duration of diabetes and other risk factors. On the other hand, there is also an appreciable rate of spontaneous regression of microalbuminuria to normoalbuminuria. These issues are discussed in the following sections.",
"   </p>",
"   <p>",
"    Renal biopsy findings in patients with type 1 diabetes and microalbuminuria can range from relatively normal histology (most often seen in patients excreting less than 45 mg of albumin per day) to clear evidence of diabetic nephropathy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/49/42777/abstract/24\">",
"     24",
"    </a>",
"    ]. Diabetic nephropathy is most likely to develop in patients with more prominent microalbuminuria, hypertension,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    a reduction in creatinine clearance [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/49/42777/abstract/24,25\">",
"     24,25",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Prevalence",
"    </span>",
"    &nbsp;&mdash;&nbsp;The development of microalbuminuria in patients with type 1 diabetes usually begins 5 to 15 years after the onset of diabetes and then increases over time [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/49/42777/abstract/26-28\">",
"     26-28",
"    </a>",
"    ]. A small proportion of patients develop microalbuminuria within less than five years of disease onset [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/49/42777/abstract/26,27\">",
"     26,27",
"    </a>",
"    ]. In a systematic review of nine longitudinal studies examining microalbuminuria in 7938 patients with type 1 diabetes, the overall prevalence of microalbuminuria was 28 percent at a mean duration of diabetes of 15 years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/49/42777/abstract/29\">",
"     29",
"    </a>",
"    ]. In another report, the prevalence of microalbuminuria reached 52 percent at 30 years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/49/42777/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Risk factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of independent risk factors have been noted in studies of patients with type 1 diabetes who developed microalbuminuria in addition to the duration of diabetes. These include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Increased albumin excretion above the upper limit of normal at baseline, even though the values are within the normal range [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/49/42777/abstract/26,30-33\">",
"       26,30-33",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Worse glycemic control as evidenced by increased hemoglobin A1c values [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/49/42777/abstract/26,30-37\">",
"       26,30-37",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Higher systolic or mean arterial pressure in most [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/49/42777/abstract/26,28,31,36,37\">",
"       26,28,31,36,37",
"      </a>",
"      ] but not all studies [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/49/42777/abstract/30,31,35\">",
"       30,31,35",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Presence and severity of retinopathy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/49/42777/abstract/30,31\">",
"       30,31",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Higher total or LDL-cholesterol [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/49/42777/abstract/32,36\">",
"       32,36",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Although these observations do not prove a cause-and-effect relationship, they are compatible with an important role for glycemic and blood pressure control. Patients with type 1 diabetes usually have a blood pressure below",
"    <span class=\"nowrap\">",
"     130/80",
"    </span>",
"    mmHg if albumin excretion is normal [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/49/42777/abstract/26,33\">",
"     26,33",
"    </a>",
"    ]. The blood pressure typically begins to rise, initially within the normal range, at or within a few years after the onset of microalbuminuria [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/49/42777/abstract/26,33\">",
"     26,33",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    These temporal changes in blood pressure were illustrated in a prospective study of 277 patients with newly diagnosed type 1 diabetes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/49/42777/abstract/26\">",
"     26",
"    </a>",
"    ]. The mean blood pressure at diabetes onset was",
"    <span class=\"nowrap\">",
"     128/80",
"    </span>",
"    mmHg in the 79 patients who later developed microalbuminuria, which was significantly higher than the value of",
"    <span class=\"nowrap\">",
"     122/76",
"    </span>",
"    mmHg in the patients who did not go on to develop microalbuminuria. At the time of progression to persistent microalbuminuria, the mean blood pressure had increased to",
"    <span class=\"nowrap\">",
"     140/84",
"    </span>",
"    mmHg, compared to",
"    <span class=\"nowrap\">",
"     127/79",
"    </span>",
"    mmHg in the microalbuminuric patients who regressed to normoalbuminuria.",
"   </p>",
"   <p>",
"    The incidence of overt hypertension is approximately 15 to 25 percent in all patients with microalbuminuria and increases as the patient progresses to overt nephropathy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/49/42777/abstract/38\">",
"     38",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/45/21210?source=see_link&amp;anchor=H1#H1\">",
"     \"Treatment of hypertension in patients with diabetes mellitus\", section on 'Introduction and prevalence'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Regression to normoalbuminuria",
"    </span>",
"    &nbsp;&mdash;&nbsp;Microalbuminuria reverts to normoalbuminuria in 15 to 65 percent of patients with type 1 diabetes (treated with insulin to maintain near normal glycemia) over follow-up periods of approximately 5 to 18 years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/49/42777/abstract/26,29,39-43\">",
"     26,29,39-43",
"    </a>",
"    ]. Independent risk factors for regression of microalbuminuria include better glycemic control [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/49/42777/abstract/26,39,40,42\">",
"     26,39,40,42",
"    </a>",
"    ], lower blood pressure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/49/42777/abstract/26,39\">",
"     26,39",
"    </a>",
"    ], lower serum cholesterol and triglyceride levels [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/49/42777/abstract/39\">",
"     39",
"    </a>",
"    ], recent onset of microalbuminuria [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/49/42777/abstract/39\">",
"     39",
"    </a>",
"    ], a lesser degree of microalbuminuria [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/49/42777/abstract/42\">",
"     42",
"    </a>",
"    ], lower baseline glomerular filtration rate (ie, less glomerular hyperfiltration) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/49/42777/abstract/41,43\">",
"     41,43",
"    </a>",
"    ], and, on renal biopsy, smaller increases in glomerular basement membrane width [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/49/42777/abstract/43\">",
"     43",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The importance of these factors was illustrated in a prospective study of 386 patients with type 1 diabetes and persistent microalbuminuria [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/49/42777/abstract/39\">",
"     39",
"    </a>",
"    ]. Regression of microalbuminuria was observed in 58 percent over a total follow-up of eight years (and an average of 3.3 urinary samples per person). Regression was independently associated with the recent onset of microalbuminuria and lower values of HbA1c (&lt;8 percent), systolic blood pressure (&lt;115 mmHg), total cholesterol (&lt;198",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    [5.12",
"    <span class=\"nowrap\">",
"     mmol/L]),",
"    </span>",
"    and triglycerides (&lt;145",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    [1.64",
"    <span class=\"nowrap\">",
"     mmol/L]).",
"    </span>",
"   </p>",
"   <p>",
"    Although the above findings do not prove a cause-and-effect relationship, they are generally compatible with a central role for glycemic, blood pressure, and lipid control in inducing regression of microalbuminuria to normoalbuminuria. ACE inhibitor therapy is another factor that promotes regression to normoalbuminuria. (See",
"    <a class=\"local\" href=\"#H18\">",
"     'Angiotensin inhibition'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Changes in the degree of abnormal albumin excretion over time also correlate with the risk for a decline in kidney function. Thus, patients with microalbuminuria that progresses, stabilizes, or regresses are at very high, intermediate, and low risk of developing a reduction in glomerular filtration rate (GFR), respectively. This was shown in a study of 267 patients with normoalbuminuria and 301 with microalbuminuria who were followed for 8 to 12 years with serial measurements of protein excretion and GFR (the latter via the serum cystatin C concentration) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/49/42777/abstract/44\">",
"     44",
"    </a>",
"    ]. An early decline in GFR occurred in 68, 32, 16, and 9 percent of patients with progression, stabilization, or regression of microalbuminuria, and normoalbuminuria, respectively.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Progression to macroalbuminuria",
"    </span>",
"    &nbsp;&mdash;&nbsp;As noted above, macroalbuminuria (also called overt proteinuria, clinical renal disease, or dipstick positive proteinuria) is defined as albumin excretion greater than 300",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    or 200",
"    <span class=\"nowrap\">",
"     &micro;g/min,",
"    </span>",
"    or a urine albumin-to-creatinine ratio greater than 300",
"    <span class=\"nowrap\">",
"     mg/g",
"    </span>",
"    of creatinine or, using standard (SI) units, greater than 34",
"    <span class=\"nowrap\">",
"     mg/mmol",
"    </span>",
"    of creatinine. Macroalbuminuria in patients with type 1 diabetes is usually first seen after 10 years of disease and then gradually increases over time [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/49/42777/abstract/26,45\">",
"     26,45",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The rate of progression from microalbuminuria to macroalbuminuria varies with the duration of type 1 diabetes. In a series of 292 patients with type 1 diabetes who were followed for 20 to 40 years, the rate of development of macroalbuminuria peaked at about 2.5 percent per year at a disease duration of 10 to 14 years and then gradually declined to 1 percent or less per year after 20 years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/49/42777/abstract/45\">",
"     45",
"    </a>",
"    ]. The cumulative incidence of macroalbuminuria, prior to the use of current preventive therapies, was 30 to 45 percent at 40 years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/49/42777/abstract/45,46\">",
"     45,46",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients with type 1 diabetes who develop microalbuminuria are at significantly increased risk for progression to macroalbuminuria compared to those without microalbuminuria [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/49/42777/abstract/26,27,45,47-50\">",
"     26,27,45,47-50",
"    </a>",
"    ]. The frequency with which microalbuminuria and progression occur was evaluated in a study of 277 patients with newly diagnosed type 1 diabetes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/49/42777/abstract/26\">",
"     26",
"    </a>",
"    ]. The following findings were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      At a median follow-up of 18 years, 79 patients (29 percent) developed persistent microalbuminuria (defined as albumin excretion rate between 30 and 300",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      in at least two out of three consecutive 24-hour urine collections obtained yearly). Predictors of persistent microalbuminuria included a 10-fold increase in albumin excretion at baseline, male sex, a 10 mmHg increased in mean arterial pressure, and a 1 percent increase in hemoglobin A1c. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Risk factors'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The 79 patients with persistent microalbuminuria were followed for a median of 7.5 years at which time progression to persistent macroalbuminuria (albumin excretion rate greater than 300",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      on 24-hour urine collection) occurred in 27 (34 percent), and permanent regression to normoalbuminuria occurred in 13 (16 percent), which was spontaneous (ie, in the absence of ACE inhibitors) in 10. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Regression to normoalbuminuria'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      None of the patients who developed macroalbuminuria spontaneously regressed to microalbuminuria or normoalbuminuria.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Other smaller studies reported variable rates of progression of microalbuminuria to macroalbuminuria: 7 of 8 at 14 years from the diagnosis of microalbuminuria [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/49/42777/abstract/49\">",
"     49",
"    </a>",
"    ], 12 of 14 at 10 years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/49/42777/abstract/47\">",
"     47",
"    </a>",
"    ], and 5 of 18 at 10 years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/49/42777/abstract/51\">",
"     51",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    These disparate findings may be due in part to the time at which microalbuminuria begins after the onset of type 1 diabetes. It has been suggested that almost all patients who develop microalbuminuria within the first 10 years progress to macroalbuminuria [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/49/42777/abstract/27\">",
"     27",
"    </a>",
"    ]. In contrast, progression to macroalbuminuria may occur in only about 30 to 50 percent of patients with later onset microalbuminuria [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/49/42777/abstract/27,51\">",
"     27,51",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The risk of developing macroalbuminuria is much lower in patients with type 1 diabetes who do not develop microalbuminuria after 10 to 15 years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/49/42777/abstract/47-50\">",
"     47-50",
"    </a>",
"    ]. In one series, for example, there were 55 patients seen in 1967 who had not developed microalbuminuria at a mean diabetes duration of nine years; these patients were reevaluated at 14 and 23 years. Macroalbuminuria developed in only 2 of the 55 patients at a 14-year follow-up in 1981 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/49/42777/abstract/49\">",
"     49",
"    </a>",
"    ] and in 5 of 53 at 23-year follow-up in 1990 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/49/42777/abstract/50\">",
"     50",
"    </a>",
"    ]. The patients with microalbuminuria at the initial evaluation also had an increased rate of cardiovascular death at 23-year follow-up. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/16/20745?source=see_link\">",
"     \"High albuminuria (microalbuminuria) and cardiovascular disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Similar findings were noted in another study of patients with a mean type 1 diabetes duration of 12 years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/49/42777/abstract/47\">",
"     47",
"    </a>",
"    ]. At a mean follow-up of 10 years, macroalbuminuria developed in none of 29 patients without microalbuminuria at study entry.",
"   </p>",
"   <p>",
"    The magnitude of the difference in risk of developing macroalbuminuria in patients with or without microalbuminuria was evaluated in the systematic review of 7938 patients with type 1 diabetes cited above [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/49/42777/abstract/29\">",
"     29",
"    </a>",
"    ]. The relative risk of macroalbuminuria in patients with compared to without microalbuminuria was 7.5 (95% CI 5.4-10.5). The patients with microalbuminuria also had a significantly greater fall in glomerular filtration rate over time and there was a significant benefit from ACE inhibitor therapy in reducing the risk of progression from microalbuminuria to macroalbuminuria. (See",
"    <a class=\"local\" href=\"#H18\">",
"     'Angiotensin inhibition'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    In addition to the presence of microalbuminuria and the duration of diabetes at the time of diagnosis of microalbuminuria, other risk factors for the development of macroalbuminuria in patients with type 1 diabetes include worse glycemic control as evidenced by increased A1c values and higher rates of microalbuminuria [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/49/42777/abstract/42\">",
"     42",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Microalbuminuria and GFR",
"    </span>",
"    &nbsp;&mdash;&nbsp;It was initially thought that microalbuminuria precedes the loss of glomerular filtration rate (GFR) in patients with type 1 diabetes. However, some patients with normoalbuminuria or microalbuminuria have significant reductions in GFR prior to the development of macroalbuminuria [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/49/42777/abstract/44,50,52\">",
"     44,50,52",
"    </a>",
"    ]. The frequency with which this occurs was evaluated in a study of 267 and 301 type 1 diabetic patients with normoalbuminuria and microalbuminuria, respectively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/49/42777/abstract/44\">",
"     44",
"    </a>",
"    ]. The patients were followed for 8 to 12 years with serial measurements of protein excretion and estimation of the GFR (using the serum cystatin C concentration, which is more accurate than the serum creatinine concentration). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/45/36570?source=see_link&amp;anchor=H23#H23\">",
"     \"Assessment of kidney function\", section on 'Serum cystatin C'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Loss of renal function, which was defined as an estimated decrease in GFR of more than 3.3 percent per year, occurred in 9 percent of patients with normoalbuminuria and 16 percent with regression of microalbuminuria. Loss of renal function occurred much more frequently (32 and 68 percent) in patients with stable or progressive microalbuminuria, respectively.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Other microvascular complications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Among patients with type 1 diabetes, the prevalence of other microvascular complications, such as retinopathy and neuropathy, increases with the degree of albuminuria. This was illustrated in a study of 981 patients who had type 1 diabetes for five or more years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/49/42777/abstract/53\">",
"     53",
"    </a>",
"    ]. Proliferative retinopathy was present in 12 percent of patients with normoalbuminuria, 28 percent with microalbuminuria, and 58 percent with macroalbuminuria. The comparable rates of impaired vibratory sense were 21, 31, and 50 percent, respectively.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Mortality",
"    </span>",
"    &nbsp;&mdash;&nbsp;Microalbuminuria is associated with increased long-term mortality in patients with type 1 diabetes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/49/42777/abstract/29,50\">",
"     29,50",
"    </a>",
"    ]. In the systematic review of 7938 patients cited above, the relative risk for all-cause mortality was 1.8 (95% CI 1.5-2.1) compared to patients with normoalbuminuria, with a suggestion of a similar relative risk for cardiovascular mortality [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/49/42777/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Microalbuminuria appears to represent a stage of diabetic nephropathy at which treatment is often successful in preventing progressive renal disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/49/42777/abstract/54\">",
"     54",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Glucose control",
"    </span>",
"    &nbsp;&mdash;&nbsp;As mentioned above, worse glycemic control is a risk factor for the development of microalbuminuria in patients with type 1 diabetes and may also be a risk factor for disease progression in patients with microalbuminuria who are treated with ACE inhibitors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/49/42777/abstract/55\">",
"     55",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H10\">",
"     'Risk factors'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    On the other hand, strict control of the serum glucose concentration (A1C less than 7.5 percent) can slow the rate of progression or even reduce proteinuria in these patients, compared to a common increase in protein excretion in conventionally treated patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/49/42777/abstract/56-58\">",
"     56-58",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/34/11817?source=see_link\">",
"     \"Glycemic control and vascular complications in type 1 diabetes mellitus\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    As described below, intensive compared to conventional insulin therapy in the Diabetes Control and Complications Trial (DCCT) was associated with a significant 39 percent adjusted risk reduction in the development of new onset microalbuminuria in the 1365 patients with normal albumin excretion at study entry [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/49/42777/abstract/56\">",
"     56",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H22\">",
"     'Glycemic control'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    There were only 73 patients in DCCT with microalbuminuria at baseline and too few of these patients progressed to macroalbuminuria to demonstrate significant benefit from intensive insulin therapy. However, the magnitude of the treatment effect of intensive insulin therapy was similar to that in the much larger population of patients without microalbuminuria at baseline.",
"   </p>",
"   <p>",
"    Issues related to glycemic control are discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/34/11817?source=see_link\">",
"     \"Glycemic control and vascular complications in type 1 diabetes mellitus\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Angiotensin inhibition",
"    </span>",
"    &nbsp;&mdash;&nbsp;Albumin excretion can be lowered and progression to macroalbuminuria reduced by blood pressure control, particularly with an angiotensin converting enzyme (ACE) inhibitor, which may be beneficial even in normotensive patients (ie, at or below goal blood pressure of",
"    <span class=\"nowrap\">",
"     130/80",
"    </span>",
"    mmHg) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/49/42777/abstract/29,59-62\">",
"     29,59-62",
"    </a>",
"    ]. We therefore initiate ACE inhibitor in normotensive type 1 diabetic patients with persistent microalbuminuria. If the patient can be monitored at three- to six-month intervals, an alternative approach, given the appreciable rate of regression of microalbuminuria, is to administer an ACE inhibitor only if there is evidence of progressive microalbuminuria or the patient becomes hypertensive.",
"   </p>",
"   <p>",
"    The renal goal of ACE inhibitor therapy is a modest reduction in urine albumin excretion. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/45/21210?source=see_link\">",
"     \"Treatment of hypertension in patients with diabetes mellitus\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The efficacy of ACE inhibitor therapy in patients with microalbuminuria has been evaluated in several randomized prospective trials. In two different trials, for example, 317 patients with type 1 diabetes, microalbuminuria, and a normal blood pressure were randomly assigned to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?8/59/9145?source=see_link\">",
"     captopril",
"    </a>",
"    or placebo [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/49/42777/abstract/60,61\">",
"     60,61",
"    </a>",
"    ]. Progression to overt proteinuria was markedly reduced at two years in the patients treated with captopril (7.6 versus 23.1 percent). In one of these trials, albumin excretion fell by 9.6 percent per year in patients receiving captopril compared to an increase of 14.2 percent per year with placebo [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/49/42777/abstract/60\">",
"     60",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The subsequent EUCLID trial evaluated 530 patients with type 1 diabetes and either microalbuminuria (79 patients) or normoalbuminuria (440 patients) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/49/42777/abstract/62\">",
"     62",
"    </a>",
"    ]. Blood pressure was above current target levels, as the resting diastolic blood pressure was between 75 and 90 mmHg, while the systolic was less than 155 mmHg. The patients were randomly assigned to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/58/937?source=see_link\">",
"     lisinopril",
"    </a>",
"    or placebo; the initial dose was 10",
"    <span class=\"nowrap\">",
"     mg/day,",
"    </span>",
"    which could be increased to 20",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    to reach the goal diastolic pressure of 75 mmHg. The subjects treated with lisinopril had a significantly lower diastolic pressure (74 versus 77 mmHg) that was maintained throughout the study.",
"   </p>",
"   <p>",
"    Among the 79 patients with microalbuminuria at baseline (mean albumin excretion rate 42",
"    <span class=\"nowrap\">",
"     &micro;g/min,",
"    </span>",
"    equivalent to 60",
"    <span class=\"nowrap\">",
"     mg/day),",
"    </span>",
"    albumin excretion fell with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/58/937?source=see_link\">",
"     lisinopril",
"    </a>",
"    and increased with placebo. On intention to treat analysis at two years, the albumin excretion rate was 34.2",
"    <span class=\"nowrap\">",
"     &micro;g/min",
"    </span>",
"    lower (equivalent to 49",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    and representing a 50 percent reduction) in the lisinopril group, a difference that was not statistically significant. The findings in the normoalbuminuric patients are described below. (See",
"    <a class=\"local\" href=\"#H21\">",
"     'Primary prevention'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    In addition to decreasing albuminuria, ACE inhibitors have significant long-term benefits. In a systematic review of 11 trials of normotensive type 1 diabetic patients with microalbuminuria, ACE inhibitor therapy significantly reduced the risk of progression to macroalbuminuria (relative risk 0.36, 95% CI 0.22-0.58) and significantly increased the risk of regression to normoalbuminuria (relative risk 5.3, 95% CI 2.5-11.5) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/49/42777/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Data are lacking on the efficacy of angiotensin II receptor blockers (ARBs) in patients with type 1 diabetes and microalbuminuria. It seems likely that these drugs are as effective as ACE inhibitors given their proven benefit in patients with type 2 diabetes and either microalbuminuria or overt nephropathy. An ARB can be substituted if the patient develops a persistent cough on an ACE inhibitor. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/33/39449?source=see_link&amp;anchor=H13#H13\">",
"     \"Microalbuminuria in type 2 diabetes mellitus\", section on 'ACE inhibitors/ARBs'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/48/40714?source=see_link&amp;anchor=H16#H16\">",
"     \"Treatment of diabetic nephropathy\", section on 'ACE inhibitor or ARB'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Other antihypertensive drugs",
"    </span>",
"    &nbsp;&mdash;&nbsp;Whether other antihypertensive drugs are as effective as ACE inhibitors in preventing progressive proteinuria in patients with type 1 diabetes and microalbuminuria is unproven. This issue was addressed in a trial that randomly assigned 42 normotensive patients with type 1 diabetes and microalbuminuria (mean 64",
"    <span class=\"nowrap\">",
"     &micro;g/min",
"    </span>",
"    at baseline) to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?21/32/22024?source=see_link\">",
"     perindopril",
"    </a>",
"    , slow-release",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?12/5/12377?source=see_link\">",
"     nifedipine",
"    </a>",
"    , or placebo [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/49/42777/abstract/63\">",
"     63",
"    </a>",
"    ]. At three years, median albumin excretion had fallen to 23",
"    <span class=\"nowrap\">",
"     &micro;g/min",
"    </span>",
"    in the perindopril group compared to the rising values of 122 and 112",
"    <span class=\"nowrap\">",
"     &micro;g/min",
"    </span>",
"    in the other two groups.",
"   </p>",
"   <p>",
"    Studies in patients with overt proteinuria have found that only",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?12/16/12554?source=see_link\">",
"     diltiazem",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/18/9514?source=see_link\">",
"     verapamil",
"    </a>",
"    may have as prominent antiproteinuric activity as ACE inhibitors in diabetic patients. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/48/40714?source=see_link&amp;anchor=H20#H20\">",
"     \"Treatment of diabetic nephropathy\", section on 'Other antihypertensive drugs and combinations'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     SCREENING",
"    </span>",
"    &nbsp;&mdash;&nbsp;The availability of effective therapy (as described in the preceding section) led to the recommendation in the 2007",
"    <span class=\"nowrap\">",
"     K/DOQI",
"    </span>",
"    guidelines on diabetes and chronic kidney disease and other publications that patients with type 1 diabetes should be screened for microalbuminuria [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/49/42777/abstract/1,54,64\">",
"     1,54,64",
"    </a>",
"    ]. Screening can be deferred for five years after the onset of disease in type 1 diabetes because microalbuminuria is uncommon before this time [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/49/42777/abstract/1,26,27\">",
"     1,26,27",
"    </a>",
"    ]. If not found at the initial screen, yearly screening for microalbuminuria is recommended [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/49/42777/abstract/1\">",
"     1",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H9\">",
"     'Prevalence'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    The",
"    <span class=\"nowrap\">",
"     K/DOQI",
"    </span>",
"    guidelines recommend use of the urine albumin-to-creatinine ratio on a spot urine sample for screening in diabetic patients and that an elevated urine albumin-to-creatinine ratio should be confirmed in the absence of urinary tract infection with at least two additional tests performed over the subsequent three to six months [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/49/42777/abstract/1\">",
"     1",
"    </a>",
"    ]. The diagnosis of microalbuminuria requires an elevated ratio on at least two of the three samples.",
"   </p>",
"   <p>",
"    The",
"    <span class=\"nowrap\">",
"     K/DOQI",
"    </span>",
"    guidelines concluded that microalbuminuria in patients with type 1 diabetes should be attributed to diabetes if the diabetes duration is at least 10 years",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    if diabetic retinopathy is present [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/49/42777/abstract/1\">",
"     1",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H14\">",
"     'Other microvascular complications'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    The guidelines also noted that other causes of chronic kidney disease should be considered when there are findings that are not characteristic of diabetic nephropathy. These include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      A low or rapidly decreasing glomerular filtration rate",
"     </li>",
"     <li>",
"      Rapidly increasing protein excretion or acute onset of nephrotic syndrome",
"     </li>",
"     <li>",
"      Refractory hypertension",
"     </li>",
"     <li>",
"      Active (nephritic) urine sediment (eg, dysmorphic hematuria and red cell or other cellular casts)",
"     </li>",
"     <li>",
"      Signs",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      symptoms of another systemic disease",
"     </li>",
"     <li>",
"      More than a 30 percent reduction in glomerular filtration rate after initiation of therapy with an ACE inhibitor or angiotensin II receptor blocker",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/63/30714?source=see_link&amp;anchor=H26#H26\">",
"     \"Overview of diabetic nephropathy\", section on 'Nondiabetic renal disease'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     PRIMARY PREVENTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Both strict glycemic control and angiotensin converting enzyme (ACE) inhibitors",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    angiotensin receptor blockers (ARBs) have been evaluated for primary prevention of microalbuminuria in patients with type 1 diabetes.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Glycemic control",
"    </span>",
"    &nbsp;&mdash;&nbsp;Strict glycemic control is recommended in all patients with type 1 diabetes because of its beneficial effects on microvascular complications. The general benefits of strict glycemic control, including the effect of strict glycemic control on the prevention of renal disease, is presented elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/34/11817?source=see_link\">",
"     \"Glycemic control and vascular complications in type 1 diabetes mellitus\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     ACE inhibitors or ARBs",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of clinical trials have evaluated the efficacy of angiotensin converting enzyme (ACE) inhibitors or angiotensin receptor blockers (ARBs) for the primary prevention of microalbuminuria in patients with type 1 diabetes mellitus. Three randomized, placebo-controlled trials of 256 to 3326 patients with type 1 diabetes and normoalbuminuria (RASS, EUCLID, AND DIRECT) showed no benefit from angiotensin inhibition [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/49/42777/abstract/62,65,66\">",
"     62,65,66",
"    </a>",
"    ]. We therefore do NOT administer these drugs for primary prevention.",
"   </p>",
"   <p>",
"    Lack of efficacy was illustrated by the results from the Diabetic Retinopathy",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/48/38663?source=see_link\">",
"     Candesartan",
"    </a>",
"    Trials (DIRECT) Program, which included 3326 patients with type 1 diabetes who were randomly assigned to candesartan (16 to 32",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    or placebo [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/49/42777/abstract/66\">",
"     66",
"    </a>",
"    ]. DIRECT was designed to assess the effect of candesartan on preventing the development or progression of diabetic retinopathy. The patients were also normoalbuminuric at baseline, which permitted assessment of the effect of candesartan on albumin excretion. The mean duration of diabetes was 6.7 years in the Prevention arm and 11 years in the Protection against progression arm",
"   </p>",
"   <p>",
"    At a mean follow-up of approximately 4.7 years, there was no difference between the",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/48/38663?source=see_link\">",
"     candesartan",
"    </a>",
"    and placebo groups in either the rate of developing microalbuminuria (6 versus 5 percent and 16 versus 16 percent [hazard ratio 1.08 and 1.03] in the prevention and progression arms, respectively) or in the annual rate of increase in urinary albumin excretion.",
"   </p>",
"   <p>",
"    Lack of prevention of microalbuminuria was also noted in the Renin Angiotensin System Study (RASS), which included 285 normotensive normoalbuminuric patients with type 1 diabetes (mean duration 11 years) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/49/42777/abstract/65\">",
"     65",
"    </a>",
"    ]. In addition, renal biopsy was performed at study onset and at five years in 90 percent of the patients. Treatment with either",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?25/35/26168?source=see_link\">",
"     losartan",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?8/19/8505?source=see_link\">",
"     enalapril",
"    </a>",
"    had no effect compared to placebo on the fraction of glomerular volume occupied by the mesangium (the primary study end point) or other histologic findings seen in diabetic nephropathy. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/63/30714?source=see_link&amp;anchor=H5#H5\">",
"     \"Overview of diabetic nephropathy\", section on 'Pathology'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In summary, there is no evidence that ACE inhibitors or ARBs are effective for the primary prevention of microalbuminuria in patients with type 1 diabetes who are normoalbuminuric and normotensive. These patients should be screened yearly for microalbuminuria after five years and angiotensin inhibition initiated if persistent microalbuminuria is documented. (See",
"    <a class=\"local\" href=\"#H20\">",
"     'Screening'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/45/21210?source=see_link&amp;anchor=H10#H10\">",
"     \"Treatment of hypertension in patients with diabetes mellitus\", section on 'Goal blood pressure'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The effect of angiotensin inhibition on retinopathy outcomes are presented elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/38/32362?source=see_link&amp;anchor=H6#H6\">",
"     \"Prevention and treatment of diabetic retinopathy\", section on 'Is angiotensin inhibition preferred?'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Beyond the Basics topic (see",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?24/4/24644?source=see_link\">",
"       \"Patient information: Diabetic kidney disease (diabetic nephropathy) (Beyond the Basics)\"",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Microalbuminuria is defined as persistent urinary albumin excretion between 30 and 300",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      (20 to 200",
"      <span class=\"nowrap\">",
"       microg/min).",
"      </span>",
"      Macroalbuminuria refers to albumin excretion above 300",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      (200",
"      <span class=\"nowrap\">",
"       microg/min).",
"      </span>",
"      (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction and definitions'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Microalbuminuria generally develops 5 to 15 years after the onset of type 1 diabetes. The reported prevalence is approximately 30 percent at 15 years and 50 percent by 30 years. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Prevalence'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Risk factors associated with the development of microalbuminuria include increased albumin excretion at baseline, poor glycemic control, hypertension, presence and severity of retinopathy, and elevated total or LDL-cholesterol. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Risk factors'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Microalbuminuria regresses to normoalbuminuria in a significant proportion of patients. Risk factors that favor the regression of microalbuminuria include better glycemic control, lower blood pressure, lower serum cholesterol and triglycerides, recent onset and lower levels of microalbuminuria, and less glomerular hyperfiltration. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Regression to normoalbuminuria'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Microalbuminuria increases the risk for developing macroalbuminuria, retinopathy, and neuropathy and increases overall mortality. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Natural history'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The preferred screening strategy for microalbuminuria is measurement of the urine albumin-to-creatinine ratio in an untimed urinary sample. A value of 30 to 300",
"      <span class=\"nowrap\">",
"       mg/g",
"      </span>",
"      of creatinine (or, using standard [SI] units, 3.4 to 34",
"      <span class=\"nowrap\">",
"       mg/mmol",
"      </span>",
"      of creatinine) suggests that albumin excretion is between 30 and 300",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      and therefore that microalbuminuria is probably present. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Urine albumin-to-creatinine ratio'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We recommend that the albumin-to-creatinine ratio be measured yearly in all patients who have had type 1 diabetes for five years or more. An elevated ratio should be confirmed with at least two additional tests performed over the subsequent three to six months, with confirmation of the diagnosis requiring at least two of three positive samples. (See",
"      <a class=\"local\" href=\"#H20\">",
"       'Screening'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Among patients with persistent microalbuminuria and blood pressures greater than",
"      <span class=\"nowrap\">",
"       130/80",
"      </span>",
"      mmHg, we recommend treatment with an ACE inhibitor rather than other antihypertensive agents (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). Other drugs are added as necessary to attain the goal blood pressure of less than",
"      <span class=\"nowrap\">",
"       130/80",
"      </span>",
"      mmHg. (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Angiotensin inhibition'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?20/45/21210?source=see_link\">",
"       \"Treatment of hypertension in patients with diabetes mellitus\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Data are limited in patients with persistent microalbuminuria who have baseline blood pressures below",
"      <span class=\"nowrap\">",
"       130/80",
"      </span>",
"      mmHg. Given the low cost and low rate of side effects of ACE inhibitor therapy, among normotensive patients with persistent microalbuminuria, we suggest treatment with an ACE inhibitor rather than observation (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). If the patient can be monitored at three- to six-month intervals, an alternative approach, given the appreciable rate of regression of microalbuminuria, is to administer an ACE inhibitor only if there is evidence of progressive microalbuminuria or the patient becomes hypertensive. The renal goal of ACE inhibitor therapy is a modest reduction in urine albumin excretion. An ARB can be substituted if the patient develops a persistent cough on an ACE inhibitor. (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Angiotensin inhibition'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H11\">",
"       'Regression to normoalbuminuria'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      There is no evidence supporting angiotensin inhibition for the primary prevention of microalbuminuria in patients with type 1 diabetes who are normoalbuminuric and normotensive. Such patients should be screened yearly for microalbuminuria and an ACE inhibitor initiated if persistent microalbuminuria is documented. (See",
"      <a class=\"local\" href=\"#H23\">",
"       'ACE inhibitors or ARBs'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H20\">",
"       'Screening'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Issues related to glycemic control, which is essential to minimize both the renal and extrarenal complications of type 1 diabetes, are discussed in detail elsewhere. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?11/34/11817?source=see_link\">",
"       \"Glycemic control and vascular complications in type 1 diabetes mellitus\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/49/42777/abstract/1\">",
"      K/DOQI clinical practice guidelines and clinical practice recommendations for diabetes and chronic kidney disease. Am J Kidney Dis 2007; 49(2 Suppl 2):S12.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/49/42777/abstract/2\">",
"      Gross JL, de Azevedo MJ, Silveiro SP, et al. Diabetic nephropathy: diagnosis, prevention, and treatment. Diabetes Care 2005; 28:164.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/49/42777/abstract/3\">",
"      Mogensen CE. Prediction of clinical diabetic nephropathy in IDDM patients. Alternatives to microalbuminuria? Diabetes 1990; 39:761.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/49/42777/abstract/4\">",
"      Ruggenenti P, Remuzzi G. Nephropathy of type-2 diabetes mellitus. J Am Soc Nephrol 1998; 9:2157.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/49/42777/abstract/5\">",
"      Ismail N, Becker B, Strzelczyk P, Ritz E. Renal disease and hypertension in non-insulin-dependent diabetes mellitus. Kidney Int 1999; 55:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/49/42777/abstract/6\">",
"      Eknoyan G, Hostetter T, Bakris GL, et al. Proteinuria and other markers of chronic kidney disease: a position statement of the national kidney foundation (NKF) and the national institute of diabetes and digestive and kidney diseases (NIDDK). Am J Kidney Dis 2003; 42:617.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/49/42777/abstract/7\">",
"      Mogensen CE, Vestbo E, Poulsen PL, et al. Microalbuminuria and potential confounders. A review and some observations on variability of urinary albumin excretion. Diabetes Care 1995; 18:572.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/49/42777/abstract/8\">",
"      Consensus development conference on the diagnosis and management of nephropathy in patients with diabetes mellitus. American Diabetes Association and the National Kidney Foundation. Diabetes Care 1994; 17:1357.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/49/42777/abstract/9\">",
"      Zelmanovitz T, Gross JL, Oliveira JR, et al. The receiver operating characteristics curve in the evaluation of a random urine specimen as a screening test for diabetic nephropathy. Diabetes Care 1997; 20:516.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/49/42777/abstract/10\">",
"      Comper WD, Osicka TM. Detection of urinary albumin. Adv Chronic Kidney Dis 2005; 12:170.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/49/42777/abstract/11\">",
"      Schwab SJ, Dunn FL, Feinglos MN. Screening for microalbuminuria. A comparison of single sample methods of collection and techniques of albumin analysis. Diabetes Care 1992; 15:1581.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/49/42777/abstract/12\">",
"      Nathan DM, Rosenbaum C, Protasowicki VD. Single-void urine samples can be used to estimate quantitative microalbuminuria. Diabetes Care 1987; 10:414.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/49/42777/abstract/13\">",
"      Ginsberg JM, Chang BS, Matarese RA, Garella S. Use of single voided urine samples to estimate quantitative proteinuria. N Engl J Med 1983; 309:1543.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/49/42777/abstract/14\">",
"      Witte EC, Lambers Heerspink HJ, de Zeeuw D, et al. First morning voids are more reliable than spot urine samples to assess microalbuminuria. J Am Soc Nephrol 2009; 20:436.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/49/42777/abstract/15\">",
"      Jefferson IG, Greene SA, Smith MA, et al. Urine albumin to creatinine ratio-response to exercise in diabetes. Arch Dis Child 1985; 60:305.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/49/42777/abstract/16\">",
"      Mattix HJ, Hsu CY, Shaykevich S, Curhan G. Use of the albumin/creatinine ratio to detect microalbuminuria: implications of sex and race. J Am Soc Nephrol 2002; 13:1034.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/49/42777/abstract/17\">",
"      Scandling JD, Myers BD. Glomerular size-selectivity and microalbuminuria in early diabetic glomerular disease. Kidney Int 1992; 41:840.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/49/42777/abstract/18\">",
"      Nakamura Y, Myers BD. Charge selectivity of proteinuria in diabetic glomerulopathy. Diabetes 1988; 37:1202.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/49/42777/abstract/19\">",
"      Tamsma JT, van den Born J, Bruijn JA, et al. Expression of glomerular extracellular matrix components in human diabetic nephropathy: decrease of heparan sulphate in the glomerular basement membrane. Diabetologia 1994; 37:313.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/49/42777/abstract/20\">",
"      Russo LM, Bakris GL, Comper WD. Renal handling of albumin: a critical review of basic concepts and perspective. Am J Kidney Dis 2002; 39:899.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/49/42777/abstract/21\">",
"      Comper WD. Charge selectively is a concept that has yet to be demonstrated. Am J Physiol Renal Physiol 2001; 281:F992.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/49/42777/abstract/22\">",
"      Osicka TM, Houlihan CA, Chan JG, et al. Albuminuria in patients with type 1 diabetes is directly linked to changes in the lysosome-mediated degradation of albumin during renal passage. Diabetes 2000; 49:1579.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/49/42777/abstract/23\">",
"      Russo LM, Sandoval RM, Campos SB, et al. Impaired tubular uptake explains albuminuria in early diabetic nephropathy. J Am Soc Nephrol 2009; 20:489.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/49/42777/abstract/24\">",
"      Fioretto P, Steffes MW, Mauer M. Glomerular structure in nonproteinuric IDDM patients with various levels of albuminuria. Diabetes 1994; 43:1358.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/49/42777/abstract/25\">",
"      Chavers BM, Bilous RW, Ellis EN, et al. Glomerular lesions and urinary albumin excretion in type I diabetes without overt proteinuria. N Engl J Med 1989; 320:966.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/49/42777/abstract/26\">",
"      Hovind P, Tarnow L, Rossing P, et al. Predictors for the development of microalbuminuria and macroalbuminuria in patients with type 1 diabetes: inception cohort study. BMJ 2004; 328:1105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/49/42777/abstract/27\">",
"      Warram JH, Gearin G, Laffel L, Krolewski AS. Effect of duration of type I diabetes on the prevalence of stages of diabetic nephropathy defined by urinary albumin/creatinine ratio. J Am Soc Nephrol 1996; 7:930.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/49/42777/abstract/28\">",
"      Microalbuminuria in type I diabetic patients. Prevalence and clinical characteristics. Microalbuminuria Collaborative Study Group. Diabetes Care 1992; 15:495.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/49/42777/abstract/29\">",
"      Newman DJ, Mattock MB, Dawnay AB, et al. Systematic review on urine albumin testing for early detection of diabetic complications. Health Technol Assess 2005; 9:iii.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/49/42777/abstract/30\">",
"      Rossing P, Hougaard P, Parving HH. Risk factors for development of incipient and overt diabetic nephropathy in type 1 diabetic patients: a 10-year prospective observational study. Diabetes Care 2002; 25:859.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/49/42777/abstract/31\">",
"      Predictors of the development of microalbuminuria in patients with Type 1 diabetes mellitus: a seven-year prospective study. The Microalbuminuria Collaborative Study Group. Diabet Med 1999; 16:918.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/49/42777/abstract/32\">",
"      Chaturvedi N, Bandinelli S, Mangili R, et al. Microalbuminuria in type 1 diabetes: rates, risk factors and glycemic threshold. Kidney Int 2001; 60:219.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/49/42777/abstract/33\">",
"      Mathiesen ER, R&oslash;nn B, Jensen T, et al. Relationship between blood pressure and urinary albumin excretion in development of microalbuminuria. Diabetes 1990; 39:245.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/49/42777/abstract/34\">",
"      Krolewski AS, Laffel LM, Krolewski M, et al. Glycosylated hemoglobin and the risk of microalbuminuria in patients with insulin-dependent diabetes mellitus. N Engl J Med 1995; 332:1251.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/49/42777/abstract/35\">",
"      Almdal T, N&ouml;rgaard K, Feldt-Rasmussen B, Deckert T. The predictive value of microalbuminuria in IDDM. A five-year follow-up study. Diabetes Care 1994; 17:120.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/49/42777/abstract/36\">",
"      Coonrod BA, Ellis D, Becker DJ, et al. Predictors of microalbuminuria in individuals with IDDM. Pittsburgh Epidemiology of Diabetes Complications Study. Diabetes Care 1993; 16:1376.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/49/42777/abstract/37\">",
"      Joner G, Brinchmann-Hansen O, Torres CG, Hanssen KF. A nationwide cross-sectional study of retinopathy and microalbuminuria in young Norwegian type 1 (insulin-dependent) diabetic patients. Diabetologia 1992; 35:1049.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/49/42777/abstract/38\">",
"      Mogensen CE, Hansen KW, Pedersen MM, Christensen CK. Renal factors influencing blood pressure threshold and choice of treatment for hypertension in IDDM. Diabetes Care 1991; 14 Suppl 4:13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/49/42777/abstract/39\">",
"      Perkins BA, Ficociello LH, Silva KH, et al. Regression of microalbuminuria in type 1 diabetes. N Engl J Med 2003; 348:2285.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/49/42777/abstract/40\">",
"      Bojestig M, Arnqvist HJ, Karlberg BE, Ludvigsson J. Glycemic control and prognosis in type I diabetic patients with microalbuminuria. Diabetes Care 1996; 19:313.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/49/42777/abstract/41\">",
"      Dahlquist G, Stattin EL, Rudberg S. Urinary albumin excretion rate and glomerular filtration rate in the prediction of diabetic nephropathy; a long-term follow-up study of childhood onset type-1 diabetic patients. Nephrol Dial Transplant 2001; 16:1382.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/49/42777/abstract/42\">",
"      Giorgino F, Laviola L, Cavallo Perin P, et al. Factors associated with progression to macroalbuminuria in microalbuminuric Type 1 diabetic patients: the EURODIAB Prospective Complications Study. Diabetologia 2004; 47:1020.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/49/42777/abstract/43\">",
"      Steinke JM, Sinaiko AR, Kramer MS, et al. The early natural history of nephropathy in Type 1 Diabetes: III. Predictors of 5-year urinary albumin excretion rate patterns in initially normoalbuminuric patients. Diabetes 2005; 54:2164.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/49/42777/abstract/44\">",
"      Perkins BA, Ficociello LH, Ostrander BE, et al. Microalbuminuria and the risk for early progressive renal function decline in type 1 diabetes. J Am Soc Nephrol 2007; 18:1353.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/49/42777/abstract/45\">",
"      Krolewski AS, Warram JH, Christlieb AR, et al. The changing natural history of nephropathy in type I diabetes. Am J Med 1985; 78:785.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/49/42777/abstract/46\">",
"      Andersen AR, Christiansen JS, Andersen JK, et al. Diabetic nephropathy in Type 1 (insulin-dependent) diabetes: an epidemiological study. Diabetologia 1983; 25:496.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/49/42777/abstract/47\">",
"      Mogensen CE, Christensen CK. Predicting diabetic nephropathy in insulin-dependent patients. N Engl J Med 1984; 311:89.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/49/42777/abstract/48\">",
"      Mogensen CE. Microalbuminuria as a predictor of clinical diabetic nephropathy. Kidney Int 1987; 31:673.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/49/42777/abstract/49\">",
"      Viberti GC, Hill RD, Jarrett RJ, et al. Microalbuminuria as a predictor of clinical nephropathy in insulin-dependent diabetes mellitus. Lancet 1982; 1:1430.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/49/42777/abstract/50\">",
"      Messent JW, Elliott TG, Hill RD, et al. Prognostic significance of microalbuminuria in insulin-dependent diabetes mellitus: a twenty-three year follow-up study. Kidney Int 1992; 41:836.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/49/42777/abstract/51\">",
"      Forsblom CM, Groop PH, Ekstrand A, Groop LC. Predictive value of microalbuminuria in patients with insulin-dependent diabetes of long duration. BMJ 1992; 305:1051.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/49/42777/abstract/52\">",
"      de Boer IH, Steffes MW. Glomerular filtration rate and albuminuria: twin manifestations of nephropathy in diabetes. J Am Soc Nephrol 2007; 18:1036.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/49/42777/abstract/53\">",
"      Parving HH, Hommel E, Mathiesen E, et al. Prevalence of microalbuminuria, arterial hypertension, retinopathy and neuropathy in patients with insulin dependent diabetes. Br Med J (Clin Res Ed) 1988; 296:156.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/49/42777/abstract/54\">",
"      Bennett PH, Haffner S, Kasiske BL, et al. Screening and management of microalbuminuria in patients with diabetes mellitus: recommendations to the Scientific Advisory Board of the National Kidney Foundation from an ad hoc committee of the Council on Diabetes Mellitus of the National Kidney Foundation. Am J Kidney Dis 1995; 25:107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/49/42777/abstract/55\">",
"      Ficociello LH, Perkins BA, Silva KH, et al. Determinants of progression from microalbuminuria to proteinuria in patients who have type 1 diabetes and are treated with angiotensin-converting enzyme inhibitors. Clin J Am Soc Nephrol 2007; 2:461.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/49/42777/abstract/56\">",
"      Effect of intensive therapy on the development and progression of diabetic nephropathy in the Diabetes Control and Complications Trial. The Diabetes Control and Complications (DCCT) Research Group. Kidney Int 1995; 47:1703.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/49/42777/abstract/57\">",
"      Feldt-Rasmussen B, Mathiesen ER, Deckert T. Effect of two years of strict metabolic control on progression of incipient nephropathy in insulin-dependent diabetes. Lancet 1986; 2:1300.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/49/42777/abstract/58\">",
"      Dahl-J&oslash;rgensen K, Bj&oslash;ro T, Kierulf P, et al. Long-term glycemic control and kidney function in insulin-dependent diabetes mellitus. Kidney Int 1992; 41:920.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/49/42777/abstract/59\">",
"      ACE Inhibitors in Diabetic Nephropathy Trialist Group. Should all patients with type 1 diabetes mellitus and microalbuminuria receive angiotensin-converting enzyme inhibitors? A meta-analysis of individual patient data. Ann Intern Med 2001; 134:370.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/49/42777/abstract/60\">",
"      Captopril reduces the risk of nephropathy in IDDM patients with microalbuminuria. The Microalbuminuria Captopril Study Group. Diabetologia 1996; 39:587.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/49/42777/abstract/61\">",
"      Viberti G, Mogensen CE, Groop LC, Pauls JF. Effect of captopril on progression to clinical proteinuria in patients with insulin-dependent diabetes mellitus and microalbuminuria. European Microalbuminuria Captopril Study Group. JAMA 1994; 271:275.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/49/42777/abstract/62\">",
"      Randomised placebo-controlled trial of lisinopril in normotensive patients with insulin-dependent diabetes and normoalbuminuria or microalbuminuria. The EUCLID Study Group. Lancet 1997; 349:1787.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/49/42777/abstract/63\">",
"      Jerums G, Allen TJ, Campbell DJ, et al. Long-term comparison between perindopril and nifedipine in normotensive patients with type 1 diabetes and microalbuminuria. Am J Kidney Dis 2001; 37:890.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/49/42777/abstract/64\">",
"      Borch-Johnsen K, Wenzel H, Viberti GC, Mogensen CE. Is screening and intervention for microalbuminuria worthwhile in patients with insulin dependent diabetes? BMJ 1993; 306:1722.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/49/42777/abstract/65\">",
"      Mauer M, Zinman B, Gardiner R, et al. Renal and retinal effects of enalapril and losartan in type 1 diabetes. N Engl J Med 2009; 361:40.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/49/42777/abstract/66\">",
"      Bilous R, Chaturvedi N, Sj&oslash;lie AK, et al. Effect of candesartan on microalbuminuria and albumin excretion rate in diabetes: three randomized trials. Ann Intern Med 2009; 151:11.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3110 Version 13.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1005-122.72.76.133-7ADB670DEC-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f41_49_42777=[""].join("\n");
var outline_f41_49_42777=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H25\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION AND DEFINITIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      DETECTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Urine albumin concentration",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Urine albumin-to-creatinine ratio",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Limitations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Detection recommendation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      MECHANISMS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      NATURAL HISTORY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Prevalence",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Risk factors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Regression to normoalbuminuria",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Progression to macroalbuminuria",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Microalbuminuria and GFR",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Other microvascular complications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Mortality",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Glucose control",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Angiotensin inhibition",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Other antihypertensive drugs",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      SCREENING",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      PRIMARY PREVENTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Glycemic control",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      ACE inhibitors or ARBs",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/45/36570?source=related_link\">",
"      Assessment of kidney function",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/37/13914?source=related_link\">",
"      Assessment of urinary protein excretion and evaluation of isolated non-nephrotic proteinuria in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?9/5/9304?source=related_link\">",
"      Biology of glomerular podocytes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?11/34/11817?source=related_link\">",
"      Glycemic control and vascular complications in type 1 diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/16/20745?source=related_link\">",
"      High albuminuria (microalbuminuria) and cardiovascular disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/33/39449?source=related_link\">",
"      Microalbuminuria in type 2 diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/63/30714?source=related_link\">",
"      Overview of diabetic nephropathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?24/4/24644?source=related_link\">",
"      Patient information: Diabetic kidney disease (diabetic nephropathy) (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/38/32362?source=related_link\">",
"      Prevention and treatment of diabetic retinopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/48/40714?source=related_link\">",
"      Treatment of diabetic nephropathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/45/21210?source=related_link\">",
"      Treatment of hypertension in patients with diabetes mellitus",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f41_49_42778="Overview of the treatment of chronic pain";
var content_f41_49_42778=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"6\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Overview of the treatment of chronic pain",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?41/49/42778/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?41/49/42778/contributors\">",
"     Zahid H Bajwa, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?41/49/42778/contributors\">",
"     Howard S Smith, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?41/49/42778/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?41/49/42778/contributors\">",
"     Mark D Aronson, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?41/49/42778/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?41/49/42778/contributors\">",
"     Kari G Doucette, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?41/49/42778/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 31, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chronic pain is among the most common reasons for seeking medical attention and is reported by 20 to 50 percent of patients seen in primary care [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/49/42778/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. A number of pharmacologic and nonpharmacologic therapies are available for patients with chronic pain. An overview of these treatments is presented here. The pathogenesis and evaluation of chronic pain are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/59/16312?source=see_link\">",
"     \"Definition and pathogenesis of chronic pain\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/22/40296?source=see_link\">",
"     \"Evaluation of chronic pain in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H185827432\">",
"    <span class=\"h1\">",
"     APPROACH TO THE PATIENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment options for chronic pain generally fall into six major categories: pharmacologic, physical medicine, behavioral medicine, neuromodulation, interventional, and surgical approaches. Optimal patient outcomes often result from multiple approaches utilized in concert, coordinated via a multidisciplinary team of pain specialists. Collaborative care models in primary care, involving clinician training and patient workshops, can improve guideline-concordant pain management and patient outcomes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/49/42778/abstract/3\">",
"     3",
"    </a>",
"    ]. Medication should not be the sole focus of treatment, but should be used when needed, in conjunction with other treatment modalities, to meet treatment goals [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/49/42778/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients with chronic pain require ongoing evaluation, education and reassurance, as well as help in setting reasonable expectations for response. Currently available treatment modalities on average result in only about a 30 percent decrease in pain [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/49/42778/abstract/5\">",
"     5",
"    </a>",
"    ]. But even a partial response of 30 percent can be clinically significant and improve the patient&rsquo;s quality of life [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/49/42778/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Pharmacologic approaches are the most widely used therapeutic options to ameliorate persistent pain. The major categories of pharmacologic agents for pain management are:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Non-opioid analgesic agents (eg",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?15/27/15802?source=see_link\">",
"       acetaminophen",
"      </a>",
"      , nonsteroidal anti-inflammatory drugs (NSAIDs)s, COX-2 Inhibitors)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?41/50/42792?source=see_link\">",
"       Tramadol",
"      </a>",
"     </li>",
"     <li>",
"      Opioids",
"     </li>",
"     <li>",
"      Alpha 2 adrenergic agonists",
"     </li>",
"     <li>",
"      Antidepressants (tricyclics and serotonin-norepinephrine reuptake inhibitors [SNRIs])",
"     </li>",
"     <li>",
"      Antiepileptic drugs (",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?19/19/19768?source=see_link\">",
"       gabapentin",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?16/31/16887?source=see_link\">",
"       pregabalin",
"      </a>",
"      , and other anticonvulsants)",
"     </li>",
"     <li>",
"      Muscle relaxants",
"     </li>",
"     <li>",
"      N-methyl-d-aspartate (NMDA) receptor antagonists",
"     </li>",
"     <li>",
"      Topical analgesic agents",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    For many patients, an approach using combinations of drugs that target different metabolic pathways may result in improved analgesia and fewer side effects because lower doses of each drug can be used. However, there are relatively few studies specifically evaluating combinations of drugs for chronic pain. Treatment response differs between individuals, and no one approach is appropriate for all patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/49/42778/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Comorbidities should be evaluated and treated. In particular, major depression and chronic pain frequently coexist, and both conditions must be addressed to maximize the treatment response for either disorder [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/49/42778/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H185828296\">",
"    <span class=\"h1\">",
"     CHOICE OF THERAPY BY TYPE OF PAIN",
"    </span>",
"    &nbsp;&mdash;&nbsp;The choice of an appropriate initial therapeutic strategy is dependent upon an accurate evaluation of the cause of the pain and the type of chronic pain syndrome. In particular, neuropathic pain should be distinguished from nociceptive pain. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/22/40296?source=see_link\">",
"     \"Evaluation of chronic pain in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Neuropathic pain, resulting from damage to or pathology within the nervous system, can be central or peripheral. Causes of neuropathic pain are multiple, and include diabetes mellitus, postherpetic neuralgia, and stroke. Nociceptive pain, in contrast, is caused by stimuli that threaten or provoke actual tissue damage. Nociceptive pain is often due to musculoskeletal conditions, inflammation, or",
"    <span class=\"nowrap\">",
"     mechanical/compressive",
"    </span>",
"    problems.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H185828303\">",
"    <span class=\"h2\">",
"     Neuropathic pain",
"    </span>",
"    &nbsp;&mdash;&nbsp;Initial management of the patient with neuropathic pain involves establishing a diagnosis, whenever possible, and pursuing treatment targeted to the specific diagnosis. Thus, if nerve function is impaired by compression or drugs, alleviating the compression or removing the offending agent, if accomplished early enough, may be all that is needed.",
"   </p>",
"   <p>",
"    When pharmacologic management of chronic neuropathic pain is required, the choice of an initial agent will be guided by individual patient factors including the pathophysiology of the pain syndrome, other symptoms and comorbidities, other medications being taken, organ reserves,",
"    <span class=\"nowrap\">",
"     pharmacokinetics/pharmacodynamics,",
"    </span>",
"    and the likelihood of adverse effects.",
"   </p>",
"   <p>",
"    For most patients, the initial treatment of neuropathic pain involves either antidepressants (tricyclic antidepressants or dual reuptake inhibitors of serotonin and norepinephrine) or calcium channel alpha 2-delta ligands (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/19/19768?source=see_link\">",
"     gabapentin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/31/16887?source=see_link\">",
"     pregabalin",
"    </a>",
"    ), with adjunctive topical therapy (eg, topical",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/34/35360?source=see_link\">",
"     lidocaine",
"    </a>",
"    ) when pain is localized (",
"    <a class=\"graphic graphic_algorithm graphicRef58265 \" href=\"mobipreview.htm?13/9/13471\">",
"     algorithm 1",
"    </a>",
"    ). Opioid medications and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?41/50/42792?source=see_link\">",
"     tramadol",
"    </a>",
"    are second line agents for most patients. Combination therapy is often required, because less than half of patients with neuropathic pain will respond to a single agent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/49/42778/abstract/8\">",
"     8",
"    </a>",
"    ]. However, evidence is scant regarding the efficacy and safety of combination treatment.",
"   </p>",
"   <p>",
"    Most studies of pharmacologic therapy for neuropathic pain have focused on monotherapy for a specific etiology (eg postherpetic neuralgia, or painful diabetic peripheral neuropathy). There are few head-to-head comparisons of drugs, so that estimates of relative drug efficacies are based upon comparative response rates between studies and are inaccurate. Additionally, study duration is typically limited (six to eight weeks) which may inadequately reflect response over time for a chronic condition.",
"   </p>",
"   <p>",
"    Evidence-based guidelines have been developed by several groups, including:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The International Association for the Study of Pain (IASP) Neuropathic Pain Special Interest Group (NeuPSIG) - These guidelines, developed by a consensus process involving an international group of pain experts, are endorsed by the American Pain Society, the Canadian Pain Society, the Finnish Pain Society, the Latin American Federation of IASP Chapters, and the Mexican Pain Society [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/49/42778/abstract/9\">",
"       9",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The European Federation of Neurological Societies (EFNS) &ndash; Guidelines for the treatment of patients with neuropathic pain were updated in 2010 [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/49/42778/abstract/10,11\">",
"       10,11",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The Canadian Pain Society &ndash; These guidelines were developed concurrently with the initial guidelines from the EFNS [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/49/42778/abstract/12\">",
"       12",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The American Academy of Neurology (AAN), the American Association of Neuromuscular and Electrodiagnostic Medicine (AANEM), and the American Academy of Physical Medicine and Rehabilitation (AAPMR) &ndash; These guidelines are targeted to the treatment of painful diabetic neuropathy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/49/42778/abstract/13\">",
"       13",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Given the limitations of the available evidence, specific drug recommendations for the pharmacologic treatment of neuropathic pain vary between these multiple guidelines. However, there is general agreement about the classes of drugs that have proven efficacy and should be considered for first-line or subsequent therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/49/42778/abstract/14\">",
"     14",
"    </a>",
"    ]. There is consensus among the guidelines that first line agents include either calcium channel alpha 2-delta ligands (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/19/19768?source=see_link\">",
"     gabapentin",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/31/16887?source=see_link\">",
"     pregabalin",
"    </a>",
"    ) or tricyclic antidepressants. Serotonin norepinephrine uptake inhibitors (SNRIs) are identified as either first or second-line agents, although they may be preferred to tricyclic antidepressants. Among the tricyclic antidepressants, side effect profiles appear to favor the secondary amine tricyclics (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?29/21/30040?source=see_link\">",
"     nortriptyline",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/14/39144?source=see_link\">",
"     desipramine",
"    </a>",
"    ), although the efficacy is the same for other tricyclics such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/30/27112?source=see_link\">",
"     amitriptyline",
"    </a>",
"    .",
"   </p>",
"   <p>",
"    For most patients with neuropathic pain, opioids should be considered a second or third-line option. They may be considered earlier in the treatment of select patients, such as those with severe intractable pain, episodic exacerbations of severe pain, or neuropathic cancer pain [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/49/42778/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Certain medications may be indicated for the treatment of specific causes of neuropathic pain. For example, first-line treatment for trigeminal neuralgia is",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?25/10/25770?source=see_link\">",
"     carbamazepine",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/25/40344?source=see_link\">",
"     oxcarbazepine",
"    </a>",
"    . (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/3/34873?source=see_link&amp;anchor=H12#H12\">",
"     \"Trigeminal neuralgia\", section on 'Medical therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H185828310\">",
"    <span class=\"h2\">",
"     Nociceptive pain",
"    </span>",
"    &nbsp;&mdash;&nbsp;In contrast to neuropathic pain, the pharmacologic approach to nociceptive pain primarily involves non-narcotic and opioid analgesia (",
"    <a class=\"graphic graphic_algorithm graphicRef71075 \" href=\"mobipreview.htm?34/36/35407\">",
"     algorithm 2",
"    </a>",
"    ). Medication is used in conjunction with nonpharmacologic therapies and approaches to relieve the source of the pain.",
"   </p>",
"   <p>",
"    When pharmacotherapy for nociceptive pain is required,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?15/27/15802?source=see_link\">",
"     acetaminophen",
"    </a>",
"    is typically recommended as a first-line therapy for pain related to osteoarthritis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/49/42778/abstract/15,16\">",
"     15,16",
"    </a>",
"    ] and chronic low back pain [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/49/42778/abstract/17\">",
"     17",
"    </a>",
"    ]. However, acetaminophen is less effective than nonsteroidal anti-inflammatory drugs (NSAIDs) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/49/42778/abstract/18,19\">",
"     18,19",
"    </a>",
"    ] and has the potential for hepatic toxicity at doses of &gt;4 g per day [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/49/42778/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    An alternative first line agent is an oral NSAID, which is effective for mild-to-moderate chronic low back pain or osteoarthritis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/49/42778/abstract/21,22\">",
"     21,22",
"    </a>",
"    ]. Opioid medications should be used on a chronic basis only in patients who are assessed to be at low risk for substance abuse, and who have persistent pain despite trials of nonopioid analgesics and antidepressants. It should be recognized that the evidence for the effectiveness of long-term opioid therapy in terms of pain relief and improved functional outcomes is limited, and that the risk of opioid overdose increases with increasing dosing [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/49/42778/abstract/23\">",
"     23",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H4\">",
"     'Opioids'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9183967\">",
"    <span class=\"h1\">",
"     NON-OPIOID ANALGESICS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Non-opioid analgesics include",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?15/27/15802?source=see_link\">",
"     acetaminophen",
"    </a>",
"    , &ldquo;traditional&rdquo; nonselective nonsteroidal anti-inflammatory drugs (NSAIDs), and cyclooxygenase 2 (COX-2) inhibitors. NSAIDs and COX 2 inhibitors have anti-inflammatory properties. The COX enzymes catalyze arachidonic acid metabolism yielding prostanoids, which play a significant role in certain pain conditions. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/19/1336?source=see_link\">",
"     \"NSAIDs: Mechanism of action\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/36/5703?source=see_link\">",
"     \"NSAIDs: Therapeutic use and variability of response in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?12/48/13066?source=see_link\">",
"     \"Overview of selective COX-2 inhibitors\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Usual doses and attributes of non-opioid analgesics and anti-inflammatory drugs are presented in a table (",
"    <a class=\"graphic graphic_table graphicRef70067 \" href=\"mobipreview.htm?23/54/24431\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9184479\">",
"    <span class=\"h2\">",
"     Acetaminophen",
"    </span>",
"    &nbsp;&mdash;&nbsp;Para-acetylaminophenol, known as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?15/27/15802?source=see_link\">",
"     acetaminophen",
"    </a>",
"    in the United States and paracetamol in Europe, is the most commonly administered over-the-counter oral analgesic. The analgesic mechanisms of acetaminophen remain uncertain [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/49/42778/abstract/24\">",
"     24",
"    </a>",
"    ]. In contrast to the NSAIDs, acetaminophen is not anti-inflammatory.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?15/27/15802?source=see_link\">",
"     Acetaminophen (paracetamol)",
"    </a>",
"    is a core recommendation for use as an analgesic in multiple guidelines for the management of hip or knee osteoarthritis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/49/42778/abstract/25-27\">",
"     25-27",
"    </a>",
"    ]. However, both the efficacy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/49/42778/abstract/28\">",
"     28",
"    </a>",
"    ] and the safety [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/49/42778/abstract/29,30\">",
"     29,30",
"    </a>",
"    ] of long-term use of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?15/27/15802?source=see_link\">",
"     acetaminophen",
"    </a>",
"    at a dose of 4",
"    <span class=\"nowrap\">",
"     g/day",
"    </span>",
"    have been questioned. A systematic review of fifteen randomized trials found reasonable evidence that acetaminophen is modestly superior in efficacy compared with placebo for the relief of pain related to osteoarthritis (OA) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/49/42778/abstract/19\">",
"     19",
"    </a>",
"    ]. However, acetaminophen was not as effective as NSAIDs for improving knee and hip pain in people with OA [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/49/42778/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?15/27/15802?source=see_link\">",
"     Acetaminophen",
"    </a>",
"    is commonly combined with opioid medications, to reduce the amount of opioid needed. However, such combination products cannot be titrated readily because the opioid dose is limited by the toxicities of acetaminophen at higher doses.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9184486\">",
"    <span class=\"h3\">",
"     Hepatic toxicity",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?15/27/15802?source=see_link\">",
"     Acetaminophen",
"    </a>",
"    use is the most common cause of acute liver failure in the United States [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/49/42778/abstract/31\">",
"     31",
"    </a>",
"    ]. The potential for concerns about hepatotoxicity exist even at therapeutic doses of acetaminophen, especially in patients with chronic alcohol use [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/49/42778/abstract/32\">",
"     32",
"    </a>",
"    ]. Sustained consumption of acetaminophen at therapeutic doses (4 g daily) can lead to asymptomatic increases of blood hepatic aminotransferase concentrations after more than four days of consumption [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/49/42778/abstract/20,33,34\">",
"     20,33,34",
"    </a>",
"    ]. Such changes do not necessarily suggest an increased risk of progression to acute liver failure. Acetaminophen can produce a more severe form of hepatotoxicity, particularly in chronic alcoholics. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/43/25274?source=see_link\">",
"     \"Acetaminophen (paracetamol) poisoning in adults: Pathophysiology, presentation, and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In the United States, concerns about unintentional overdose have been rising, and government regulators have suggested that a maximum dose should be 2.6",
"    <span class=\"nowrap\">",
"     g/day",
"    </span>",
"    (eight tablets per day of a formulation containing 325 mg per dose unit), and that patients with significant liver disease or heavy alcohol use should be considered to have a relative contraindication to this drug. In 2011, the US Food and Drug Administration (FDA) asked drug manufacturers to limit the strength of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?15/27/15802?source=see_link\">",
"     acetaminophen",
"    </a>",
"    in prescription drug products to 325 mg per dosage unit [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/49/42778/abstract/35\">",
"     35",
"    </a>",
"    ]. The FDA also is considering reducing the maximum dose to 3250",
"    <span class=\"nowrap\">",
"     mg/d,",
"    </span>",
"    recognizing that the margin between the maximum recommended dose and a potentially toxic dose is lower than with other medications [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/49/42778/abstract/36\">",
"     36",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h2\">",
"     Nonsteroidal antiinflammatory drugs",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nonsteroidal antiinflammatory drugs (NSAIDs) primarily are indicated for mild to moderate pain, particularly of somatic origin, although a number of newer compounds carry an indication for severe pain. They are frequently used for soft tissue injury, strains, sprains, headaches, and arthritis. They also exert synergy when paired with opioids, producing a dose-sparing effect. The analgesic effect of NSAIDs derives both from its peripheral action on the enzyme cyclooxygenase, which plays a central role in inflammatory conditions, as well as an effect on the central nervous system, at least in certain pain states [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/49/42778/abstract/37\">",
"     37",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A systematic review of NSAIDs for the treatment of low back pain found that NSAIDs were more effective than placebo for pain relief, although had significantly more side effects [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/49/42778/abstract/38\">",
"     38",
"    </a>",
"    ]. This review did not find NSAIDs more effective than",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?15/27/15802?source=see_link\">",
"     acetaminophen",
"    </a>",
"    . Although several guidelines recommend oral NSAIDs as a first-line therapy in selected patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/49/42778/abstract/16,17\">",
"     16,17",
"    </a>",
"    ], the American Geriatric Society (AGS) guidelines for the management of persistent pain in older patients and the National Institute for Health and Clinical Excellence (NICE) guidelines for OA suggest that systemic NSAIDs should be avoided when possible [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/49/42778/abstract/39,40\">",
"     39,40",
"    </a>",
"    ]. For patients with localized pain in specific joints, topical NSAIDs may be a reasonable option for a trial of therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/49/42778/abstract/41-43\">",
"     41-43",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H9188590\">",
"     'Topical agents'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    A systematic review and meta-analysis evaluating oral cyclo-oxygenase 2 inhibitors (COX-2 inhibitors) found COX-2 inhibitors to be equal to nonselective NSAIDs for treating pain after soft tissue injuries, with fewer gastrointestinal adverse effects than NSAIDs [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/49/42778/abstract/44\">",
"     44",
"    </a>",
"    ].",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/11/40120?source=see_link\">",
"     Celecoxib",
"    </a>",
"    is an option for patients who require chronic NSAID treatment who are at risk for gastropathy. Doses above 200 mg per day have been associated with increased cardiovascular risk. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/27/39351?source=see_link&amp;anchor=H5#H5\">",
"     \"COX-2 selective inhibitors: Adverse cardiovascular effects\", section on 'Celecoxib'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There are many NSAIDs from which to choose (",
"    <a class=\"graphic graphic_table graphicRef70067 \" href=\"mobipreview.htm?23/54/24431\">",
"     table 1",
"    </a>",
"    ). There is little literature substantiating improved efficacy of one NSAID over another [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/49/42778/abstract/38\">",
"     38",
"    </a>",
"    ]. A patient who does not tolerate or respond to a particular NSAID may do well on another. Compliance can be improved by switching to a two times a day or once daily preparation. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/36/5703?source=see_link\">",
"     \"NSAIDs: Therapeutic use and variability of response in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h3\">",
"     Side effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;The main adverse effects of NSAIDs are inhibition of platelets (with potential promotion of bleeding), gastrointestinal insult, renal insult, and adverse cardiovascular effects. NSAIDs have significant potential for interaction with drugs commonly prescribed to patients with heart disease, most notably antihypertensive drugs [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/49/42778/abstract/45\">",
"     45",
"    </a>",
"    ],",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/49/42778/abstract/46\">",
"     46",
"    </a>",
"    ], and low-dose",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/49/42778/abstract/47\">",
"     47",
"    </a>",
"    ]. Thus, regular NSAID use should be avoided, if possible, in patients taking low-dose aspirin for cardiovascular protection. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/49/17177?source=see_link\">",
"     \"Nonselective NSAIDs: Overview of adverse effects\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/4/24648?source=see_link\">",
"     \"Nonselective NSAIDs: Adverse cardiovascular effects\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Most NSAIDs interfere with platelet aggregation; two exceptions are",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?41/43/42677?source=see_link\">",
"       choline magnesium trisalicylate",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/49/42778/abstract/48\">",
"       48",
"      </a>",
"      ], and the selective COX-2 inhibitors. Despite its short half-life,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      irreversibly inhibits platelet aggregation for the lifetime of the platelet (four to seven days); the inhibitory effect of other NSAIDs lasts about two days.",
"     </li>",
"     <li>",
"      NSAIDs produce adverse gastrointestinal side effects, including dyspepsia and gastric ulceration. Patients who are deemed at high risk for peptic ulcer disease or its complications (due to advanced age, a history of peptic ulcer disease or prior NSAID gastroduodenopathy, advanced illness or bleeding diathesis, or concurrent glucocorticoid use) have a relative contraindication to use of an NSAID. Food and antacids may help patients with less dyspepsia tolerate NSAIDs. In addition, protection against gastroduodenal toxicity can be achieved with a proton pump inhibitor. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?37/31/38393?source=see_link\">",
"       \"NSAIDs (including aspirin): Primary prevention of gastroduodenal toxicity\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Nephrotoxicity associated with NSAID includes reversible renal insufficiency due to renal vasoconstriction, acute interstitial nephritis, and a predisposition to acute tubular necrosis in the patient with low renal perfusion. In addition, NSAIDs lead to fluid retention and should be prescribed with caution in patients with hypertension, renal insufficiency, or heart failure. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?24/0/24582?source=see_link\">",
"       \"NSAIDs: Acute kidney injury (acute renal failure) and nephrotic syndrome\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?37/57/38803?source=see_link\">",
"       \"NSAIDs: Electrolyte complications\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      In patients with cardiovascular disease, NSAIDs interfere with the cardioprotective effect of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      , potentially exacerbate heart failure, and may raise blood pressure. NSAIDs also have some prothrombotic effects and are relatively contraindicated in patients with a history of venous thrombosis. In patients with or at risk for cardiovascular disease, NSAIDs should be used in the lowest effective dose, for the shortest duration necessary.",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?42/43/43705?source=see_link\">",
"       Naproxen",
"      </a>",
"      is the preferred nonselective NSAID in such patients. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?24/4/24648?source=see_link\">",
"       \"Nonselective NSAIDs: Adverse cardiovascular effects\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Other side effects of NSAIDS include hepatic toxicity, even at normally recommended doses; confusion and an inability to concentrate; allergic reactions. Some patients who are allergic to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    may also be allergic to other NSAIDs. Elevations in liver enzymes are generally mild and reversible with discontinuation of the NSAID.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     OPIOIDS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The role of opioid therapy in the more severe forms of acute pain and in cancer pain is well established, but opioid administration in chronic noncancer pain remains controversial [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/49/42778/abstract/23,49,50\">",
"     23,49,50",
"    </a>",
"    ]. Opioid prescriptions for the management of noncancer pain have increased over the last 10 to 20 years, and opioids are the most commonly prescribed class of medication in the United States [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/49/42778/abstract/51\">",
"     51",
"    </a>",
"    ]. In a 2000 to 2001 representative survey of households in the United States, approximately 2 percent of the respondents reported opioid use for at least one month; arthritis and back pain were the most prevalent conditions for which opioids were prescribed [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/49/42778/abstract/52\">",
"     52",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/43/43704?source=see_link\">",
"     \"Cancer pain management: General principles and risk management for patients receiving opioids\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/7/30842?source=see_link\">",
"     \"Cancer pain management with opioids: Optimizing analgesia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/24/19850?source=see_link\">",
"     \"Subacute and chronic low back pain: Pharmacologic and noninterventional treatment\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    For patients with chronic nonmalignant pain, the decision to begin long-term opioid therapy must be weighed carefully. Opioid therapy should be reserved for patients with moderate to severe chronic pain that is having an adverse impact on function or quality of life. (See",
"    <a class=\"local\" href=\"#H185828296\">",
"     'Choice of therapy by type of pain'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients with nociceptive pain syndromes may require opioid therapy if they do not respond to nonopioid analgesics or if their pain is severe at the outset. However, a systematic review and meta-analysis found that the use of opioids in patients with chronic back pain, compared to placebo and non-opioid analgesics, did not result in significant improvement in pain scores [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/49/42778/abstract/53\">",
"       53",
"      </a>",
"      ]. In addition, there was no significant reduction in pain from baseline in an efficacy comparison of different opioids.",
"     </li>",
"     <li>",
"      Patients with neuropathic pain may require opioids, but other medications (anticonvulsants and antidepressants) are considered first and second line, and should be initiated prior to opioid therapy.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Before initiating chronic opioid therapy, an assessment of the risks and benefits of therapy for the individual patient should be based upon the history, physical examination, and assessment of the risk of substance abuse, misuse, or addiction. Principles of risk management during opioid treatment for pain are shown in a table (",
"    <a class=\"graphic graphic_table graphicRef50477 \" href=\"mobipreview.htm?23/31/24061\">",
"     table 2",
"    </a>",
"    ). Screening to identify drug abusers is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/58/5033?source=see_link\">",
"     \"Substance use disorders: Principles for recognition and assessment in general medical care\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A personal or family history of alcohol or drug abuse is the most strongly predictive factor for aberrant drug-related behaviors related to chronic opioid therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/49/42778/abstract/54\">",
"     54",
"    </a>",
"    ]. A personal history of past drug abuse may be considered a contraindication to long-term opioid therapy, although this remains controversial. Guidelines from the American Pain Society and the American Academy of Pain Medicine recommend that patients at high risk be evaluated by a mental health or addiction specialist, and be willing to comply with more frequent and stringent monitoring [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/49/42778/abstract/55\">",
"     55",
"    </a>",
"    ]. The benefit-to-harm evaluation of chronic opioid therapy should be considered and documented on an ongoing and periodic basis during treatment with chronic opioids.",
"   </p>",
"   <p>",
"    Opioid therapy can be used safely and without the development of tolerance or addiction in properly selected patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/49/42778/abstract/56\">",
"     56",
"    </a>",
"    ]. Guidelines that have been established for opioid therapy should be followed closely [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/49/42778/abstract/55\">",
"     55",
"    </a>",
"    ]. Patients should be closely monitored, especially after initiation of opioid therapy as the risk for an adverse event is greatest shortly after initiation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/49/42778/abstract/57\">",
"     57",
"    </a>",
"    ]. Additionally, patients receiving higher doses are at increased risk for overdose. Doses should be adjusted in a goal-directed manner, with increases dependent upon clearly demonstrable functional improvement [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/49/42778/abstract/58\">",
"     58",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Prior to initiating chronic opioid therapy, patients should be assessed by their clinician for the psychological impact that pain is having on their lives, for possible psychological comorbidity that may be interfering with treatment, and for the risk of opioid addiction. Referral to a trained mental health professional should be considered, and is a component of routine evaluation prior to initiating chronic (&gt;three months) opioid therapy in several pain center programs. Ongoing psychologic support should be available to all patients requiring chronic opioid therapy. The dispensation of drugs and associated follow-up should be performed by a single clinician and pharmacy, allowing maximum consistency and continuity of treatment.",
"   </p>",
"   <p>",
"    It is important for clinicians to understand the difference between the terms \"physical dependence,\" \"tolerance,\" and \"addiction\" when prescribing opioids.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Physical dependence means that the rapid discontinuation of opioid following prolonged administration, usually one month or longer, will result in withdrawal symptoms such as dysphoria, anxiety, and volatility of mood, as well as physical findings such as hypertension, tachycardia, and sweating.",
"     </li>",
"     <li>",
"      Tolerance is present when increasing amounts of opioid are required to produce an equivalent level of efficacy.",
"     </li>",
"     <li>",
"      Addiction is a form of psychological dependence and refers to the extreme behavior patterns that are associated with procuring and consuming the drug.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    None, any, or all of these factors may present in patients who take opioids for prolonged periods of time. A discussion of prescription drug abuse is presented separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/43/36535?source=see_link\">",
"     \"Prescription drug abuse and addiction: Clinical features, epidemiology, and contributing factors\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/33/27160?source=see_link\">",
"     \"Prescription drug abuse and addiction: Prevention, identification, and management\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The US Food and Drug Administration is under a Congressional mandate to create Risk Evaluation and Mitigation Strategies (REMS) for abusable prescription drugs in an effort to reduce the rising prevalence of prescription drug abuse [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/49/42778/abstract/59\">",
"     59",
"    </a>",
"    ]. REMS require that the company marketing targeted opioids develop prescriber training and medication guides to reduce the potential for serious adverse outcomes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/49/42778/abstract/60\">",
"     60",
"    </a>",
"    ]. At present, REMS are being developed for new drugs, including the effervescent",
"    <a class=\"external\" href=\"file://www.uptodate.com/contents/fentanyl-drug-information?source=see_link\">",
"     fentanyl",
"    </a>",
"    &nbsp;buccal tablet, the buccal",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/52/38730?source=see_link\">",
"     fentanyl",
"    </a>",
"    soluble film, and the new long-acting",
"    <a class=\"external\" href=\"file://www.uptodate.com/contents/hydromorphone-drug-information?source=see_link\">",
"     hydromorphone",
"    </a>",
"    &nbsp;formulation. In the future it is likely that a consistent REMS will be applied to other long-acting and extended-release prescription opioids.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Mechanism of action",
"    </span>",
"    &nbsp;&mdash;&nbsp;Opioids exert their analgesic effect through at least three groups of receptors, and probably other subpopulations as well (",
"    <a class=\"graphic graphic_table graphicRef72705 \" href=\"mobipreview.htm?22/19/22843\">",
"     table 3",
"    </a>",
"    ). The distribution of these receptors throughout the body, along with their tissue densities within numerous organ systems, account for the global and varied effects of these drugs.",
"   </p>",
"   <p>",
"    The most profound analgesic effects of opioids are mediated at the mu receptors. Within the central nervous system (CNS), mu receptors are found in large numbers in the midbrain periaqueductal gray and the substantial gelatinosa in the dorsal horn of the spinal cord where they induce intense analgesia, and a number of other effects such as bradycardia, sedation, euphoria, physical dependence, and respiratory depression.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Preparations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Opioids are available in a variety of preparations. In addition to the common oral and parenteral routes of administration, they may be administered via transdermal (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/52/38730?source=see_link\">",
"     fentanyl",
"    </a>",
"    patch), transmucosal (fentanyl oral,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/48/25353?source=see_link\">",
"     hydromorphone",
"    </a>",
"    suppository), or intraspinal routes. A table shows usual starting doses for several available oral opioids (",
"    <a class=\"graphic graphic_table graphicRef58864 \" href=\"mobipreview.htm?11/31/11760\">",
"     table 4",
"    </a>",
"    ). It is helpful for the clinician to be familiar with a variety of these drugs since there is significant variability in patient response regarding opioid requirements, development of side effects and biases for or against various agents. It should be noted that propoxyphene, a weak opioid, has been voluntarily withdrawn from US markets due to reports of fatal cardiac arrhythmias and is not recommended for the treatment of chronic pain [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/49/42778/abstract/61\">",
"     61",
"    </a>",
"    ]. Meperidine should not be used for chronic pain because of CNS toxicity and availability of less toxic and more effective alternative drugs [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/49/42778/abstract/62\">",
"     62",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The body's endogenous antinociceptive mediators (comprising three classes of opioid peptides, the enkephalins, endorphins, and dynorphins) target their receptors and can produce dramatic degrees of analgesia when challenged. The potency of exogenously administered opioids equates to the affinity of these compounds for their binding sites. In pain management, the equianalgesic dose refers to the dose of an opioid that produces an equal degree of analgesia with the standard of comparison being",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/31/19962?source=see_link\">",
"     morphine sulfate",
"    </a>",
"    &nbsp;(",
"    <a class=\"graphic graphic_table graphicRef58864 \" href=\"mobipreview.htm?11/31/11760\">",
"     table 4",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    In patients requiring the most potent opioids, transdermal",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/52/38730?source=see_link\">",
"     fentanyl",
"    </a>",
"    may be preferable to sustained release oral",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/31/19962?source=see_link\">",
"     morphine",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/49/42778/abstract/63,64\">",
"     63,64",
"    </a>",
"    ]. A randomized study comparing transdermal fentanyl with sustained release oral morphine in 680 patients with chronic low back pain showed equivalent pain relief and less constipation for the group randomly assigned to fentanyl [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/49/42778/abstract/64\">",
"     64",
"    </a>",
"    ]. Stable long-term doses of transdermal fentanyl do not seem to significantly impair the ability to drive a car [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/49/42778/abstract/65\">",
"     65",
"    </a>",
"    ]. It should be noted that fentanyl should only be prescribed for patients with moderate to severe pain who have been taking regular doses of oral opioids for at least one week and who are considered to be opioid-tolerant [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/49/42778/abstract/66\">",
"     66",
"    </a>",
"    ]. The fentanyl patch must be protected from exposure to excessive heat which can increase transdermal absorption.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     WHO recommendations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Much of what is practiced in the use of opioids to manage chronic pain comes from experience with cancer pain. The World Health Organization's (WHO) \"analgesic ladder\" approach to cancer pain management, which was originally published in the mid-1980s, outlines an approach to pain control that is based upon the severity of pain (",
"    <a class=\"graphic graphic_figure graphicRef63298 \" href=\"mobipreview.htm?0/45/724\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/49/42778/abstract/67\">",
"     67",
"    </a>",
"    ]. The WHO analgesic ladder should not be viewed as evidence-based or a best practice guideline, but it has widely influenced cancer pain management, and many of the strategies are used in nonmalignant pain. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/43/43704?source=see_link&amp;anchor=H4#H4\">",
"     \"Cancer pain management: General principles and risk management for patients receiving opioids\", section on 'General principles of pain management'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The following is a summary of recommendations:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Medications should be administered through the most effective and comfortable route allowing patients the maximum control.",
"     </li>",
"     <li>",
"      Analgesics given for moderate to severe pain are given on a fixed dose schedule around the clock and not on an &ldquo;as needed&rdquo; or &ldquo;prn&rdquo; basis. This allows for more consistent pain relief since patients do not have to \"play catch-up\" with the previous dose that has largely worn off. Patients given scheduled analgesics are more comfortable and use less medication overall.",
"     </li>",
"     <li>",
"      A stepwise approach for the administration of pain medications suggests a sequence of medications: nonopioid medication (&plusmn; adjuvants) first. This is followed by the use of opioids (eg,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?35/0/35848?source=see_link\">",
"       codeine",
"      </a>",
"      ) for mild to moderate nociceptive pain, &plusmn; adjuvants, &plusmn; nonopioids. For pain that persists, opioids (eg,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?19/31/19962?source=see_link\">",
"       morphine",
"      </a>",
"      ) for moderate to severe pain are employed, &plusmn; adjuvants, &plusmn; nonopioids.",
"     </li>",
"     <li>",
"      There is a great deal of interpatient variability regarding opioid requirements to relieve pain. The maximal dose varies by patient, and is identified by the amount needed to relieve the pain without producing intolerable side effects.",
"     </li>",
"     <li>",
"      Adjuvants are used for enhancing analgesics, controlling side effects, and managing other symptoms that are associated with chronic pain, such as nausea, depression, sedation, insomnia, and anxiety.",
"     </li>",
"     <li>",
"      Follow-up closely with patients and look for changes in function and symptoms. Modify drug regimens as the symptoms dictate and continually educate the patient regarding the medication he or she is taking.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Initiation of therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with chronic nonmalignant pain may be candidates for opioid therapy after all other appropriate therapies have failed. Initial treatment with opioids should be considered as a therapeutic trial to determine whether chronic opioid therapy is effective and appropriate [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/49/42778/abstract/55\">",
"     55",
"    </a>",
"    ]. Opioid therapy should be goal-directed, with continued or increased dosing dependent upon demonstrable improvements in function or quality of life [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/49/42778/abstract/68\">",
"     68",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The use of opioids in chronic nonmalignant pain in no way excludes other treatment modalities. It is expected that full advantage will be taken of improvements in pain to permit the patient fuller involvement in a multidisciplinary program.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Opioid treatment agreements",
"    </span>",
"    &nbsp;&mdash;&nbsp;Opioid treatment agreements, also known as opioid contracts, can serve several purposes: to provide informed consent regarding risks and benefits of opioid treatment; to foster adherence to the treatment program and limit the potential for opioid abuse; and to improve the efficiency of the pain treatment program. There is debate whether contracts actually achieve these aims [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/49/42778/abstract/69\">",
"     69",
"    </a>",
"    ]. A systematic review of four observational studies that compared participants in pain programs that used a treatment agreement with matched controls or historical controls found a modest decrease (7 to 23 percent) in opioid misuse for the groups that used a treatment agreement, with or without urine testing [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/49/42778/abstract/70\">",
"     70",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Care should be taken to avoid the possible negative aspects of negotiating a formal agreement: patient stigmatization; undertreatment of pain; interference with the",
"    <span class=\"nowrap\">",
"     patient/clinician",
"    </span>",
"    relationship due to expression of lack of trust; and discriminatory behavior, as contracts are more likely to be invoked for minority classes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/49/42778/abstract/69\">",
"     69",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Components of the opioid treatment agreement may include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Informed consent should be obtained for all patients prior to initiation of chronic opioid therapy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/49/42778/abstract/55\">",
"       55",
"      </a>",
"      ]. Informed consent should include goals, expectations, risks including the likelihood of physical dependence and cognitive impairment, and alternative treatments. Female patients of childbearing age must understand the implication of becoming pregnant while taking opioids and the likelihood that children will be born with opioid dependence.",
"     </li>",
"     <li>",
"      Agreement to obtain prescriptions only from the contracting physician and, preferably, from one designated pharmacy.",
"     </li>",
"     <li>",
"      Agreement to take the medication only as prescribed, with provisions for some latitude for the consumption of more or less medication as symptoms dictate.",
"     </li>",
"     <li>",
"      Acknowledgment that patients are responsible for their written prescriptions, medication, and the arranging of refills during regular office hours. They also must plan ahead so as not to run out of medication during weekends or vacation periods.",
"     </li>",
"     <li>",
"      Agreement for random urine drug screens and office visits at a specified minimum interval.",
"     </li>",
"     <li>",
"      Specified terms for agreement violation, and understanding that lack of adherence may result in weaning and discontinuation of opioid therapy.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Initial therapy and dosing",
"    </span>",
"    &nbsp;&mdash;&nbsp;The selection of an initial opioid regimen should be individualized and the dose titrated until the goal for pain control is achieved or side effects limit further dose escalation. Some adverse effects may decrease with longer exposure, and some adverse effects can be managed by additional treatment. (See",
"    <a class=\"local\" href=\"#H13\">",
"     'Opioid side effects'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H14\">",
"     'Prevention of opioid side effects'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Evidence is insufficient to recommend a particular opioid for initial therapy, whether long-acting or short-acting medications are preferred, and specific dosing schedules [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/49/42778/abstract/55\">",
"     55",
"    </a>",
"    ]. Opioid-na&iuml;ve patients should be started at a low dose. Frail older patients and those with comorbidities should be prescribed the lowest initial dose. We prefer to initiate opioid therapy with a short-acting (immediate-release) drug and titrate upward to effect, with vigilance for side effects. The amount of drug used in a 24-hour period is then converted to a sustained release form and administered two or three times a day around the clock. If the patient is prone to breakthrough pain, rescue doses of immediate release preparations are provided for use when needed.",
"   </p>",
"   <p>",
"    In July 2012 the US Food and Drug Administration determined that a Risk Evaluation and Mitigation Strategy (REMS) is needed for all extended-release and long-acting opioid analgesics [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/49/42778/abstract/71\">",
"     71",
"    </a>",
"    ]. The REMS will involve provider training through an accredited continuing education program, patient counseling, and distribution of a medication guide for patients, specific for the opioid medication, each time it is dispensed. Medications affected by this REMS include extended-release formulations of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/48/25353?source=see_link\">",
"     hydromorphone",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/31/19962?source=see_link\">",
"     morphine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/34/10792?source=see_link\">",
"     oxycodone",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/8/32903?source=see_link\">",
"     oxymorphone",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/20/27975?source=see_link\">",
"     tapentadol",
"    </a>",
"    ;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/52/38730?source=see_link\">",
"     fentanyl",
"    </a>",
"    and buprenorphine-containing transdermal delivery systems; and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/57/36761?source=see_link\">",
"     methadone",
"    </a>",
"    tablets and solutions used for analgesia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9191146\">",
"    <span class=\"h2\">",
"     Monitoring",
"    </span>",
"    &nbsp;&mdash;&nbsp;Monitoring should take place at each visit and involve documentation of pain intensity, functional status, progress toward therapy goals, adverse effects, and adherence with prescribed pharmacologic and ancillary treatment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/49/42778/abstract/55\">",
"     55",
"    </a>",
"    ]. Visits should take place at a minimum every three to six months for patients who are on stable doses of opioids and more frequently at the initiation of therapy or during dose titrations. More intense monitoring is indicated for patients who have a history of substance abuse, have comorbid medical or psychiatric conditions, are older, or who have unstable social supports. Weekly monitoring is appropriate for patients at very high risk for adverse outcomes from chronic opioid treatment.",
"   </p>",
"   <p>",
"    Guidelines from the American Pain Society and the American Academy of Pain Medicine recommend periodic urine drug screens to confirm adherence for patients who are at high risk for aberrant drug related behaviors; drug screens should also be considered for patients who are not at high risk [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/49/42778/abstract/55\">",
"     55",
"    </a>",
"    ]. Periodic urine testing may identify the absence of prescribed opioids or presence of unprescribed drugs, although interpretation of the results can be challenging [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/49/42778/abstract/72\">",
"     72",
"    </a>",
"    ]. A systematic review of 11 studies that evaluated the effect of opioid contracts or urine drug testing on drug misuse found the studies to be generally of poor to fair quality, with inconsistent evidence that these interventions were effective [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/49/42778/abstract/70\">",
"     70",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9191277\">",
"    <span class=\"h2\">",
"     Risk of overdose",
"    </span>",
"    &nbsp;&mdash;&nbsp;The rate of unintentional overdose death in the United States more than doubled between 1999 and 2007 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/49/42778/abstract/73\">",
"     73",
"    </a>",
"    ]. Several studies have found that the rate of overdose and drug mortality is correlated with prescriptions for higher opioid doses in patients with chronic pain [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/49/42778/abstract/57,73,74\">",
"     57,73,74",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A cohort study of nearly 10,000 patients with chronic pain who were treated with chronic opioid therapy in a managed care setting found that the annual overdose rate correlated with the daily dose of opioids: 0.2, 0.7 and 1.8 percent overdose rate for patients receiving &lt;20",
"      <span class=\"nowrap\">",
"       mg/d,",
"      </span>",
"      50 to 99",
"      <span class=\"nowrap\">",
"       mg/d,",
"      </span>",
"      and &gt;100",
"      <span class=\"nowrap\">",
"       mg/d",
"      </span>",
"      of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?19/31/19962?source=see_link\">",
"       morphine",
"      </a>",
"      equivalent, respectively [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/49/42778/abstract/57\">",
"       57",
"      </a>",
"      ]. The risk for an adverse event was greatest either shortly after the initial opioid prescription or after a dose escalation, indicating the need for closer monitoring with new and changing doses.",
"     </li>",
"     <li>",
"      A case cohort study in US veterans compared opioid doses for patients who had an unintentional opioid overdose with a sample of other patients who were prescribed opioids for pain. Among patients with chronic pain, patients who were prescribed opioids at a dose of &gt;100",
"      <span class=\"nowrap\">",
"       mg/d,",
"      </span>",
"      compared with those who received &lt;20",
"      <span class=\"nowrap\">",
"       mg/d,",
"      </span>",
"      had a seven-fold increase in overdose death [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/49/42778/abstract/73\">",
"       73",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    It is not clear if the correlation between overdose and prescription dosing reflects patient differences or the impact of higher opioid doses.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9191218\">",
"    <span class=\"h2\">",
"     Discontinuing therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients who exhibit repeated aberrant drug-related behaviors, who do not demonstrate progress toward therapeutic goals, or who experience intolerable adverse effects should be tapered off of chronic opioid therapy. A slow taper of a 10 percent dose reduction per week will minimize withdrawal systems, but rapid tapers may entail 25 to 50 percent reductions every few days. The weaning rate may be rapid for patients taking high opioid doses (the equivalent of 200 mg per day of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/31/19962?source=see_link\">",
"     morphine",
"    </a>",
"    ), and slowed when daily doses approach the equivalent of 60 to 80 mg morphine.",
"   </p>",
"   <p>",
"    Patients who are withdrawn from opioid therapy should continue to be treated for their painful conditions, as well as for substance abuse or psychiatric conditions as needed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Opioid side effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;The side effects of opioids are mediated at multiple sites.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Nausea and vomiting result from activation of the chemoreceptor trigger zone in the medulla and from changes in the vestibular system.",
"     </li>",
"     <li>",
"      Within the gastrointestinal system, opioids delay gastric emptying and cause constipation via an effect upon the central vagus nerve and the mesenteric plexus in the gut.",
"     </li>",
"     <li>",
"      The cardiovascular effects of opioids are mediated centrally at the central vagal nucleus and, in the case of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?19/31/19962?source=see_link\">",
"       morphine",
"      </a>",
"      , directly in the sinoatrial node. Much of the blood pressure instability that occurs with morphine results from histamine release; there also are direct effects upon venous and arterial vasculature. In general, opioids administered in patients who are not hypovolemic maintain cardiac stability fairly well and depress myocardial contractility only slightly.",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?11/44/11976?source=see_link\">",
"       Meperidine",
"      </a>",
"      is the notable exception, displaying a mild vagolytic and a negative inotropic effect.",
"     </li>",
"     <li>",
"      Opioid-induced hyperalgesia is a state of nociceptive sensitization with a paradoxical response whereby a patient receiving opioids for the treatment of pain may actually become more sensitive to certain painful stimuli and in some cases, experience pain from ordinarily non-painful stimuli (allodynia) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/49/42778/abstract/75\">",
"       75",
"      </a>",
"      ]. The phenomenon of opioid-induced hyperalgesia has been demonstrated in animal models, but has uncertain relevance in the clinical setting [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/49/42778/abstract/75-77\">",
"       75-77",
"      </a>",
"      ]. When suspected, it is reasonable to consider opioid rotation [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/49/42778/abstract/78\">",
"       78",
"      </a>",
"      ], or the use of a non-opioid strategy for pain control.",
"     </li>",
"     <li>",
"      The narcotic bowel syndrome is a form of opioid-induced hyperalgesia resulting in severe chronic abdominal pain in the setting of chronic opioid use, with relief upon gradual opioid withdrawal [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/49/42778/abstract/79\">",
"       79",
"      </a>",
"      ]. &nbsp; &nbsp;",
"     </li>",
"     <li>",
"      Other opioid actions are seen in the biliary tract, the genitourinary system, and the skin.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Prevention of opioid side effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients who are treated with opioids, either for short-term use or chronic administration, can experience a variety of unpleasant side effects including nausea and vomiting, abdominal cramping, pruritus, sedation, changes in mentation, and constipation. Antihistamines and antiemetics are available to treat pruritus and nausea, respectively, and should be instituted early when patients require them.",
"   </p>",
"   <p>",
"    Some untoward effects of opioids may subside with time. However, meticulous attention to treating side effects as they occur can make the difference between tolerance of the medication with good analgesic effect versus complete treatment failure. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/4/9290?source=see_link\">",
"     \"Cancer pain management with opioids: Prevention and management of side effects\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h4\">",
"     Constipation",
"    </span>",
"    &nbsp;&mdash;&nbsp;A bowel regimen aimed at preventing constipation should be initiated in patients treated with opioids, particularly for those who are prone to this condition. Predisposing factors to constipation include advanced age, immobility, poor diet, intraabdominal pathology, neuropathy, hypercalcemia, and concurrent use of other constipating drugs. Some patients are able to improve bowel function by dietary modifications, including increased consumption of fluids and dietary fiber. Others may require a prophylactic laxative regimen that might include a stool softener and contact cathartic (eg,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?21/41/22165?source=see_link\">",
"     docusate",
"    </a>",
"    100 mg orally twice daily and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/21/40276?source=see_link\">",
"     senna",
"    </a>",
"    two tablets at bedtime) or daily administration of an osmotic laxative (eg,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/34/33316?source=see_link\">",
"     lactulose",
"    </a>",
"    30 ml daily or polyethylene glycol two tablespoons daily).",
"   </p>",
"   <p>",
"    Two peripherally acting opioid-receptor antagonists are available for the management of opioid-induced constipation:",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/29/2516?source=see_link\">",
"     methylnaltrexone",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/7/5236?source=see_link\">",
"     alvimopan",
"    </a>",
"    . They do not cross the blood-brain barrier and have no antianalgesic effect. Methylnaltrexone was approved by the US FDA in 2008 as a subcutaneous injection for the treatment of opioid-induced constipation in patients with terminal illness requiring palliative care [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/49/42778/abstract/80\">",
"     80",
"    </a>",
"    ]. Randomized trials report some effectiveness for oral alvimopan in the treatment of opioid-induced constipation in patients with chronic pain [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/49/42778/abstract/81\">",
"     81",
"    </a>",
"    ], although guidelines from the American Pain Society conclude that evidence is insufficient to recommend oral opioid antagonists for prevention or treatment of constipation in patients with chronic pain who are receiving opioid therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/49/42778/abstract/55\">",
"     55",
"    </a>",
"    ]. In addition, a 12-month study found an increased incidence of myocardial infarction in patients with chronic pain who were prescribed alvimopan 0.5 mg twice daily compared to placebo [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/49/42778/abstract/82\">",
"     82",
"    </a>",
"    ]; although this relationship has not been seen in other studies, use of alvimopan in the ambulatory setting is not recommended, pending further data.",
"   </p>",
"   <p>",
"    There is an increased risk of intestinal perforation with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/29/2516?source=see_link\">",
"     methylnaltrexone",
"    </a>",
"    , particularly in patients with advanced illness who have risk factors for perforation including gastrointestinal cancer, ulcer, or concomitant use of NSAIDs or glucocorticoids.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h4\">",
"     Sedation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Opioid therapy can cause somnolence or mental clouding. Symptoms typically wane over a period of days or weeks, but are persistent in some patients. Opioid dose reduction (up to 25 percent) may be tried for patients who have reasonable analgesia. If this is not successful, opioid rotation or adjuvant therapy may provide opioid-sparing.",
"   </p>",
"   <p>",
"    Stimulants have been used with good effect when sedation is an issue with opioids, particularly in cancer patients requiring large doses. They also appear to possess analgesic, antidepressant, and euphoric effects. The precise mechanism of action of stimulants is not clear; however, it is likely related to their sympathomimetic action with effects upon serotonin, norepinephrine and the endogenous opioids. These drugs must be used cautiously since they are associated with tolerance and side effects of their own, and there are numerous contraindications to their use.",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/60/39881?source=see_link\">",
"     Methylphenidate",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?1/8/1159?source=see_link\">",
"     modafinil",
"    </a>",
"    have been used most frequently; other psychostimulants such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/44/32454?source=see_link\">",
"     dextroamphetamine",
"    </a>",
"    may be beneficial but should be reserved for patients who did not tolerate or respond to methylphenidate or modafinil. Tolerance may develop and older patients may be susceptible to cognitive disturbance. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/4/9290?source=see_link&amp;anchor=H8#H8\">",
"     \"Cancer pain management with opioids: Prevention and management of side effects\", section on 'Psychostimulants'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9191351\">",
"    <span class=\"h2\">",
"     Specific preparations and routes",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9191451\">",
"    <span class=\"h3\">",
"     Tramadol and tapentadol",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?41/50/42792?source=see_link\">",
"     Tramadol",
"    </a>",
"    (Ultram&trade;) is a novel analgesic that has some activity at mu receptors. It also inhibits the reuptake of serotonin and norepinephrine and may provide analgesia through this mechanism. A systematic review found that tramadol was effective for relief of neuropathic pain [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/49/42778/abstract/83\">",
"     83",
"    </a>",
"    ], and another systematic review concluded that tramadol improved functional outcomes and pain in patients with fibromyalgia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/49/42778/abstract/84\">",
"     84",
"    </a>",
"    ]. That same systematic review, however, did not find tramadol more effective than NSAIDs or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?29/21/30040?source=see_link\">",
"     nortriptyline",
"    </a>",
"    for relief of other chronic pain.",
"   </p>",
"   <p>",
"    The side effect profile of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?41/50/42792?source=see_link\">",
"     tramadol",
"    </a>",
"    is similar to that of other weak opioids, although the incidence of gastric upset may be higher. Seizures are an additional risk, particularly in patients who take antidepressants, neuroleptics, or other drugs that decrease the seizure threshold. Tramadol has been associated with increased risk for suicide [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/49/42778/abstract/85\">",
"     85",
"    </a>",
"    ]. In May 2010, the US Federal Drug Administration required labeling to indicate this risk, particularly in patients who have emotional disturbance, suicidal ideation or attempts in the past, or are addiction-prone. Tramadol is not scheduled as a controlled substance although psychological and physical dependence may occur [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/49/42778/abstract/62\">",
"     62",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?41/50/42792?source=see_link\">",
"     Tramadol",
"    </a>",
"    is extensively metabolized with one pharmacologically active metabolite, M1. This is a P-450 generated molecule that is subject to enzyme induction and inhibition. The dose is reduced in patients with hepatic dysfunction and in older patients. Tramadol is available in both short- and long-acting formulations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/49/42778/abstract/86\">",
"     86",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/20/27975?source=see_link\">",
"     Tapentadol",
"    </a>",
"    is an oral mu receptor agonist and norepinephrine reuptake inhibitor. It has the potential advantage of reduced gastrointestinal side effects. Tapentadol is classified as a Schedule II controlled substance in the United States and can lead to addiction.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21149184\">",
"    <span class=\"h3\">",
"     Methadone",
"    </span>",
"    &nbsp;&mdash;&nbsp;The use of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/57/36761?source=see_link\">",
"     methadone",
"    </a>",
"    for management of chronic pain has increased, and may be one factor in the significant rise in methadone-associated deaths in the United States [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/49/42778/abstract/55\">",
"     55",
"    </a>",
"    ]. Methadone disproportionately accounts for deaths from overdose in patients receiving opioid treatment for chronic pain, accounting for one-third of opioid-related overdose deaths, though only a few percent of opioid prescriptions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/49/42778/abstract/87\">",
"     87",
"    </a>",
"    ]. Methadone, when used for analgesia, has been designated for a Risk Evaluation and Mitigation Strategy (REMS) program in the United States, as of July 2012 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/49/42778/abstract/71\">",
"     71",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The pharmacokinetics of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/57/36761?source=see_link\">",
"     methadone",
"    </a>",
"    are complex, with a half life up to five days and the potential for drug accumulation. Use requires close monitoring and methadone should be prescribed only by clinicians with experience in using the drug; equianalgesic dose ratios to other opioids are variable. Methadone may cause QTc prolongation and cardiac arrhythmias, particularly at higher doses (&gt;120 mg per day). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/52/29514?source=see_link&amp;anchor=H6#H6\">",
"     \"Treatment of opioid abuse and dependence\", section on 'Methadone'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21149152\">",
"    <span class=\"h3\">",
"     Intrathecal therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;For patients who require particularly large doses of opioids, the systemic effect may become intolerable. Such patients may be candidates for an implantable spinal delivery system that permits intrathecal administration of opioid, usually",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/31/19962?source=see_link\">",
"     morphine",
"    </a>",
"    . The advantage of this route of administration is the ability to get the opioid directly to the opioid receptors in the spinal cord, thereby reducing the systemic concentration and minimizing side effects. Patients may continue to use oral analgesics on a rescue basis. However, pump technology often permits dosing to be matched to variations in day-to-day requirements. Their small size and complete implantation allows the patient a tremendous degree of freedom in daily life.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19064636\">",
"    <span class=\"h2\">",
"     Opioid rotation",
"    </span>",
"    &nbsp;&mdash;&nbsp;With gradual escalation of the opioid dose, a favorable balance between analgesia and side effects can be achieved in most patients. However, some patients experience intolerable side effects before adequate analgesia is reached and some do not achieve adequate analgesia. Several strategies may be employed in efforts to reduce toxicity and improve pain control, including aggressive treatment of side effects; use of coanalgesics or intravenous agents or anesthetic procedures; and use of nonpharmacologic interventions. An alternative approach is to change to another opioid in an attempt to allow titration to adequate pain control while limiting side effects.",
"   </p>",
"   <p>",
"    The practice of changing from one opioid to another, referred to as opioid rotation, is most commonly undertaken when adequate analgesia cannot be achieved or is limited by the occurrence of problematic side effects. An interdisciplinary expert panel defined opioid rotation (or switching) as a change in the opioid drug or route of administration with the goal of improving outcomes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/49/42778/abstract/88\">",
"     88",
"    </a>",
"    ]. The principle of rotation is based upon the observation that a patient&rsquo;s response can vary from opioid to opioid, both for analgesia and adverse effects. An inadequate response or the occurrence of intolerable side effects with one opioid does not necessarily predict a similar response to another [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/49/42778/abstract/89\">",
"     89",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Potential reasons why a particular opioid may not provide adequate analgesia may include the accumulation of",
"    <span class=\"nowrap\">",
"     toxic/active",
"    </span>",
"    metabolites, changes in pain pathophysiology, individual pharmacogenetic drug differences, drug interactions, and incomplete cross-tolerance.",
"   </p>",
"   <p>",
"    The effectiveness of opioid rotation has been reported only in uncontrolled retrospective studies and case reports [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/49/42778/abstract/90\">",
"     90",
"    </a>",
"    ]. Randomized trials are needed to establish whether opioid switching can improve pain management outcomes, and to evaluate which drugs are best used for first or second-line switching, and in what ratios of conversion.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19064538\">",
"    <span class=\"h3\">",
"     Indications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Indications for a switch in existing opioid therapy include [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/49/42778/abstract/88\">",
"     88",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Intolerable adverse effects during dose titration",
"     </li>",
"     <li>",
"      Poor analgesic efficacy despite aggressive dose titration",
"     </li>",
"     <li>",
"      Problematic drug-drug interactions",
"     </li>",
"     <li>",
"      Preference or need for a different route of administration",
"     </li>",
"     <li>",
"      Change in clinical status (eg, concern about drug abuse, development of malabsorption syndrome) or clinical settings that suggest benefit from an opioid with different pharmacokinetic properties",
"     </li>",
"     <li>",
"      Financial or drug-availability considerations",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19064691\">",
"    <span class=\"h3\">",
"     Initiating opioid rotation",
"    </span>",
"    &nbsp;&mdash;&nbsp;To implement opioid rotation, a clinician must first calculate an approximate equianalgesic dose between the current opioid and the new opioid. This calculated starting dose must be safe, neither high enough to cause opioid toxicity nor low enough to cause withdrawal, and sufficiently efficacious to produce no worsening of the pain [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/49/42778/abstract/91\">",
"     91",
"    </a>",
"    ]. Equianalgesic doses of opioids used in the treatment of chronic pain are shown in a table (",
"    <a class=\"graphic graphic_table graphicRef58864 \" href=\"mobipreview.htm?11/31/11760\">",
"     table 4",
"    </a>",
"    ). These equivalent doses are generally estimates based upon empiric information, and may need to be revised as more rigorous evidence emerges regarding comparative efficacy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/49/42778/abstract/91\">",
"     91",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Because it is difficult to predict a patient&rsquo;s response to a new opioid, care should be taken to achieve analgesia without excessive dosing. Rotating to a percentage of the equianalgesic dose is prudent, since incomplete cross-tolerance is unpredictable. In the process of titrating to an appropriate dose, supplemental short-acting breakthrough medication should be made available to avoid &ldquo;underdosing&rdquo; resulting in increased pain.",
"   </p>",
"   <p>",
"    Several key points should be emphasized when implementing opioid rotation:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Utilize an opioid equianalgesic table that is",
"      <span class=\"nowrap\">",
"       appropriate/relevant",
"      </span>",
"      for your practice, and use it consistently.",
"     </li>",
"     <li>",
"      In deciding on an alternative opioid, consider all patient factors (eg, what is the best route of drug delivery in this patient? Which drug is most convenient for the",
"      <span class=\"nowrap\">",
"       patient/treating",
"      </span>",
"      team? Is cost an issue? Is the new drug available in the community?).",
"     </li>",
"     <li>",
"      In rotating opioids, consider all medical factors that may be relevant (eg, renal function, liver function, age, comorbidities), and adjust equianalgesic dose based on these factors.",
"     </li>",
"     <li>",
"      In rotating to an opioid other than",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?35/57/36761?source=see_link\">",
"       methadone",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/52/38730?source=see_link\">",
"       fentanyl",
"      </a>",
"      , decrease the equianalgesic dose by 25 to 50 percent.",
"     </li>",
"     <li>",
"      In rotating to",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?35/57/36761?source=see_link\">",
"       methadone",
"      </a>",
"      , reduce the dose by 75 to 90 percent.",
"     </li>",
"     <li>",
"      In rotating to transdermal",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/52/38730?source=see_link\">",
"       fentanyl",
"      </a>",
"      , maintain the equianalgesic dose.",
"     </li>",
"     <li>",
"      In rotating because of uncontrolled pain, consider a lesser dose reduction than usual.",
"     </li>",
"     <li>",
"      Ensure that appropriate",
"      <span class=\"nowrap\">",
"       rescue/breakthrough",
"      </span>",
"      doses are available. Use 5 to 15 percent of the total daily opioid dose as a guide, and reassess and retitrate the new opioid.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27481771\">",
"    <span class=\"h2\">",
"     Driving safety",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cognitive and psychomotor adverse effects of opioids could potentially impair the ability to drive or work safely. Opioids can slow reaction time, cause drowsiness, or cloud judgment, particularly when they are first started or when doses are increased [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/49/42778/abstract/92\">",
"     92",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There are no large trials examining the risk of driving while on opioids. Epidemiologic studies and reviews suggest that motor vehicle accidents and fatalities, and citations for impaired driving, are",
"    <em>",
"     not",
"    </em>",
"    disproportionally increased among patients receiving chronic stable doses of opioids (no dose changes for at least one week [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/49/42778/abstract/93\">",
"     93",
"    </a>",
"    ]):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A literature review concluded that the majority of studies found no impaired psychomotor abilities among",
"      <span class=\"nowrap\">",
"       opioid-dependent/tolerant",
"      </span>",
"      patients [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/49/42778/abstract/94\">",
"       94",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In another study, which videotaped patients while actually driving, those on chronic opioid therapy versus healthy controls showed neither a difference in driving errors in community or obstacle course driving, nor in tests of attention [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/49/42778/abstract/95\">",
"       95",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    No studies have evaluated the effects of chronic opioid therapy on work safety.",
"   </p>",
"   <p>",
"    These data, while limited, support the view that patients who have been on a stable dose of opioids for at least one week who feel no cognitive changes can drive. Clinicians should counsel all patients on chronic opioid therapy about the potential for transient or lasting cognitive impairment that may affect driving or work safety.",
"   </p>",
"   <p>",
"    For patients initiating opioid therapy for chronic pain or changing doses, most experts agree that driving or operating heavy machinery is unsafe and should probably be avoided until a stable dose has been reached [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/49/42778/abstract/55,93,96\">",
"     55,93,96",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     ANTICONVULSANTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Antiepileptic medications have been used for pain management since the 1960s. Three antiepileptic drugs (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/19/19768?source=see_link\">",
"     gabapentin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/31/16887?source=see_link\">",
"     pregabalin",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?25/10/25770?source=see_link\">",
"     carbamazepine",
"    </a>",
"    ) are among the five drugs approved by the US Food and Drug Administration (FDA) for the treatment of neuropathic pain [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/49/42778/abstract/97\">",
"     97",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9185924\">",
"    <span class=\"h2\">",
"     Gabapentin and pregabalin",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/19/19768?source=see_link\">",
"     Gabapentin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/31/16887?source=see_link\">",
"     pregabalin",
"    </a>",
"    bind to the voltage-gated calcium channels at the alpha 2-delta subunit and inhibit neurotransmitter release. They have proven efficacy versus placebo in several neuropathic pain conditions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/49/42778/abstract/9,98-100\">",
"     9,98-100",
"    </a>",
"    ]. Gabapentin has primarily been studied and found effective for the treatment of postherpetic neuralgia and painful diabetic neuropathy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/49/42778/abstract/101,102\">",
"     101,102",
"    </a>",
"    ]. Treatment with gabapentin should be initiated at low dosage with gradual increases until pain relief, dose limiting adverse affects, or 3600 mg per day in three divided doses is achieved. An adequate trial of treatment with gabapentin can require two months or more.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/31/16887?source=see_link\">",
"     Pregabalin",
"    </a>",
"    was designed as a lipophilic gamma aminobutyric acid (GABA) analog to facilitate diffusion across the blood-brain barrier [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/49/42778/abstract/103\">",
"     103",
"    </a>",
"    ]. Pregabalin may provide analgesia more quickly than",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/19/19768?source=see_link\">",
"     gabapentin",
"    </a>",
"    , both because a lower initial dosage (150",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    was efficacious in some trials and because of a shorter time required to titrate to a full dosage [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/49/42778/abstract/104\">",
"     104",
"    </a>",
"    ]. A 2009 systematic review of 19 randomized trials of pregabalin in patients with postherpetic neuralgia, painful diabetic neuropathy, central neuropathic pain, or fibromyalgia found pregabalin at doses of 300 mg to 600 mg daily more effective than placebo [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/49/42778/abstract/105\">",
"     105",
"    </a>",
"    ]. Response rates were lower for patients with central neuropathic pain or fibromyalgia, compared to patients with postherpetic neuralgia or painful diabetic neuropathy.",
"   </p>",
"   <p>",
"    Although",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/19/19768?source=see_link\">",
"     gabapentin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/31/16887?source=see_link\">",
"     pregabalin",
"    </a>",
"    have few drug interactions, both can produce dose-dependent dizziness and sedation that can be reduced by starting with lower dosages and titrating cautiously. Pregabalin has been reported to cause euphoria, and is classified as a Schedule V controlled substance in the United States. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/61/43994?source=see_link\">",
"     \"Pharmacology of antiepileptic drugs\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9185931\">",
"    <span class=\"h2\">",
"     Other antiepileptics",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other antiepileptic drugs, including",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/27/5561?source=see_link\">",
"     topiramate",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/28/6602?source=see_link\">",
"     lamotrigine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?42/52/43847?source=see_link\">",
"     levetiracetam",
"    </a>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/48/35594?source=see_link\">",
"     phenytoin",
"    </a>",
"    , sodium",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?25/11/25785?source=see_link\">",
"     valproate",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/2/10279?source=see_link\">",
"     zonisamide",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/22/26982?source=see_link\">",
"     tiagabine",
"    </a>",
"    , and the benzodiazepine",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?25/45/26328?source=see_link\">",
"     clonazepam",
"    </a>",
"    , have been utilized anecdotally and in randomized trials for various pain conditions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/49/42778/abstract/106\">",
"     106",
"    </a>",
"    ]. Evidence of their effectiveness is not as robust as for",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/19/19768?source=see_link\">",
"     gabapentin",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/31/16887?source=see_link\">",
"     pregabalin",
"    </a>",
"    , and in general these agents should be reserved for second line treatment in patients who don&rsquo;t respond to or cannot tolerate other medications. A systematic review of lamotrigine for acute and chronic pain concluded that it does not have a place in the treatment of pain, given other more effective therapies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/49/42778/abstract/107\">",
"     107",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    One exception is the use of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?25/10/25770?source=see_link\">",
"     carbamazepine",
"    </a>",
"    or its derivative",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/25/40344?source=see_link\">",
"     oxcarbazepine",
"    </a>",
"    as specific first-line therapy in the management of trigeminal neuralgia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/49/42778/abstract/108\">",
"     108",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/3/34873?source=see_link&amp;anchor=H12#H12\">",
"     \"Trigeminal neuralgia\", section on 'Medical therapy'",
"    </a>",
"    .) Limited evidence from short term trials suggests carbamazepine is moderately effective for other chronic neuropathic pain [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/49/42778/abstract/109\">",
"     109",
"    </a>",
"    ] but its adverse effect profile indicates that other drugs may be a better choice for pain syndromes other than trigeminal neuralgia.",
"   </p>",
"   <p>",
"    Mechanisms of action for the anticonvulsants are different and not fully understood. The activity of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/48/35594?source=see_link\">",
"     phenytoin",
"    </a>",
"    seems to be related to its membrane stabilizing action.",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?25/10/25770?source=see_link\">",
"     Carbamazepine",
"    </a>",
"    , which is pharmacologically related to the tricyclic antidepressants, prevents repeated discharges in neurons, an action that is consistent with its ability to relieve lancinating pain. Valproic acid and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?25/45/26328?source=see_link\">",
"     clonazepam",
"    </a>",
"    are believed to work through enhancement of GABA inhibitory systems.",
"   </p>",
"   <p>",
"    A complete blood count and baseline liver function tests should be obtained prior to starting patients on older anticonvulsants such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/48/35594?source=see_link\">",
"     phenytoin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?25/10/25770?source=see_link\">",
"     carbamazepine",
"    </a>",
"    , and valproic acid. It is recommended that blood tests be followed for the first three weeks and periodically thereafter. Blood levels do not generally correlate with efficacy; doses are gradually titrated upward until pain symptoms are improved or adverse effects occur. Blood levels may be helpful in determining compliance during dose escalations.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9187567\">",
"    <span class=\"h1\">",
"     ANTIDEPRESSANTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Antidepressants are a heterogeneous group of medications approved to treat major depressive disorders. Both tricyclic antidepressants (TCAs) and serotonin norepinephrine reuptake inhibitors (SNRIs) possess analgesic qualities while the evidence for the effectiveness of selective serotonin reuptake inhibitors (SSRIs) is weaker [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/49/42778/abstract/110\">",
"     110",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/20/36169?source=see_link\">",
"     \"Unipolar depression in adults and tricyclic and tetracyclic drugs: Pharmacology, administration, and side effects\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/28/5578?source=see_link\">",
"     \"Serotonin-norepinephrine reuptake inhibitors (SNRIs): Pharmacology, administration, and side effects\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/56/31626?source=see_link\">",
"     \"Unipolar depression in adults and selective serotonin reuptake inhibitors (SSRIs): Pharmacology, administration, and side effects\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Multiple studies have found that antidepressants provide effective pain relief in neuropathic pain conditions with a number needed to treat of two to three [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/49/42778/abstract/111-114\">",
"     111-114",
"    </a>",
"    ]. Antidepressants may also be effective for other painful conditions (eg,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?36/62/37864?source=see_link\">",
"     duloxetine",
"    </a>",
"    for fibromyalgia and chronic low back pain).",
"   </p>",
"   <p>",
"    Analgesic antidepressants may provide pain separate from their antidepressant effect, since analgesic effects appear to occur earlier (eg, after approximately a week) and at lower doses than for antidepressant effects. In addition, the analgesic efficacy of antidepressants in neuropathic pain has been established in non-depressed patients. For some patients, an effect on underlying depression, especially for SSRIs, may also contribute to relief of pain symptomatology. (See",
"    <a class=\"local\" href=\"#H9188953\">",
"     'Concurrent depression'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9187574\">",
"    <span class=\"h2\">",
"     Tricyclic antidepressants",
"    </span>",
"    &nbsp;&mdash;&nbsp;None of the tricyclic antidepressants (TCAs) carries an indication for pain management. Nevertheless, they remain a pharmacological mainstay in a variety of chronic pain states, with or without coexisting depression.",
"   </p>",
"   <p>",
"    TCAs can be divided into tertiary amines and their demethylated secondary amine derivatives. In addition, although a tetracyclic and not a tricyclic antidepressant,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/18/16678?source=see_link\">",
"     maprotiline",
"    </a>",
"    (Ludiomil) is often considered with these drugs.",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/30/27112?source=see_link\">",
"     Amitriptyline",
"    </a>",
"    has been the most widely studied TCA in chronic pain [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/49/42778/abstract/115,116\">",
"     115,116",
"    </a>",
"    ], although a number of others, including",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/51/32560?source=see_link\">",
"     doxepin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/41/41624?source=see_link\">",
"     imipramine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?29/21/30040?source=see_link\">",
"     nortriptyline",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/14/39144?source=see_link\">",
"     desipramine",
"    </a>",
"    also have been used with success. TCAs are believed to have independent analgesic effects as well as an ability to relieve the depressive symptoms associated with chronic pain.",
"   </p>",
"   <p>",
"    The mechanism of their analgesic action is uncertain; it has been theorized that the analgesic properties are associated with their action as serotonin and norepinephrine reuptake inhibitors. Consistent with this theory is the observation that TCAs with the greatest effect upon serotonin seem to have the greatest analgesic effect. There is also some evidence that TCAs potentiate the endogenous opioid system [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/49/42778/abstract/117\">",
"     117",
"    </a>",
"    ]. Still, it remains to be explained why a drug like",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?14/49/15130?source=see_link\">",
"     fluoxetine",
"    </a>",
"    , a potent serotonin reuptake inhibitor, has little or no analgesic effect on its own, but seems to add to the efficacy of some TCAs.",
"   </p>",
"   <p>",
"    TCAs prescribed for chronic pain have typically been given at lower doses than those used in depression, although higher doses have provided superior analgesia in some studies. Some patients respond only as the dose is steadily increased. TCAs (eg,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?29/21/30040?source=see_link\">",
"     nortriptyline",
"    </a>",
"    ) may be started at 10",
"    <span class=\"nowrap\">",
"     mg/d",
"    </span>",
"    and slowly titrated up to an effective analgesic dose (eg, 75",
"    <span class=\"nowrap\">",
"     mg/d).",
"    </span>",
"    It can take up to six to eight weeks, including two weeks at the highest dosage tolerated, for an adequate trial of treatment with TCA, although the onset of analgesia may be after one week and typically occurs at lower doses than needed for the treatment of depression [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/49/42778/abstract/9,118\">",
"     9,118",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although TCAs have reasonable analgesic properties, they are also associated with multiple undesirable adverse effects that vary depending on the individual agent (",
"    <a class=\"graphic graphic_table graphicRef74319 \" href=\"mobipreview.htm?18/17/18716\">",
"     table 5",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef62488 \" href=\"mobipreview.htm?37/46/38639\">",
"     table 6",
"    </a>",
"    ). Adverse effects include anticholinergic effects, antihistaminergic effects (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/51/32560?source=see_link\">",
"     doxepin",
"    </a>",
"    has the most potent antihistaminergic effects), alpha-1 adrenergic receptor blockade, and cardiac effects (increasing intraventricular conduction, prolonged QT interval, prolonged conduction through the atrioventricular node).",
"   </p>",
"   <p>",
"    Among the TCAs,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/30/27112?source=see_link\">",
"     amitriptyline",
"    </a>",
"    has the most potent anticholinergic effects and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/14/39144?source=see_link\">",
"     desipramine",
"    </a>",
"    has the least, and thus is the least sedating. Anticholinergic adverse affects including dry mouth, orthostatic hypotension, constipation and urinary retention can be reduced by starting with low dosages administered at bedtime and with slow titration to higher dosage, as well as by using a secondary amine TCAs (eg,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?29/21/30040?source=see_link\">",
"     nortriptyline",
"    </a>",
"    or desipramine).",
"   </p>",
"   <p>",
"    Clinicians must explain to the patient why TCAs are used, how to administer them, and what benefits and side effects might be expected.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Sedation, a well-known side effect of TCAs, can be turned into a benefit since many chronic pain patients suffer from sleep disturbances; the induction of sleep occurs one to three hours following ingestion. Patients should be instructed to match this period with their normal sleep interval.",
"     </li>",
"     <li>",
"      If patients awake with a morning \"hangover,\" medication should be taken earlier in the evening.",
"     </li>",
"     <li>",
"      Stool softeners can be used if there is a tendency toward constipation.",
"     </li>",
"     <li>",
"      Patients should understand that although analgesia may occur in days, it frequently will take weeks to obtain any significant benefit.",
"     </li>",
"     <li>",
"      It is important for patients to know that many of the unpleasant side effects, such as dry mouth, mental clouding, and others, may diminish in days to weeks.",
"     </li>",
"     <li>",
"      Doses should be increased gradually to the point of effect or intolerable side effects. When one antidepressant does not work, another can be tried. Sometimes decreasing the dose or substituting a different member of this class, one with fewer anticholinergic effects, will make the difference.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    TCAs (mainly those with greater anticholinergic effects) are relatively contraindicated in patients with severe cardiac disease, particularly conduction disturbances; obtaining a pretreatment ECG is recommended. They should also be avoided in patients with severe gastrointestinal dysfunction since such symptoms may be exacerbated.",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/14/39144?source=see_link\">",
"     Desipramine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?29/21/30040?source=see_link\">",
"     nortriptyline",
"    </a>",
"    can be used safely in older patients; their starting dose should be reduced by one-half, and patients should be watched carefully for untoward effects as the doses are escalated slowly. Guidelines from the International Association for the Study of Pain (IASP) recommend prescribing TCAs with caution in patients with ischemic cardiac disease or ventricular conduction abnormalities, limiting the dosages to less than 100 mg per day when possible, and obtaining a screening electrocardiogram for patients older than 40 years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/49/42778/abstract/9\">",
"     9",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9187603\">",
"    <span class=\"h2\">",
"     Serotonin norepinephrine reuptake inhibitors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Four serotonin norepinephrine reuptake inhibitors (SNRIs) are available in the United States:",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?21/45/22233?source=see_link\">",
"     venlafaxine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?18/33/18967?source=see_link\">",
"     desvenlafaxine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?36/62/37864?source=see_link\">",
"     duloxetine",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/32/36358?source=see_link\">",
"     milnacipran",
"    </a>",
"    . Venlafaxine and desvenlafaxine are approved by the US Food and Drug Administration (FDA) for the treatment of major depressive disorder and anxiety disorders. Desvenlafaxine is the main active metabolite of venlafaxine and side effect profiles for venlafaxine and desvenlafaxine are similar. Milnacipran is FDA approved for the treatment of fibromyalgia but not for depression, although systematic reviews have found that its efficacy as an antidepressant is comparable to others. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/28/5578?source=see_link\">",
"     \"Serotonin-norepinephrine reuptake inhibitors (SNRIs): Pharmacology, administration, and side effects\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?36/62/37864?source=see_link\">",
"     Duloxetine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?21/45/22233?source=see_link\">",
"     venlafaxine",
"    </a>",
"    have been studied in peripheral neuropathic pain while",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/32/36358?source=see_link\">",
"     milnacipran",
"    </a>",
"    has been studied only in fibromyalgia. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9187629\">",
"    <span class=\"h3\">",
"     Venlafaxine",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?21/45/22233?source=see_link\">",
"     Venlafaxine",
"    </a>",
"    has shown efficacy in painful diabetic peripheral neuropathy and painful polyneuropathies of different origins, but not in post herpetic neuralgia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/49/42778/abstract/9,110\">",
"     9,110",
"    </a>",
"    ]. Typically two to four weeks are required to titrate to an efficacious dosage (150 to 225 mg per day). At very low doses venlafaxine has activity similar to an SSRI but its properties as an SNRI prevail as the dose is increased.",
"   </p>",
"   <p>",
"    Cardiac conduction abnormalities have been reported in a small number of patients, and blood pressure increases can occur; therefore",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?21/45/22233?source=see_link\">",
"     venlafaxine",
"    </a>",
"    should be prescribed with caution in patients with cardiac disease. In addition, venlafaxine should be tapered when treatment is being discontinued because of withdrawal symptoms. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9187649\">",
"    <span class=\"h3\">",
"     Duloxetine",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?36/62/37864?source=see_link\">",
"     Duloxetine",
"    </a>",
"    hydrochloride has been shown to be effective in the treatment of painful diabetic neuropathy, fibromyalgia, and more recently chronic low back pain and osteoarthritis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/49/42778/abstract/119-121\">",
"     119-121",
"    </a>",
"    ]. Duloxetine was approved by the US Food and Drug Administration in 2010 for the treatment of chronic musculoskeletal pain including discomfort from osteoarthritis and chronic lower back pain, and had been previously approved for the treatment of diabetic peripheral neuropathy and fibromyalgia, as well as major depression, anxiety, and stress urinary incontinence.",
"   </p>",
"   <p>",
"    A systematic review of six randomized trials (three in patients with painful diabetic neuropathy and three in patients with fibromyalgia) found evidence that",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?36/62/37864?source=see_link\">",
"     duloxetine",
"    </a>",
"    60 mg daily was more effective than placebo with response rates suggesting efficacy similar to other antidepressants, but there are no direct comparison trials available [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/49/42778/abstract/122\">",
"     122",
"    </a>",
"    ]. Three randomized trials in patients with chronic low back pain, conducted by the manufacturer, have been reported [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/49/42778/abstract/123-125\">",
"     123-125",
"    </a>",
"    ]. In two trials, response rates for at least a 30 percent reduction in pain were somewhat greater for duloxetine than placebo (53 to 56 percent for duloxetine and 40 to 49 percent for placebo) but the third trial found that the initial differential response was no longer seen by weeks 12 to 13.",
"   </p>",
"   <p>",
"    The most common side effects reported with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?36/62/37864?source=see_link\">",
"     duloxetine",
"    </a>",
"    include nausea, dry mouth, insomnia, drowsiness, constipation, fatigue, and dizziness. Side effects are reduced by administering duloxetine 30 mg once daily for one week before increasing to 60 mg once daily. Duloxetine should be avoided in patients with hepatic or severe renal insufficiency. Gradual tapering is recommended at discontinuation to avoid withdrawal symptoms.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9188953\">",
"    <span class=\"h2\">",
"     Concurrent depression",
"    </span>",
"    &nbsp;&mdash;&nbsp;Analgesia with SSRIs may be associated with the primary relief of depression, especially in somatically-expressive instances of depression. In many of these patients, effective treatment of the primary depression can ameliorate or even resolve the complaint of chronic pain. In other patients, for whom the symptoms of depression are a complicating feature and sometimes natural sequel to life with chronic pain, favorable response to an SSRI will greatly relieve the subjective experience of distress and the affective and emotional intensity with which physical pain is experienced.",
"   </p>",
"   <p>",
"    In a randomized trial of patients with concurrent depression and musculoskeletal pain, a stepped care approach of initial optimization of antidepressant treatment followed by a supervised pain self-management program over 12 weeks significantly improved severity scores for both depression and pain at 6 and 12 month follow-up, compared to usual care [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/49/42778/abstract/126\">",
"     126",
"    </a>",
"    ]. In this trial,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?21/45/22233?source=see_link\">",
"     venlafaxine",
"    </a>",
"    was used in 61 percent of the intervention patients, an SSRI in 32 percent, and other antidepressants or combinations in the remainder.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     ZICONOTIDE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intrathecal analgesic therapy should be reserved for intractable severe pain with significant impact on quality of life that is refractory to all other appropriate treatments.",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/55/38773?source=see_link\">",
"     Ziconotide",
"    </a>",
"    is a novel intrathecal pain medication that was approved in 2004 by the US Food and Drug Administration for use in patients who are intolerant of or refractory to other treatments for pain including intrathecal",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/31/19962?source=see_link\">",
"     morphine",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/49/42778/abstract/127,128\">",
"     127,128",
"    </a>",
"    ]. Ziconotide, a synthetic drug with an amino acid sequence derived from marine sea snail venom (a conopeptide), binds to neural N-type calcium channels [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/49/42778/abstract/129\">",
"     129",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A randomized trial in 111 adults with cancer or AIDS and refractory pain found that more patients had moderate to complete relief of pain with intrathecal",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/55/38773?source=see_link\">",
"     ziconotide",
"    </a>",
"    than with placebo (53 versus 18 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/49/42778/abstract/130\">",
"     130",
"    </a>",
"    ]. Central nervous system side effects were significantly more common than with placebo (83 versus 35 percent) and included dizziness, nystagmus, somnolence, and confusion. Fewer side effects were seen with slower titration of ziconotide to a lower final dose in a subsequent randomized trial of patients with chronic pain, three-quarters of whom had neuropathic pain [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/49/42778/abstract/131\">",
"     131",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The US prescribing information for",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/55/38773?source=see_link\">",
"     ziconotide",
"    </a>",
"    includes a \"black box\" warning about neurologic impairment and psychiatric symptoms and states that patients with a preexisting history of psychosis should not be treated with ziconotide [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/49/42778/abstract/127\">",
"     127",
"    </a>",
"    ]. We recommend that, at this point, it only be used in patients with no other reasonable options for pain control.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     ADJUVANT MEDICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The usefulness of pairing adjuvant agents with pain medications is well known to pain management specialists. Some adjuvants are used to treat the side effects associated with pain medications, while others potentiate analgesia. The goal for treatment is maximizing analgesia and the relief of emotional distress. When chronic pain has remained intractable or largely inert to the recognized and well-documented medication regimens, a certain amount of exploration and innovation may be medically indicated.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Benzodiazepines",
"    </span>",
"    &nbsp;&mdash;&nbsp;Benzodiazepines may be utilized in patients who would benefit from anxiolysis. These are commonly employed in cancer patients and in non-cancer pain complicated by anxiety disorder (",
"    <a class=\"graphic graphic_table graphicRef56777 \" href=\"mobipreview.htm?7/14/7403\">",
"     table 7",
"    </a>",
"    ). The disadvantage of this class of drugs relates to their addictive potential, as well as their potentiation of sedative effects and respiratory depression in patients who use opioids concurrently.",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?25/45/26328?source=see_link\">",
"     Clonazepam",
"    </a>",
"    may be especially useful for neuropathic pain.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Antispasmodics",
"    </span>",
"    &nbsp;&mdash;&nbsp;A wide variety of pain conditions, both acute and chronic, may be accompanied by painful muscle spasm. Antispasmodics can be useful in treating this aspect of the patient's symptoms, but their action may be more the result of sedation rather than muscle relaxation. Commonly used muscle relaxants are listed in a table (",
"    <a class=\"graphic graphic_table graphicRef76475 \" href=\"mobipreview.htm?3/20/3403\">",
"     table 8",
"    </a>",
"    ). These medications may also cause CNS depression and should be used cautiously when combined with other CNS depressant medications.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9188590\">",
"    <span class=\"h2\">",
"     Topical agents",
"    </span>",
"    &nbsp;&mdash;&nbsp;Topical agents for the management of pain have several potential advantages over systemic drugs: delivery at the site of insult, lower initial rates of systemic absorption, fewer systemic effects, and patient preference. Patients often perceive topical preparations to be safer than their oral equivalents. However, significant systemic concentration can be achieved by topical application and systemic side effects are possible.",
"   </p>",
"   <p>",
"    The 5%",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/34/35360?source=see_link\">",
"     lidocaine",
"    </a>",
"    patch has shown efficacy and excellent tolerability in trials involving patients with postherpetic neuralgia and allodynia and in patients with allodynia due to different types of peripheral neuropathic pain [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/49/42778/abstract/132,133\">",
"     132,133",
"    </a>",
"    ]. Lidocaine gel (5%), which is less expensive than the patch, has also shown efficacy in patients with postherpetic neuralgia and allodynia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/49/42778/abstract/133\">",
"     133",
"    </a>",
"    ]. Topical lidocaine is most appropriate for patients with well localized neuropathic pain. Although it can be used as monotherapy, it is often used as an adjunct to systemic medication.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?13/44/14022?source=see_link\">",
"     Capsaicin",
"    </a>",
"    is an alkaloid derived from chili peppers; repeated application is thought to deplete substance P from primary afferent neurons [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/49/42778/abstract/134\">",
"     134",
"    </a>",
"    ]. Capsaicin is available as a cream (0.025% or 0.075%), and as a high concentration patch (8%). A systematic review found that capsaicin had moderate to poor efficacy for relief of chronic musculoskeletal or neuropathic pain, but might be useful as an adjunctive therapy or for patients unresponsive to other treatments [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/49/42778/abstract/135\">",
"     135",
"    </a>",
"    ]. Capsaicin has been used in patients with post herpetic neuralgia, HIV neuropathy, and diabetic neuropathy. Capsaicin cream must be applied three to four times per day over the entire painful area for up to six to eight weeks before optimal pain relief can be achieved, while the patch, administered under close physician supervision, is applied as a single 60-minute application. The major adverse effects of capsaicin are burning, stinging, and erythema at the site of application, leading to intolerance in up to one-third of patients.",
"   </p>",
"   <p>",
"    Topical nonsteroidal anti-inflammatory drugs, in the form of a gel, spray, or cream, provide modest relief for acute musculoskeletal pain [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/49/42778/abstract/136\">",
"     136",
"    </a>",
"    ]. Evidence of effectiveness for these agents for chronic low back pain, widespread musculoskeletal pain, and peripheral neuropathic pain, however, is weaker than for acute pain [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/49/42778/abstract/137\">",
"     137",
"    </a>",
"    ]. A systematic review of four randomized trials found that a topical 1.5% solution of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/29/38352?source=see_link\">",
"     diclofenac",
"    </a>",
"    was more effective than a control vehicle in the relief of knee osteoarthritic pain, and was generally well tolerated [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/49/42778/abstract/138\">",
"     138",
"    </a>",
"    ]. A systematic review found that response rates for",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?29/23/30072?source=see_link\">",
"     topical salicylates",
"    </a>",
"    for chronic pain are lower than for topical nonsteroidals [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/49/42778/abstract/139\">",
"     139",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Topical",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/51/32560?source=see_link\">",
"     doxepin",
"    </a>",
"    , available in topical formulation for the treatment of pruritis, had only minimal effect on pain reduction in one small trial [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/49/42778/abstract/140\">",
"     140",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9188826\">",
"    <span class=\"h2\">",
"     Botulinum toxin",
"    </span>",
"    &nbsp;&mdash;&nbsp;Botulinum toxin type A (BTX-A), a potent neurotoxin, may be effective in reducing the dose of opioids needed for analgesia in patients with severe post herpetic neuralgia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/49/42778/abstract/141\">",
"     141",
"    </a>",
"    ], but further study in larger trials is needed for its role in both neuropathic and nociceptive chronic pain [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/49/42778/abstract/142\">",
"     142",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h1\">",
"     NONPHARMACOLOGIC THERAPIES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nonpharmacologic therapies encompass a wide array of treatments which may be grouped into the physical interventions (including physical therapy, acupuncture, chiropractic manipulation, massage, and others) and the psychoeducational interventions such as cognitive-behavioral therapy, family therapy, psychotherapy, and patient education.",
"   </p>",
"   <p>",
"    Chronic pain is a summation of physical and psychological derangements. Thus, successful management requires addressing all of its aspects. This begins with making patients aware of what is available therapeutically and explaining what each therapy component offers. There is evidence that combination therapies are more effective than any single approach for maintaining long-term gains [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/49/42778/abstract/143\">",
"     143",
"    </a>",
"    ]. Patients with chronic back pain or fibromyalgia may respond to multidisciplinary programs more successfully than patients with chronic pain of more diverse etiologies.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A meta-analysis considering the role of adjunctive therapies in the management of chronic nonmalignant pain found that the combination of exercise and psychoeducational approaches can lead to a significant reduction in pain and improvement in functional status for a number of musculoskeletal conditions [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/49/42778/abstract/144\">",
"       144",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A multifaceted collaborative intervention involving 400 patients with chronic musculoskeletal pain (12 weeks or longer) being managed in primary care through the Veterans Administration system was evaluated in a cluster randomized controlled trial [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/49/42778/abstract/3\">",
"       3",
"      </a>",
"      ]. Patients randomized to receive collaborative care (involving clinician and patient education, a multidisciplinary care program based on individual patient assessment, and recommendations to primary care clinicians) compared to usual care, showed small improvement in a pain-related disability scale and pain scale. Collaborative care patients were more likely to be prescribed nonopioid adjunctive medications, and when opioids were used they were more likely to be long-acting.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In the context of multimodal interventions, interventions other than systemic pharmacologic treatments for chronic pain may include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Behavioral medicine approaches",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Cognitive behavioral therapy",
"     </li>",
"     <li>",
"      Biofeedback",
"     </li>",
"     <li>",
"      Relaxation therapy",
"     </li>",
"     <li>",
"      Psychotherapy and individual or group counseling",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Aerobic exercise",
"     </li>",
"     <li>",
"      Acupuncture",
"     </li>",
"     <li>",
"      Physical and occupational therapy",
"     </li>",
"     <li>",
"      Chiropractics and osteopathic manipulation",
"     </li>",
"     <li>",
"      Ultrasonic stimulation",
"     </li>",
"     <li>",
"      Electrical neuromodulation",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Transcutaneous electrical nerve stimulation (TENS)",
"     </li>",
"     <li>",
"      Spinal cord stimulation",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Thermal applications",
"      <span class=\"nowrap\">",
"       (heat/cold)",
"      </span>",
"     </li>",
"     <li>",
"      Interventional approaches",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Ablative techniques",
"     </li>",
"     <li>",
"      Botulinum toxin injections",
"     </li>",
"     <li>",
"      Nerve blocks",
"     </li>",
"     <li>",
"      Trigger point injections",
"     </li>",
"     <li>",
"      Epidural steroid injections",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Surgical approaches",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Minimally invasive techniques",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2234320\">",
"    <span class=\"h2\">",
"     Behavioral medicine approaches",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2234327\">",
"    <span class=\"h3\">",
"     Cognitive-behavioral therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cognitive-behavioral therapy (CBT) is the most commonly used behavioral medicine approach for pain patients. CBT focuses simultaneously on the environment, behavior, and cognition. Cognitive behavioral therapy is structured, goal directed, problem focused, and time limited (often 10 to 20 sessions) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/49/42778/abstract/145\">",
"     145",
"    </a>",
"    ]. Patients learn how their thoughts contribute to symptoms of their disorder, and how to modify these thoughts. Increased cognitive awareness is combined with specific behavioral techniques. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/3/29751?source=see_link&amp;anchor=H432862147#H432862147\">",
"     \"Overview of psychotherapies\", section on 'Cognitive and behavioral therapies'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/24/19850?source=see_link&amp;anchor=H22#H22\">",
"     \"Subacute and chronic low back pain: Pharmacologic and noninterventional treatment\", section on 'Cognitive behavioral therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    CBT for pain incorporates three components: patient education, behavioral skill training, and cognitive-skill training [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/49/42778/abstract/146\">",
"     146",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Behavioral skill training involves education related to the behavioral principles, such as conditioning, reinforcement,",
"      <span class=\"nowrap\">",
"       pain/illness",
"      </span>",
"      behaviors, and attentional training, and how those principles interact with pain and disability.",
"     </li>",
"     <li>",
"      Relaxation and controlled-breathing exercises are especially useful in the skills-acquisition phase because they can be readily learned by almost all patients.",
"     </li>",
"     <li>",
"      Typical cognitive training for pain management begins with helping patients understand their own cognitive response system. Specifically, patients can learn to monitor situational factors that trigger their",
"      <span class=\"nowrap\">",
"       pain/stress",
"      </span>",
"      and what they actually experience emotionally, behaviorally, and physically when they have",
"      <span class=\"nowrap\">",
"       pain/stress.",
"      </span>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Although often delivered as a structured course of one-on-one sessions with a therapist, it appears that CBT can be effectively administered in a variety of other formats, including in a group, via the computer, or by telephone. In a randomized trial of patients with chronic widespread pain, symptom improvement at six months was reported in 8 percent of patients assigned to usual care, 35 percent assigned to CBT via telephone, and 37 percent assigned to a combination of telephone CBT and exercise [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/49/42778/abstract/147\">",
"     147",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2234483\">",
"    <span class=\"h3\">",
"     Biofeedback",
"    </span>",
"    &nbsp;&mdash;&nbsp;A systematic review found that biofeedback was more effective than waiting list controls for the treatment of migraine and tension-type headache, with the greatest impact on headache frequency, and additional significant effects on anxiety and medication consumption [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/49/42778/abstract/148\">",
"     148",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2234700\">",
"    <span class=\"h2\">",
"     Physical medicine approaches",
"    </span>",
"    &nbsp;&mdash;&nbsp;An exercise regimen specifically tailored to the patient is at the core of a physical or occupational therapy program. Stretching is a key component to restoring normal range of motion (ROM). ROM exercises vary from passive (in which there is no voluntary muscle contraction and with the application of total external force) to active assisted (in which there is partial contraction and external force). After ROM is normalized, muscle conditioning is addressed to improve stability, function, and pain. Muscle conditioning focuses on three areas: strength, endurance, and re-education [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/49/42778/abstract/149\">",
"     149",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/24/19850?source=see_link&amp;anchor=H15#H15\">",
"     \"Subacute and chronic low back pain: Pharmacologic and noninterventional treatment\", section on 'Activity and physical treatments'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/43/6841?source=see_link\">",
"     \"Exercise-based therapy for low back pain\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21149344\">",
"    <span class=\"h3\">",
"     Spinal manipulation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The use of spinal manipulation in the treatment of musculoskeletal pain is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/16/41222?source=see_link\">",
"     \"Spinal manipulation in the treatment of musculoskeletal pain\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2234772\">",
"    <span class=\"h2\">",
"     Neuromodulation approaches",
"    </span>",
"    &nbsp;&mdash;&nbsp;Systems used to provide neuromodulation analgesia can be classified into four major categories: external peripheral, internal peripheral, spinal, and supraspinal. External peripheral systems can be further subdivided into surface and percutaneous systems. The most common surface external peripheral neuromodulation system is transcutaneous nerve stimulation (TENS).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2234884\">",
"    <span class=\"h3\">",
"     TENS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Transcutaneous Electrical Stimulation (TENS) involves the application of electrical currents to the skin primarily for the purposes of pain relief. It is a safe, non-invasive treatment that can be self-applied.",
"   </p>",
"   <p>",
"    The clinical application of TENS involves the delivery of a low voltage electrical current from a small battery-operated device to the skin via surface electrodes. The majority of TENS devices offer variable frequency, pulse duration, intensity and type of output (burst or continuous). Combinations of different stimulation parameters are used to produce four main modes of TENS: conventional TENS (high frequency, short pulse duration, low intensity); acupuncture-like TENS (low frequency, long pulse duration, high intensity); burst TENS (high frequency trains of pulses delivered at a low frequency); and brief-intense TENS (high frequency and long pulse duration pulses delivered at a high intensity) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/49/42778/abstract/150\">",
"     150",
"    </a>",
"    ]. Conventional TENS produces paraesthesia in the area under the electrodes whereas the production of muscle twitches is desirable with acupuncture-like TENS.",
"   </p>",
"   <p>",
"    Research on TENS for pain relief has suffered from a lack of rigorous randomized controlled trials (RCTs) and systematic reviews have found variable and inconclusive results of efficacy of TENS in chronic pain management [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/49/42778/abstract/151\">",
"     151",
"    </a>",
"    ]. Further evidence is required to determine the efficacy, parameter specific effects and cost-effectiveness of TENS. Optimal stimulation parameters and treatment durations should be considered while interpreting the outcome of systematic reviews on TENS.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2234891\">",
"    <span class=\"h3\">",
"     Spinal cord stimulation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Spinal cord stimulation (SCS), a spinal neuromodulation analgesic system, is an option for chronic neuropathic pain which can arise after nerve or nervous system injury. SCS is a minimally invasive and reversible treatment option which can be permanently implanted after an appropriately conducted temporary screening trial with an external pulse generator to assess therapeutic efficacy and adverse effects.",
"   </p>",
"   <p>",
"    The European Federation of Neurological Societies (EFNS) found spinal cord stimulation to be efficacious in failed back surgery syndrome and complex regional pain syndrome type 1 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/49/42778/abstract/152\">",
"     152",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2235078\">",
"    <span class=\"h3\">",
"     Deep brain stimulation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although neuromodulation of the brain to achieve analgesia is in its infancy, anecdotal reports of deep brain stimulation and motor cortex stimulation have been described for the treatment of intractable severe persistent pain states [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/49/42778/abstract/152\">",
"     152",
"    </a>",
"    ]. The EFNS guidelines on neurostimulation for neuropathic pain found that motor cortex stimulation is efficacious in central post-stroke and facial pain and that deep brain stimulation should only be performed in experienced centers [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/49/42778/abstract/152\">",
"     152",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2235090\">",
"    <span class=\"h2\">",
"     Interventional approaches",
"    </span>",
"    &nbsp;&mdash;&nbsp;Interventional approaches may play a complementary role to other strategies and typically attempt to target the presumed \"pain generators.\" The most common interventional procedures are percutaneous injections, whereby small bore needles are inserted through the skin and directed (often with the assistance of imaging) to the presumed \"problem\" site. A pharmacologic agent is then deposited, usually glucocorticoid",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    local anesthetic. Neural \"ablation\" (with cryoanalgesia radiofrequency thermocoagulation, or neurolytic agents such as alcohol or phenol) is generally reserved for situations of severe cancer pain where the patient has a guarded prognosis.",
"   </p>",
"   <p>",
"    Interventional procedures for noncancer pain including intercostal nerve blockade, spinal injections (epidural steroid injections, selective nerve root injections, and medial nerve injections of the facet or zygopophyseal joint), occipital nerve injections, and multiple other peripheral nerve injections. Injections may provide short-term analgesia for well selected patient to facilitate physical therapy; however, evidence for significant improvements in long-term outcomes is limited. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/52/39753?source=see_link\">",
"     \"Subacute and chronic low back pain: Nonsurgical interventional treatment\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2235267\">",
"    <span class=\"h2\">",
"     Surgical approaches",
"    </span>",
"    &nbsp;&mdash;&nbsp;Surgical neuroablative techniques of the spinal cord pain pathway are mainly used to treat cancer pain. Evidence supporting destructive procedures for noncancer pain conditions remains limited [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/49/42778/abstract/153\">",
"     153",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Nonablative surgical treatment options for chronic low back pain are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/5/34905?source=see_link\">",
"     \"Subacute and chronic low back pain: Surgical treatment\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?23/12/23746?source=see_link\">",
"       \"Patient information: Chronic pain (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?8/42/8867?source=see_link\">",
"       \"Patient information: Neuropathic pain (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?11/6/11363?source=see_link\">",
"       \"Patient information: Narcotic pain medicines (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H195876576\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Optimal patient outcomes for chronic pain often result from multiple approaches (pharmacologic, physical medicine, behavioral medicine, neuromodulation, and interventional approaches) utilized in concert, coordinated via a multidisciplinary team of pain specialists. Medication should not be the sole focus of treatment but should be used when needed, in conjunction with other treatment modalities, to meet treatment goals. (See",
"      <a class=\"local\" href=\"#H185827432\">",
"       'Approach to the patient'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H24\">",
"       'Nonpharmacologic therapies'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The choice of an appropriate initial therapeutic strategy is dependent upon an accurate evaluation of the cause of the pain and the type of chronic pain syndrome. In particular, neuropathic pain should be distinguished from nociceptive pain. For most patients, the initial treatment of neuropathic pain involves either antidepressants (tricyclic antidepressants or dual reuptake inhibitors of serotonin and norepinephrine) or calcium channel alpha 2-delta ligands (",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?19/19/19768?source=see_link\">",
"       gabapentin",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?16/31/16887?source=see_link\">",
"       pregabalin",
"      </a>",
"      ), with adjunctive topical therapy when pain is localized. Opioid medications and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?41/50/42792?source=see_link\">",
"       tramadol",
"      </a>",
"      are second line agents for most patients with neuropathic pain. In contrast, the pharmacologic approach to nociceptive pain primarily involves non-narcotic and opioid analgesia. (See",
"      <a class=\"local\" href=\"#H185828296\">",
"       'Choice of therapy by type of pain'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Non-opioid analgesics include",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?15/27/15802?source=see_link\">",
"       acetaminophen",
"      </a>",
"      , &ldquo;traditional&rdquo; nonselective nonsteroidal anti-inflammatory drugs (NSAIDs), and cyclooxygenase 2 (COX-2) inhibitors (",
"      <a class=\"graphic graphic_table graphicRef70067 \" href=\"mobipreview.htm?23/54/24431\">",
"       table 1",
"      </a>",
"      ). Acetaminophen is not as effective as NSAIDs for the treatment of knee and hip pain related to osteoarthritis and may cause hepatic damage in patients with underlying liver disease or at higher doses. NSAIDs should be avoided in older adults when possible. (See",
"      <a class=\"local\" href=\"#H9183967\">",
"       'Non-opioid analgesics'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Opioids are increasingly used for chronic pain, but should be reserved for selected patients with moderate to severe chronic pain that adversely impacts function or quality of life. Before initiating chronic opioid therapy, an assessment of the risks and benefits of therapy for the individual patient should be based upon the history, physical examination, and assessment of the risk of substance abuse, misuse, or addiction. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Opioids'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Guidelines from the World Health Organization provide a framework for pain control with opioids, based upon the severity of the pain (",
"      <a class=\"graphic graphic_figure graphicRef63298 \" href=\"mobipreview.htm?0/45/724\">",
"       figure 1",
"      </a>",
"      ). Initial treatment with opioids should be considered as a therapeutic trial to determine whether chronic opioid therapy is effective and appropriate. Opioid therapy should be goal-directed, with continued or increased dosing dependent upon demonstrable improvements in function or quality of life. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'WHO recommendations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In initiating opioid therapy, we prefer to initiate a short-acting drug and then convert to a sustained release form to be given on a schedule, although evidence is unclear regarding benefits of a specific regimen or whether long-acting or short-acting medications are preferred. Patients should be closely monitored for side effects, adherence, and progress towards goal. Urine drug testing is indicated for patients at increased risk of drug misuse, and may be helpful to monitor adherence in all patients. The risk of overdose is greatest with higher opioid doses, at initiation of therapy and with dose changes. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Initiation of therapy'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H9191146\">",
"       'Monitoring'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H9191277\">",
"       'Risk of overdose'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Some side effects of opioid therapy (sedation and mental clouding) may be transient and subside with ongoing treatment. A bowel regimen may prevent constipation. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Opioid side effects'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?35/57/36761?source=see_link\">",
"       Methadone",
"      </a>",
"      is increasingly used for chronic pain and should be prescribed by a clinician with experience in prescribing and monitoring this drug with complex pharmacokinetics. (See",
"      <a class=\"local\" href=\"#H21149184\">",
"       'Methadone'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?19/19/19768?source=see_link\">",
"       Gabapentin",
"      </a>",
"      is effective for the treatment of postherpetic neuralgia and painful diabetic neuropathy.",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?16/31/16887?source=see_link\">",
"       Pregabalin",
"      </a>",
"      may provide analgesia more quickly than gabapentin but has been associated with euphoria and is a Schedule V controlled substance. (See",
"      <a class=\"local\" href=\"#H9185924\">",
"       'Gabapentin and pregabalin'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Both tricyclic antidepressants (TCAs) and serotonin norepinephrine reuptake inhibitors (SNRIs) possess analgesic qualities while the evidence for the effectiveness of selective serotonin reuptake inhibitors (SSRIs) is weaker. (See",
"      <a class=\"local\" href=\"#H9187567\">",
"       'Antidepressants'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/49/42778/abstract/1\">",
"      Elliott AM, Smith BH, Penny KI, et al. The epidemiology of chronic pain in the community. Lancet 1999; 354:1248.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/49/42778/abstract/2\">",
"      Gureje O, Von Korff M, Simon GE, Gater R. Persistent pain and well-being: a World Health Organization Study in Primary Care. JAMA 1998; 280:147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/49/42778/abstract/3\">",
"      Dobscha SK, Corson K, Perrin NA, et al. Collaborative care for chronic pain in primary care: a cluster randomized trial. JAMA 2009; 301:1242.",
"     </a>",
"    </li>",
"    <li>",
"     Institute for Clinical Systems Improvement. Health care guideline: Assessment and management of chronic pain. Fourth edition November 2009. file://www.icsi.org/pain__chronic__assessment_and_management_of_14399/pain__chronic__assessment_and_management_of__guideline_.html (Accessed on December 09, 2010).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/49/42778/abstract/5\">",
"      Turk DC, Wilson HD, Cahana A. Treatment of chronic non-cancer pain. Lancet 2011; 377:2226.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/49/42778/abstract/6\">",
"      Farrar JT, Young JP Jr, LaMoreaux L, et al. Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale. Pain 2001; 94:149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/49/42778/abstract/7\">",
"      Arnow BA, Hunkeler EM, Blasey CM, et al. Comorbid depression, chronic pain, and disability in primary care. Psychosom Med 2006; 68:262.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/49/42778/abstract/8\">",
"      Freynhagen R, Bennett MI. Diagnosis and management of neuropathic pain. BMJ 2009; 339:b3002.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/49/42778/abstract/9\">",
"      Dworkin RH, O'Connor AB, Backonja M, et al. Pharmacologic management of neuropathic pain: evidence-based recommendations. Pain 2007; 132:237.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/49/42778/abstract/10\">",
"      Attal N, Cruccu G, Haanp&auml;&auml; M, et al. EFNS guidelines on pharmacological treatment of neuropathic pain. Eur J Neurol 2006; 13:1153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/49/42778/abstract/11\">",
"      Attal N, Cruccu G, Baron R, et al. EFNS guidelines on the pharmacological treatment of neuropathic pain: 2010 revision. Eur J Neurol 2010; 17:1113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/49/42778/abstract/12\">",
"      Moulin DE, Clark AJ, Gilron I, et al. Pharmacological management of chronic neuropathic pain - consensus statement and guidelines from the Canadian Pain Society. Pain Res Manag 2007; 12:13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/49/42778/abstract/13\">",
"      Bril V, England J, Franklin GM, et al. Evidence-based guideline: Treatment of painful diabetic neuropathy: report of the American Academy of Neurology, the American Association of Neuromuscular and Electrodiagnostic Medicine, and the American Academy of Physical Medicine and Rehabilitation. Neurology 2011; 76:1758.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/49/42778/abstract/14\">",
"      O'Connor AB, Dworkin RH. Treatment of neuropathic pain: an overview of recent guidelines. Am J Med 2009; 122:S22.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/49/42778/abstract/15\">",
"      Zhang W, Doherty M, Leeb BF, et al. EULAR evidence based recommendations for the management of hand osteoarthritis: report of a Task Force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis 2007; 66:377.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/49/42778/abstract/16\">",
"      Zhang W, Moskowitz RW, Nuki G, et al. OARSI recommendations for the management of hip and knee osteoarthritis, Part II: OARSI evidence-based, expert consensus guidelines. Osteoarthritis Cartilage 2008; 16:137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/49/42778/abstract/17\">",
"      Chou R, Qaseem A, Snow V, et al. Diagnosis and treatment of low back pain: a joint clinical practice guideline from the American College of Physicians and the American Pain Society. Ann Intern Med 2007; 147:478.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/49/42778/abstract/18\">",
"      Lee C, Straus WL, Balshaw R, et al. A comparison of the efficacy and safety of nonsteroidal antiinflammatory agents versus acetaminophen in the treatment of osteoarthritis: a meta-analysis. Arthritis Rheum 2004; 51:746.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/49/42778/abstract/19\">",
"      Towheed TE, Maxwell L, Judd MG, et al. Acetaminophen for osteoarthritis. Cochrane Database Syst Rev 2006; :CD004257.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/49/42778/abstract/20\">",
"      Watkins PB, Kaplowitz N, Slattery JT, et al. Aminotransferase elevations in healthy adults receiving 4 grams of acetaminophen daily: a randomized controlled trial. JAMA 2006; 296:87.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/49/42778/abstract/21\">",
"      Bjordal JM, Ljunggren AE, Klovning A, Sl&oslash;rdal L. Non-steroidal anti-inflammatory drugs, including cyclo-oxygenase-2 inhibitors, in osteoarthritic knee pain: meta-analysis of randomised placebo controlled trials. BMJ 2004; 329:1317.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/49/42778/abstract/22\">",
"      Fendrick AM, Greenberg BP. A review of the benefits and risks of nonsteroidal anti-inflammatory drugs in the management of mild-to-moderate osteoarthritis. Osteopath Med Prim Care 2009; 3:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/49/42778/abstract/23\">",
"      Von Korff M, Kolodny A, Deyo RA, Chou R. Long-term opioid therapy reconsidered. Ann Intern Med 2011; 155:325.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/49/42778/abstract/24\">",
"      Smith HS. Potential analgesic mechanisms of acetaminophen. Pain Physician 2009; 12:269.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/49/42778/abstract/25\">",
"      Zhang W, Moskowitz RW, Nuki G, et al. OARSI recommendations for the management of hip and knee osteoarthritis, part I: critical appraisal of existing treatment guidelines and systematic review of current research evidence. Osteoarthritis Cartilage 2007; 15:981.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/49/42778/abstract/26\">",
"      Zhang W, Doherty M, Arden N, et al. EULAR evidence based recommendations for the management of hip osteoarthritis: report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis 2005; 64:669.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/49/42778/abstract/27\">",
"      Jordan KM, Arden NK, Doherty M, et al. EULAR Recommendations 2003: an evidence based approach to the management of knee osteoarthritis: Report of a Task Force of the Standing Committee for International Clinical Studies Including Therapeutic Trials (ESCISIT). Ann Rheum Dis 2003; 62:1145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/49/42778/abstract/28\">",
"      Case JP, Baliunas AJ, Block JA. Lack of efficacy of acetaminophen in treating symptomatic knee osteoarthritis: a randomized, double-blind, placebo-controlled comparison trial with diclofenac sodium. Arch Intern Med 2003; 163:169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/49/42778/abstract/29\">",
"      Garc&iacute;a Rodr&iacute;guez LA, Hern&aacute;ndez-D&iacute;az S. Relative risk of upper gastrointestinal complications among users of acetaminophen and nonsteroidal anti-inflammatory drugs. Epidemiology 2001; 12:570.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/49/42778/abstract/30\">",
"      Rahme E, Pettitt D, LeLorier J. Determinants and sequelae associated with utilization of acetaminophen versus traditional nonsteroidal antiinflammatory drugs in an elderly population. Arthritis Rheum 2002; 46:3046.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/49/42778/abstract/31\">",
"      Larson AM, Polson J, Fontana RJ, et al. Acetaminophen-induced acute liver failure: results of a United States multicenter, prospective study. Hepatology 2005; 42:1364.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/49/42778/abstract/32\">",
"      Jalan R, Williams R, Bernuau J. Paracetamol: are therapeutic doses entirely safe? Lancet 2006; 368:2195.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/49/42778/abstract/33\">",
"      Temple AR, Lynch JM, Vena J, et al. Aminotransferase activities in healthy subjects receiving three-day dosing of 4, 6, or 8 grams per day of acetaminophen. Clin Toxicol (Phila) 2007; 45:36.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/49/42778/abstract/34\">",
"      Heard K, Green JL, Bailey JE, et al. A randomized trial to determine the change in alanine aminotransferase during 10 days of paracetamol (acetaminophen) administration in subjects who consume moderate amounts of alcohol. Aliment Pharmacol Ther 2007; 26:283.",
"     </a>",
"    </li>",
"    <li>",
"     FDA Drug Safety Communication available online at file://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm239955.htm (Accessed on January 14, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/49/42778/abstract/36\">",
"      Kuehn BM. FDA focuses on drugs and liver damage: labeling and other changes for acetaminophen. JAMA 2009; 302:369.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/49/42778/abstract/37\">",
"      McCormack K. Non-steroidal anti-inflammatory drugs and spinal nociceptive processing. Pain 1994; 59:9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/49/42778/abstract/38\">",
"      Roelofs PD, Deyo RA, Koes BW, et al. Nonsteroidal anti-inflammatory drugs for low back pain: an updated Cochrane review. Spine (Phila Pa 1976) 2008; 33:1766.",
"     </a>",
"    </li>",
"    <li>",
"     National Collaborating Centre for Chronic Conditions (NCCCC). Osteoarthritis: the care and management of osteoarthritis in adults, Royal College of Physicians, London 2008.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/49/42778/abstract/40\">",
"      American Geriatrics Society Panel on Pharmacological Management of Persistent Pain in Older Persons. Pharmacological management of persistent pain in older persons. J Am Geriatr Soc 2009; 57:1331.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/49/42778/abstract/41\">",
"      Altman RD, Dreiser RL, Fisher CL, et al. Diclofenac sodium gel in patients with primary hand osteoarthritis: a randomized, double-blind, placebo-controlled trial. J Rheumatol 2009; 36:1991.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/49/42778/abstract/42\">",
"      Barthel HR, Haselwood D, Longley S 3rd, et al. Randomized controlled trial of diclofenac sodium gel in knee osteoarthritis. Semin Arthritis Rheum 2009; 39:203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/49/42778/abstract/43\">",
"      Simon LS, Grierson LM, Naseer Z, et al. Efficacy and safety of topical diclofenac containing dimethyl sulfoxide (DMSO) compared with those of topical placebo, DMSO vehicle and oral diclofenac for knee osteoarthritis. Pain 2009; 143:238.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/49/42778/abstract/44\">",
"      Jones P, Lamdin R. Oral cyclo-oxygenase 2 inhibitors versus other oral analgesics for acute soft tissue injury: systematic review and meta-analysis. Clin Drug Investig 2010; 30:419.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/49/42778/abstract/45\">",
"      Antman EM, Bennett JS, Daugherty A, et al. Use of nonsteroidal antiinflammatory drugs: an update for clinicians: a scientific statement from the American Heart Association. Circulation 2007; 115:1634.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/49/42778/abstract/46\">",
"      Cheetham TC, Levy G, Niu F, Bixler F. Gastrointestinal safety of nonsteroidal antiinflammatory drugs and selective cyclooxygenase-2 inhibitors in patients on warfarin. Ann Pharmacother 2009; 43:1765.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/49/42778/abstract/47\">",
"      Farkouh ME, Greenberg JD, Jeger RV, et al. Cardiovascular outcomes in high risk patients with osteoarthritis treated with ibuprofen, naproxen or lumiracoxib. Ann Rheum Dis 2007; 66:764.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/49/42778/abstract/48\">",
"      Stuart JJ, Pisko EJ. Choline magnesium trisalicylate does not impair platelet aggregation. Pharmatherapeutica 1981; 2:547.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/49/42778/abstract/49\">",
"      Ballantyne JC, Mao J. Opioid therapy for chronic pain. N Engl J Med 2003; 349:1943.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/49/42778/abstract/50\">",
"      Portenoy RK. Opioid therapy for chronic nonmalignant pain: a review of the critical issues. J Pain Symptom Manage 1996; 11:203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/49/42778/abstract/51\">",
"      Kuehn BM. Prescription drug abuse rises globally. JAMA 2007; 297:1306.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/49/42778/abstract/52\">",
"      Hudson TJ, Edlund MJ, Steffick DE, et al. Epidemiology of regular prescribed opioid use: results from a national, population-based survey. J Pain Symptom Manage 2008; 36:280.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/49/42778/abstract/53\">",
"      Martell BA, O'Connor PG, Kerns RD, et al. Systematic review: opioid treatment for chronic back pain: prevalence, efficacy, and association with addiction. Ann Intern Med 2007; 146:116.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/49/42778/abstract/54\">",
"      Edlund MJ, Steffick D, Hudson T, et al. Risk factors for clinically recognized opioid abuse and dependence among veterans using opioids for chronic non-cancer pain. Pain 2007; 129:355.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/49/42778/abstract/55\">",
"      Chou R, Fanciullo GJ, Fine PG, et al. Clinical guidelines for the use of chronic opioid therapy in chronic noncancer pain. J Pain 2009; 10:113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/49/42778/abstract/56\">",
"      Joranson DE, Ryan KM, Gilson AM, Dahl JL. Trends in medical use and abuse of opioid analgesics. JAMA 2000; 283:1710.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/49/42778/abstract/57\">",
"      Dunn KM, Saunders KW, Rutter CM, et al. Opioid prescriptions for chronic pain and overdose: a cohort study. Ann Intern Med 2010; 152:85.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/49/42778/abstract/58\">",
"      McLellan AT, Turner BJ. Chronic noncancer pain management and opioid overdose: time to change prescribing practices. Ann Intern Med 2010; 152:123.",
"     </a>",
"    </li>",
"    <li>",
"     file://www.fda.gov/drugs/drugsafety/informationbydrugclass/ucm163647.htm.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/49/42778/abstract/60\">",
"      Okie S. A flood of opioids, a rising tide of deaths. N Engl J Med 2010; 363:1981.",
"     </a>",
"    </li>",
"    <li>",
"     U.S. Food and Drug Administaion. Propoxyphene-containing products www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm233800.htm (Accessed on November 21, 2010).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/49/42778/abstract/62\">",
"      Drugs for pain. Treat Guidel Med Lett 2010; 8:25.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/49/42778/abstract/63\">",
"      Allan L, Hays H, Jensen NH, et al. Randomised crossover trial of transdermal fentanyl and sustained release oral morphine for treating chronic non-cancer pain. BMJ 2001; 322:1154.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/49/42778/abstract/64\">",
"      Allan L, Richarz U, Simpson K, Slappendel R. Transdermal fentanyl versus sustained release oral morphine in strong-opioid na&iuml;ve patients with chronic low back pain. Spine (Phila Pa 1976) 2005; 30:2484.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/49/42778/abstract/65\">",
"      Sabatowski R, Schwalen S, Rettig K, et al. Driving ability under long-term treatment with transdermal fentanyl. J Pain Symptom Manage 2003; 25:38.",
"     </a>",
"    </li>",
"    <li>",
"     www.fda.gov/medwatch/safety/2007/safety07.htm#Fentanyl (Accessed on October 11, 2011).",
"    </li>",
"    <li>",
"     World Health Organization. Cancer pain releif. World Health Organization; Geneva, 1990.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/49/42778/abstract/68\">",
"      Gourlay DL, Heit HA, Almahrezi A. Universal precautions in pain medicine: a rational approach to the treatment of chronic pain. Pain Med 2005; 6:107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/49/42778/abstract/69\">",
"      Arnold RM, Han PK, Seltzer D. Opioid contracts in chronic nonmalignant pain management: objectives and uncertainties. Am J Med 2006; 119:292.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/49/42778/abstract/70\">",
"      Starrels JL, Becker WC, Alford DP, et al. Systematic review: treatment agreements and urine drug testing to reduce opioid misuse in patients with chronic pain. Ann Intern Med 2010; 152:712.",
"     </a>",
"    </li>",
"    <li>",
"     Risk Evaluation and Mitigation Strategy (REMS) for extended-release and long-acting opioids file://www.fda.gov/drugs/drugsafety/informationbydrugclass/ucm163647.htm (Accessed on July 30, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/49/42778/abstract/72\">",
"      Christo PJ, Manchikanti L, Ruan X, et al. Urine drug testing in chronic pain. Pain Physician 2011; 14:123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/49/42778/abstract/73\">",
"      Bohnert AS, Valenstein M, Bair MJ, et al. Association between opioid prescribing patterns and opioid overdose-related deaths. JAMA 2011; 305:1315.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/49/42778/abstract/74\">",
"      Gomes T, Mamdani MM, Dhalla IA, et al. Opioid dose and drug-related mortality in patients with nonmalignant pain. Arch Intern Med 2011; 171:686.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/49/42778/abstract/75\">",
"      Chu LF, Angst MS, Clark D. Opioid-induced hyperalgesia in humans: molecular mechanisms and clinical considerations. Clin J Pain 2008; 24:479.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/49/42778/abstract/76\">",
"      Fishbain DA, Cole B, Lewis JE, et al. Do opioids induce hyperalgesia in humans? An evidence-based structured review. Pain Med 2009; 10:829.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/49/42778/abstract/77\">",
"      Silverman SM. Opioid induced hyperalgesia: clinical implications for the pain practitioner. Pain Physician 2009; 12:679.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/49/42778/abstract/78\">",
"      Induru RR, Davis MP. Buprenorphine for neuropathic pain--targeting hyperalgesia. Am J Hosp Palliat Care 2009; 26:470.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/49/42778/abstract/79\">",
"      Drossman DA, Morris CB, Edwards H, et al. Diagnosis, characterization, and 3-month outcome after detoxification of 39 patients with narcotic bowel syndrome. Am J Gastroenterol 2012; 107:1426.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/49/42778/abstract/80\">",
"      Thomas J, Karver S, Cooney GA, et al. Methylnaltrexone for opioid-induced constipation in advanced illness. N Engl J Med 2008; 358:2332.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/49/42778/abstract/81\">",
"      Paulson DM, Kennedy DT, Donovick RA, et al. Alvimopan: an oral, peripherally acting, mu-opioid receptor antagonist for the treatment of opioid-induced bowel dysfunction--a 21-day treatment-randomized clinical trial. J Pain 2005; 6:184.",
"     </a>",
"    </li>",
"    <li>",
"     Alvimopan prescribing information available online at file://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?id=33202&amp;CFID=11456208&amp;CFTOKEN=1f74eda9f81e615f-6771DE68-92AA-956A-3738E4B0F5A05DA7&amp;jsessionid=ca30a9ea6200406e283f (Accessed on September 12, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/49/42778/abstract/83\">",
"      Duhmke RM, Cornblath DD, Hollingshead JR. Tramadol for neuropathic pain. Cochrane Database Syst Rev 2004; :CD003726.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/49/42778/abstract/84\">",
"      Furlan AD, Sandoval JA, Mailis-Gagnon A, Tunks E. Opioids for chronic noncancer pain: a meta-analysis of effectiveness and side effects. CMAJ 2006; 174:1589.",
"     </a>",
"    </li>",
"    <li>",
"     www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlerfsfor HumanMedicalProducts/ucm213264 (Accessed on July 16, 2008).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/49/42778/abstract/86\">",
"      Another once-daily formulation of tramadol (Ryzolt). Med Lett Drugs Ther 2010; 52:39.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/49/42778/abstract/87\">",
"      Centers for Disease Control and Prevention (CDC). Vital signs: risk for overdose from methadone used for pain relief - United States, 1999-2010. MMWR Morb Mortal Wkly Rep 2012; 61:493.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/49/42778/abstract/88\">",
"      Fine PG, Portenoy RK, Ad Hoc Expert Panel on Evidence Review and Guidelines for Opioid Rotation. Establishing \"best practices\" for opioid rotation: conclusions of an expert panel. J Pain Symptom Manage 2009; 38:418.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/49/42778/abstract/89\">",
"      Inturrisi CE. Clinical pharmacology of opioids for pain. Clin J Pain 2002; 18:S3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/49/42778/abstract/90\">",
"      Quigley C. Opioid switching to improve pain relief and drug tolerability. Cochrane Database Syst Rev 2004; :CD004847.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/49/42778/abstract/91\">",
"      Knotkova H, Fine PG, Portenoy RK. Opioid rotation: the science and the limitations of the equianalgesic dose table. J Pain Symptom Manage 2009; 38:426.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/49/42778/abstract/92\">",
"      Galski T, Williams JB, Ehle HT. Effects of opioids on driving ability. J Pain Symptom Manage 2000; 19:200.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/49/42778/abstract/93\">",
"      Schisler RE, Groninger H, Rosielle DA. Counseling patients on side effects and driving when starting opioids #248. J Palliat Med 2012; 15:484.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/49/42778/abstract/94\">",
"      Fishbain DA, Cutler RB, Rosomoff HL, Rosomoff RS. Are opioid-dependent/tolerant patients impaired in driving-related skills? A structured evidence-based review. J Pain Symptom Manage 2003; 25:559.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/49/42778/abstract/95\">",
"      Byas-Smith MG, Chapman SL, Reed B, Cotsonis G. The effect of opioids on driving and psychomotor performance in patients with chronic pain. Clin J Pain 2005; 21:345.",
"     </a>",
"    </li>",
"    <li>",
"     Canadian Guideline for safe and effective use of opioids for chronic non-cancer pain. National Opioid Use Guideline Group. April 30, 2010. Available online at www.nationalpaincentre.mcmaster.ca/opioid/documents.html (Accessed on May 03, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/49/42778/abstract/97\">",
"      Dobecki DA, Schocket SM, Wallace MS. Update on pharmacotherapy guidelines for the treatment of neuropathic pain. Curr Pain Headache Rep 2006; 10:185.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/49/42778/abstract/98\">",
"      Finnerup NB, Otto M, Jensen TS, Sindrup SH. An evidence-based algorithm for the treatment of neuropathic pain. MedGenMed 2007; 9:36.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/49/42778/abstract/99\">",
"      Finnerup NB, Sindrup SH, Jensen TS. The evidence for pharmacological treatment of neuropathic pain. Pain 2010; 150:573.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/49/42778/abstract/100\">",
"      Finnerup NB, Jensen TS. Clinical use of pregabalin in the management of central neuropathic pain. Neuropsychiatr Dis Treat 2007; 3:885.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/49/42778/abstract/101\">",
"      Moore RA, Wiffen PJ, Derry S, McQuay HJ. Gabapentin for chronic neuropathic pain and fibromyalgia in adults. Cochrane Database Syst Rev 2011; :CD007938.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/49/42778/abstract/102\">",
"      Chou R, Carson S, Chan BK. Gabapentin versus tricyclic antidepressants for diabetic neuropathy and post-herpetic neuralgia: discrepancies between direct and indirect meta-analyses of randomized controlled trials. J Gen Intern Med 2009; 24:178.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/49/42778/abstract/103\">",
"      Feng MR, Turluck D, Burleigh J, et al. Brain microdialysis and PK/PD correlation of pregabalin in rats. Eur J Drug Metab Pharmacokinet 2001; 26:123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/49/42778/abstract/104\">",
"      Stacey BR, Barrett JA, Whalen E, et al. Pregabalin for postherpetic neuralgia: placebo-controlled trial of fixed and flexible dosing regimens on allodynia and time to onset of pain relief. J Pain 2008; 9:1006.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/49/42778/abstract/105\">",
"      Moore RA, Straube S, Wiffen PJ, et al. Pregabalin for acute and chronic pain in adults. Cochrane Database Syst Rev 2009; :CD007076.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/49/42778/abstract/106\">",
"      Silberstein SD, Lipton RB, Dodick DW, et al. Efficacy and safety of topiramate for the treatment of chronic migraine: a randomized, double-blind, placebo-controlled trial. Headache 2007; 47:170.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/49/42778/abstract/107\">",
"      Wiffen PJ, Rees J. Lamotrigine for acute and chronic pain. Cochrane Database Syst Rev 2007; :CD006044.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/49/42778/abstract/108\">",
"      Gronseth G, Cruccu G, Alksne J, et al. Practice parameter: the diagnostic evaluation and treatment of trigeminal neuralgia (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology and the European Federation of Neurological Societies. Neurology 2008; 71:1183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/49/42778/abstract/109\">",
"      Wiffen PJ, Derry S, Moore RA, McQuay HJ. Carbamazepine for acute and chronic pain in adults. Cochrane Database Syst Rev 2011; :CD005451.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/49/42778/abstract/110\">",
"      Saarto T, Wiffen PJ. Antidepressants for neuropathic pain: a Cochrane review. J Neurol Neurosurg Psychiatry 2010; 81:1372.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/49/42778/abstract/111\">",
"      Sindrup SH, Jensen TS. Efficacy of pharmacological treatments of neuropathic pain: an update and effect related to mechanism of drug action. Pain 1999; 83:389.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/49/42778/abstract/112\">",
"      McQuay HJ, Tram&egrave;r M, Nye BA, et al. A systematic review of antidepressants in neuropathic pain. Pain 1996; 68:217.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/49/42778/abstract/113\">",
"      Sindrup SH, Otto M, Finnerup NB, Jensen TS. Antidepressants in the treatment of neuropathic pain. Basic Clin Pharmacol Toxicol 2005; 96:399.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/49/42778/abstract/114\">",
"      Collins SL, Moore RA, Wiffen P. Antidepressants and anticonvulsants for diabetic neuropathy and postherpetic neuralgia: a quantitative systematic review. J Pain Symptom Manage 2000; 20:449.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/49/42778/abstract/115\">",
"      Pilowsky I, Hallett EC, Bassett DL, et al. A controlled study of amitriptyline in the treatment of chronic pain. Pain 1982; 14:169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/49/42778/abstract/116\">",
"      Jaeschke R, Adachi J, Guyatt G, et al. Clinical usefulness of amitriptyline in fibromyalgia: the results of 23 N-of-1 randomized controlled trials. J Rheumatol 1991; 18:447.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/49/42778/abstract/117\">",
"      Godfrey RG. A guide to the understanding and use of tricyclic antidepressants in the overall management of fibromyalgia and other chronic pain syndromes. Arch Intern Med 1996; 156:1047.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/49/42778/abstract/118\">",
"      Finnerup NB, Otto M, McQuay HJ, et al. Algorithm for neuropathic pain treatment: an evidence based proposal. Pain 2005; 118:289.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/49/42778/abstract/119\">",
"      Duloxetine (Cymbalta) for diabetic neuropathic pain. Med Lett Drugs Ther 2005; 47:67.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/49/42778/abstract/120\">",
"      Duloxetine (cymbalta) for fibromyalgia. Med Lett Drugs Ther 2008; 50:57.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/49/42778/abstract/121\">",
"      Duloxetine (Cymbalta) for chronic musculoskeletal pain. Med Lett Drugs Ther 2011; 53:33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/49/42778/abstract/122\">",
"      Lunn MP, Hughes RA, Wiffen PJ. Duloxetine for treating painful neuropathy or chronic pain. Cochrane Database Syst Rev 2009; :CD007115.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/49/42778/abstract/123\">",
"      Skljarevski V, Zhang S, Desaiah D, et al. Duloxetine versus placebo in patients with chronic low back pain: a 12-week, fixed-dose, randomized, double-blind trial. J Pain 2010; 11:1282.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/49/42778/abstract/124\">",
"      Skljarevski V, Desaiah D, Liu-Seifert H, et al. Efficacy and safety of duloxetine in patients with chronic low back pain. Spine (Phila Pa 1976) 2010; 35:E578.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/49/42778/abstract/125\">",
"      Skljarevski V, Ossanna M, Liu-Seifert H, et al. A double-blind, randomized trial of duloxetine versus placebo in the management of chronic low back pain. Eur J Neurol 2009; 16:1041.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/49/42778/abstract/126\">",
"      Kroenke K, Bair MJ, Damush TM, et al. Optimized antidepressant therapy and pain self-management in primary care patients with depression and musculoskeletal pain: a randomized controlled trial. JAMA 2009; 301:2099.",
"     </a>",
"    </li>",
"    <li>",
"     www.prialt.com/downloads/product_information.pdf (Accessed on March 07, 2005).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/49/42778/abstract/128\">",
"      Ziconotide (Prialt) for chronic pain. Med Lett Drugs Ther 2005; 47:103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/49/42778/abstract/129\">",
"      Sharp D. Novel pain relief via marine snails. Lancet 2005; 366:439.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/49/42778/abstract/130\">",
"      Staats PS, Yearwood T, Charapata SG, et al. Intrathecal ziconotide in the treatment of refractory pain in patients with cancer or AIDS: a randomized controlled trial. JAMA 2004; 291:63.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/49/42778/abstract/131\">",
"      Rauck RL, Wallace MS, Leong MS, et al. A randomized, double-blind, placebo-controlled study of intrathecal ziconotide in adults with severe chronic pain. J Pain Symptom Manage 2006; 31:393.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/49/42778/abstract/132\">",
"      Davies PS, Galer BS. Review of lidocaine patch 5% studies in the treatment of postherpetic neuralgia. Drugs 2004; 64:937.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/49/42778/abstract/133\">",
"      Khaliq W, Alam S, Puri N. Topical lidocaine for the treatment of postherpetic neuralgia. Cochrane Database Syst Rev 2007; :CD004846.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/49/42778/abstract/134\">",
"      Lee SS, Sohn YW, Yoo ES, Kim KH. Neurotoxicity and long lasting analgesia induced by capsaicinoids. J Toxicol Sci 1991; 16 Suppl 1:3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/49/42778/abstract/135\">",
"      Mason L, Moore RA, Derry S, et al. Systematic review of topical capsaicin for the treatment of chronic pain. BMJ 2004; 328:991.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/49/42778/abstract/136\">",
"      Massey T, Derry S, Moore RA, McQuay HJ. Topical NSAIDs for acute pain in adults. Cochrane Database Syst Rev 2010; :CD007402.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/49/42778/abstract/137\">",
"      Haroutiunian S, Drennan DA, Lipman AG. Topical NSAID therapy for musculoskeletal pain. Pain Med 2010; 11:535.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/49/42778/abstract/138\">",
"      Towheed TE. Pennsaid therapy for osteoarthritis of the knee: a systematic review and metaanalysis of randomized controlled trials. J Rheumatol 2006; 33:567.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/49/42778/abstract/139\">",
"      Matthews P, Derry S, Moore RA, McQuay HJ. Topical rubefacients for acute and chronic pain in adults. Cochrane Database Syst Rev 2009; :CD007403.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/49/42778/abstract/140\">",
"      McCleane G. Topical doxepin hydrochloride reduces neuropathic pain: A randomized, double-blind placebo controlled study. Pain Clin 2000; 12:47.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/49/42778/abstract/141\">",
"      Xiao L, Mackey S, Hui H, et al. Subcutaneous injection of botulinum toxin a is beneficial in postherpetic neuralgia. Pain Med 2010; 11:1827.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/49/42778/abstract/142\">",
"      Yuan RY, Sheu JJ, Yu JM, et al. Botulinum toxin for diabetic neuropathic pain: a randomized double-blind crossover trial. Neurology 2009; 72:1473.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/49/42778/abstract/143\">",
"      Scascighini L, Toma V, Dober-Spielmann S, Sprott H. Multidisciplinary treatment for chronic pain: a systematic review of interventions and outcomes. Rheumatology (Oxford) 2008; 47:670.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/49/42778/abstract/144\">",
"      Allegrante JP. The role of adjunctive therapy in the management of chronic nonmalignant pain. Am J Med 1996; 101:33S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/49/42778/abstract/145\">",
"      Beck AT. How an anomalous finding led to a new system of psychotherapy. Nat Med 2006; 12:1139.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/49/42778/abstract/146\">",
"      Okifuji A, Ackerlind S. Behavioral medicine approaches to pain. Med Clin North Am 2007; 91:45.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/49/42778/abstract/147\">",
"      McBeth J, Prescott G, Scotland G, et al. Cognitive behavior therapy, exercise, or both for treating chronic widespread pain. Arch Intern Med 2012; 172:48.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/49/42778/abstract/148\">",
"      Nestoriuc Y, Martin A, Rief W, Andrasik F. Biofeedback treatment for headache disorders: a comprehensive efficacy review. Appl Psychophysiol Biofeedback 2008; 33:125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/49/42778/abstract/149\">",
"      Stanos SP, McLean J, Rader L. Physical medicine rehabilitation approach to pain. Med Clin North Am 2007; 91:57.",
"     </a>",
"    </li>",
"    <li>",
"     Walsh DM, Basford JR. Transcutaneous electrical nerve stimulation, chapter 47. In: Current Therapy in Pain, Smith HS.  (Ed), Saunders/Elsevier, Philadelphia, PA 2009. p.541-546.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/49/42778/abstract/151\">",
"      Nnoaham KE, Kumbang J. Transcutaneous electrical nerve stimulation (TENS) for chronic pain. Cochrane Database Syst Rev 2008; :CD003222.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/49/42778/abstract/152\">",
"      Cruccu G, Aziz TZ, Garcia-Larrea L, et al. EFNS guidelines on neurostimulation therapy for neuropathic pain. Eur J Neurol 2007; 14:952.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/49/42778/abstract/153\">",
"      Cetas JS, Saedi T, Burchiel KJ. Destructive procedures for the treatment of nonmalignant pain: a structured literature review. J Neurosurg 2008; 109:389.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2785 Version 17.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-201.211.0.116-39486C3A7C-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f41_49_42778=[""].join("\n");
var outline_f41_49_42778=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H195876576\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H185827432\">",
"      APPROACH TO THE PATIENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H185828296\">",
"      CHOICE OF THERAPY BY TYPE OF PAIN",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H185828303\">",
"      Neuropathic pain",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H185828310\">",
"      Nociceptive pain",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9183967\">",
"      NON-OPIOID ANALGESICS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9184479\">",
"      Acetaminophen",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9184486\">",
"      - Hepatic toxicity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      Nonsteroidal antiinflammatory drugs",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      - Side effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      OPIOIDS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Mechanism of action",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Preparations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      WHO recommendations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Initiation of therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Opioid treatment agreements",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Initial therapy and dosing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9191146\">",
"      Monitoring",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9191277\">",
"      Risk of overdose",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9191218\">",
"      Discontinuing therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Opioid side effects",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Prevention of opioid side effects",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Constipation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Sedation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9191351\">",
"      Specific preparations and routes",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9191451\">",
"      - Tramadol and tapentadol",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21149184\">",
"      - Methadone",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21149152\">",
"      - Intrathecal therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19064636\">",
"      Opioid rotation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19064538\">",
"      - Indications",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19064691\">",
"      - Initiating opioid rotation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27481771\">",
"      Driving safety",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      ANTICONVULSANTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9185924\">",
"      Gabapentin and pregabalin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9185931\">",
"      Other antiepileptics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9187567\">",
"      ANTIDEPRESSANTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9187574\">",
"      Tricyclic antidepressants",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9187603\">",
"      Serotonin norepinephrine reuptake inhibitors",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9187629\">",
"      - Venlafaxine",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9187649\">",
"      - Duloxetine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9188953\">",
"      Concurrent depression",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      ZICONOTIDE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      ADJUVANT MEDICATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Benzodiazepines",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Antispasmodics",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9188590\">",
"      Topical agents",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9188826\">",
"      Botulinum toxin",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      NONPHARMACOLOGIC THERAPIES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2234320\">",
"      Behavioral medicine approaches",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H2234327\">",
"      - Cognitive-behavioral therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H2234483\">",
"      - Biofeedback",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2234700\">",
"      Physical medicine approaches",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21149344\">",
"      - Spinal manipulation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2234772\">",
"      Neuromodulation approaches",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H2234884\">",
"      - TENS",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H2234891\">",
"      - Spinal cord stimulation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H2235078\">",
"      - Deep brain stimulation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2235090\">",
"      Interventional approaches",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2235267\">",
"      Surgical approaches",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H195876576\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PC/2785\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PC/2785|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"mobipreview.htm?13/9/13471\" title=\"algorithm 1\">",
"      Treatment algorithm for neuropathic pain",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"mobipreview.htm?34/36/35407\" title=\"algorithm 2\">",
"      Treatment algorithm for nociceptive pain",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PC/2785|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?0/45/724\" title=\"figure 1\">",
"      WHO analgesic ladder",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PC/2785|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/54/24431\" title=\"table 1\">",
"      Nonopioid analgesic and NSAID table",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/31/24061\" title=\"table 2\">",
"      Principles of risk management during opioid treatment for pain",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?22/19/22843\" title=\"table 3\">",
"      Properties of opioid receptors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?11/31/11760\" title=\"table 4\">",
"      Select opioids chronic pain and equianalgesic doses",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?18/17/18716\" title=\"table 5\">",
"      Side effects TCAs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?37/46/38639\" title=\"table 6\">",
"      Side effects antidepressants",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?7/14/7403\" title=\"table 7\">",
"      Benzodiazepines chronic pain",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?3/20/3403\" title=\"table 8\">",
"      Muscle relaxants chronic pain",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/43/25274?source=related_link\">",
"      Acetaminophen (paracetamol) poisoning in adults: Pathophysiology, presentation, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/27/39351?source=related_link\">",
"      COX-2 selective inhibitors: Adverse cardiovascular effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/7/30842?source=related_link\">",
"      Cancer pain management with opioids: Optimizing analgesia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?9/4/9290?source=related_link\">",
"      Cancer pain management with opioids: Prevention and management of side effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/43/43704?source=related_link\">",
"      Cancer pain management: General principles and risk management for patients receiving opioids",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/59/16312?source=related_link\">",
"      Definition and pathogenesis of chronic pain",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/22/40296?source=related_link\">",
"      Evaluation of chronic pain in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?6/43/6841?source=related_link\">",
"      Exercise-based therapy for low back pain",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/31/38393?source=related_link\">",
"      NSAIDs (including aspirin): Primary prevention of gastroduodenal toxicity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/0/24582?source=related_link\">",
"      NSAIDs: Acute kidney injury (acute renal failure) and nephrotic syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/57/38803?source=related_link\">",
"      NSAIDs: Electrolyte complications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?1/19/1336?source=related_link\">",
"      NSAIDs: Mechanism of action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?5/36/5703?source=related_link\">",
"      NSAIDs: Therapeutic use and variability of response in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/4/24648?source=related_link\">",
"      Nonselective NSAIDs: Adverse cardiovascular effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?16/49/17177?source=related_link\">",
"      Nonselective NSAIDs: Overview of adverse effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/3/29751?source=related_link\">",
"      Overview of psychotherapies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?12/48/13066?source=related_link\">",
"      Overview of selective COX-2 inhibitors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?23/12/23746?source=related_link\">",
"      Patient information: Chronic pain (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?11/6/11363?source=related_link\">",
"      Patient information: Narcotic pain medicines (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?8/42/8867?source=related_link\">",
"      Patient information: Neuropathic pain (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/61/43994?source=related_link\">",
"      Pharmacology of antiepileptic drugs",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/43/36535?source=related_link\">",
"      Prescription drug abuse and addiction: Clinical features, epidemiology, and contributing factors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/33/27160?source=related_link\">",
"      Prescription drug abuse and addiction: Prevention, identification, and management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?5/28/5578?source=related_link\">",
"      Serotonin-norepinephrine reuptake inhibitors (SNRIs): Pharmacology, administration, and side effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/16/41222?source=related_link\">",
"      Spinal manipulation in the treatment of musculoskeletal pain",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/52/39753?source=related_link\">",
"      Subacute and chronic low back pain: Nonsurgical interventional treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/24/19850?source=related_link\">",
"      Subacute and chronic low back pain: Pharmacologic and noninterventional treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/5/34905?source=related_link\">",
"      Subacute and chronic low back pain: Surgical treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?4/58/5033?source=related_link\">",
"      Substance use disorders: Principles for recognition and assessment in general medical care",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/52/29514?source=related_link\">",
"      Treatment of opioid abuse and dependence",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/3/34873?source=related_link\">",
"      Trigeminal neuralgia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/56/31626?source=related_link\">",
"      Unipolar depression in adults and selective serotonin reuptake inhibitors (SSRIs): Pharmacology, administration, and side effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/20/36169?source=related_link\">",
"      Unipolar depression in adults and tricyclic and tetracyclic drugs: Pharmacology, administration, and side effects",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f41_49_42779="Risk assess crit breast ovar CA";
var content_f41_49_42779=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F65717&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F65717&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Risk assessment criteria for inherited breast-ovarian cancer syndome, combining several guidelines",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Non-Jewish families",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Any of the following:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        One case of breast cancer &le;40 yo in a FDR or SDR*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        One FDR or SDR with breast and ovarian cancer, at any age",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Two or more cases of breast cancer in FDRs or SDRs if one is diagnosed at &le;50 years old, or is bilateral",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        One FDR or SDR with breast cancer at &le;50 years old, or bilateral and one FDR or SDR with ovarian cancer",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Three cases of breast and ovarian cancer (at least one case of ovarian cancer) in FDRs and SDRs",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Two cases of ovarian cancer in FDRs and SDRs",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        One case of male breast cancer in an FDR or SDR if another FDR or SDR has (male or female) breast or ovarian cancer",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Jewish families",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Any of the following:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        One or more cases of breast cancer &le;50 years old in an FDR or SDR",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        One or more cases of ovarian cancer at any age in a FDR or SDR",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        One or more FDRs or SDRs with breast cancer at any age, if another FDR or SDR has breast and/or ovarian cancer at any age",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        One or more cases of male breast cancer in an FDR or SDR",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * FDR: first-degree relative; SDR: second-degree relative.",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from: Hampel H, et al. J Med Genet 2004; 41:81.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f41_49_42779=[""].join("\n");
var outline_f41_49_42779=null;
var title_f41_49_42780="Protocol for noninvasive vent";
var content_f41_49_42780=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F64422&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F64422&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Protocol for noninvasive nocturnal ventilation for patients with COPD",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td colspan=\"1\" rowspan=\"2\">",
"       Device",
"      </td>",
"      <td>",
"       Bilevel positive pressure device",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Portable home ventilator",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Location",
"      </td>",
"      <td>",
"       Chronic ventilator or step-down unit versus intensive care unit",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Monitors",
"      </td>",
"      <td>",
"       <p>",
"        Trend pulse oximetry (SpO2)",
"       </p>",
"       <p>",
"        Heart rate",
"       </p>",
"       <p>",
"        Respiratory rate",
"       </p>",
"      </td>",
"     </tr>",
"     <tr>",
"      <td colspan=\"1\" rowspan=\"4\">",
"       Initial setup",
"      </td>",
"      <td>",
"       Select/adjust nasal mask",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Connect patient to bilevel positive pressure device (BPAP) in spontaneous mode",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Start IPAP = 6; EPAP = 2 cmH2O",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Supplemental oxygen at 0-3 LPM for SpO2 less than 89 percent",
"      </td>",
"     </tr>",
"     <tr>",
"      <td colspan=\"1\" rowspan=\"6\">",
"       Observe",
"      </td>",
"      <td>",
"       Tolerance (log patient's complaints)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Dyspnea (Borg scale)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Synchrony (rib cage/abdominal excursion with IPAP onset)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       SpO2",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Vital signs",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Arterial blood gas in the morning",
"      </td>",
"     </tr>",
"     <tr>",
"      <td colspan=\"1\" rowspan=\"4\">",
"       Nasal mask titration",
"      </td>",
"      <td>",
"       Increase IPAP by 2 cmH2O as tolerated up to a maximum of 20 cmH2O",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Increase EPAP to 4 to 6 cmH2O as needed to improve SpO2 or decrease work of breathing in COPD patients",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       FiO2 increased only after ventilation improved. Goal is to achieve SpO2 90 to 93 percent",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Switch to spontaneous/timed (S/T) mode at 12 breaths/min if indicated",
"      </td>",
"     </tr>",
"     <tr>",
"      <td colspan=\"1\" rowspan=\"2\">",
"       Face mask titration",
"      </td>",
"      <td>",
"       Patients failing nasal mask will proceed to full face mask and above titration will be repeated",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Patients failing full face mask and BPAP will proceed to volume ventilator (See Failure of nocturnal noninvasive ventilatory support below)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td colspan=\"1\" rowspan=\"6\">",
"       Volume ventilator",
"      </td>",
"      <td>",
"       Full face mask",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Mode - assist control",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Flow - start 60 LPM",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Rate - set 2 to 4 bpm below patient spontaneous rate",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Volume - as tolerated but target minute ventilation &gt;10 LPM",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       FiO2 increased only after ventilation improved. Goal is to achieve SpO2 90 to 93 percent",
"      </td>",
"     </tr>",
"     <tr>",
"      <td colspan=\"1\" rowspan=\"4\">",
"       Failure of nocturnal noninvasive ventilatory support",
"      </td>",
"      <td>",
"       Patient refuses to accept either the nasal or face mask (anytime during the trial)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Unacceptable deterioration in mental status (anytime)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Intolerable dyspnea at any time or Borg scale &gt;15 with no improvement",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Consider tracheostomy or other more acute treatment",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     IPAP: Inspiratory positive airway pressure; EPAP: Expiratory positive airway pressure; LPM: Liters per minute; FIO2: Fractional concentration of inspired oxygen; SpO2: Oxygen saturation.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f41_49_42780=[""].join("\n");
var outline_f41_49_42780=null;
var title_f41_49_42781="Contents: Pediatric surgical emergencies";
var content_f41_49_42781=[" <script type=\"text/javascript\">",
"  $$.inlineInitCustomer(",
"	false);",
"	var quirksmode = document.compatMode == \"CSS1Compat\";",
"	if (quirksmode) {",
"		$(\"html\").addClass(\"ie-standards\");",
"	}",
" </script>",
" <div id=\"message-wrap\">",
"  <div id=\"message-bg\">",
"  </div>",
"  <iframe id=\"message-bk\">",
"  </iframe>",
"  <dl id=\"message-container\">",
"   <dt id=\"message-title\">",
"   </dt>",
"   <dd id=\"message-body\">",
"   </dd>",
"   <dd id=\"message-controls\">",
"   </dd>",
"  </dl>",
" </div>",
" <div id=\"topPanel\">",
"  <div id=\"header\">",
"   <div id=\"header_container\">",
"    <h2 id=\"logo\">",
"     <a href=\"./toc\">",
"      Wolters Kluwer Health UpToDate",
"     </a>",
"    </h2>",
"    <div id=\"header_right\">",
"     <div id=\"searchpanel\">",
"      <a href=\"/login\" id=\"loginbutton\">",
"       Log in",
"      </a>",
"      <div id=\"cmsSearchBox\">",
"       <div class=\"header-search\">",
"        <form action=\"./search\" id=\"cmssearch\" method=\"get\" name=\"SearchForm\">",
"         <div class=\"header-search-left\">",
"          <input autocomplete=\"off\" class=\"searchfield\" id=\"cmsTxtBox\" name=\"search\" placeholder=\"Search UpToDate\" type=\"text\"/>",
"         </div>",
"         <div class=\"header-search-right\">",
"          <input alt=\"Search\" id=\"cmsSearchSubmit\" src=\"/sites/all/themes/uptodate/images/search_button.png\" type=\"image\"/>",
"         </div>",
"         <div class=\"clear\">",
"         </div>",
"        </form>",
"       </div>",
"      </div>",
"      <div id=\"cms_lang_dropdown\">",
"       <form accept-charset=\"UTF-8\" action=\"/\" id=\"lang-dropdown-form\" method=\"post\">",
"        <div class=\"form-item form-type-select form-item-lang-dropdown-select\">",
"         <select class=\"lang-dropdown-select-element form-select\" id=\"edit-lang-dropdown-select\" name=\"lang_dropdown_select\" style=\"width:100px\">",
"          <option selected=\"selected\" value=\"en\">",
"           English",
"          </option>",
"          <option value=\"ja\">",
"           ",
"          </option>",
"         </select>",
"        </div>",
"        <input name=\"lang_dropdown_type\" type=\"hidden\" value=\"language\">",
"         <input name=\"en\" type=\"hidden\" value=\"/\">",
"          <input name=\"ja\" type=\"hidden\" value=\"/ja\">",
"           <noscript>",
"            <div>",
"             <input class=\"form-submit\" id=\"edit-submit\" name=\"op\" type=\"submit\" value=\"Go\"/>",
"            </div>",
"           </noscript>",
"           <input name=\"form_build_id\" type=\"hidden\" value=\"form-on4lUWpxHun_wp6revUkjCG6rK2IBuCGME9Cw0HXeok\">",
"            <input name=\"form_id\" type=\"hidden\" value=\"lang_dropdown_form\">",
"            </input>",
"           </input>",
"          </input>",
"         </input>",
"        </input>",
"       </form>",
"      </div>",
"      <div class=\"clear\">",
"      </div>",
"     </div>",
"     <ul id=\"utility\">",
"      <li class=\"first\">",
"       <a href=\"/home/about-us\">",
"        About Us",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/news-events\">",
"        News &amp; Events",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/contact-us\">",
"        Contact Us",
"       </a>",
"      </li>",
"      <li class=\"last\">",
"       <a href=\"/help\">",
"        Help",
"       </a>",
"      </li>",
"     </ul>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"nav\">",
"    <ul>",
"     <li id=\"productTab\">",
"      <a href=\"/home/product\">",
"       Product",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"editoralTab\">",
"      <a href=\"/home/editorial\">",
"       Editorial",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"whyUptodateTab\">",
"      <a href=\"/home/why-uptodate\">",
"       Why UpToDate",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"supscriptionOptionsTab\">",
"      <a href=\"/home/subscription-options\">",
"       Subscription Options",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"/store\">",
"       Subscribe",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"wkhcsTab\">",
"      <a href=\"/home/wolters-kluwer-health-clinical-solutions\">",
"       Wolters Kluwer Health Clinical Solutions",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"    </ul>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"greyBar\">",
"    <div id=\"greyBarTitle\">",
"     <span class=\"emphasis\">",
"      <a href=\"mobipreview.htm?3/3/3134\">",
"       Contents",
"      </a>",
"     </span>",
"     <img src=\"./../images/space_arrows.myextg\">",
"      <a href=\"mobipreview.htm?17/55/18302\">",
"       Pediatrics",
"      </a>",
"      <img src=\"./../images/space_arrows.myextg\">",
"       Pediatric surgical emergencies",
"      </img>",
"     </img>",
"    </div>",
"    <div id=\"greyBarButtons\">",
"     <div id=\"printGB\">",
"      <a class=\"icontxt\" href=\"?view=print\">",
"       <img align=\"middle\" alt=\"Print this page\" border=\"0\" height=\"20\" src=\"./../images/icn_print.myextg\" width=\"24\"/>",
"      </a>",
"      <a class=\"icontxt\" href=\"?view=print\" title=\"Print this page\">",
"       Print",
"      </a>",
"     </div>",
"    </div>",
"   </div>",
"   <!-- menuMessage.jsp -->",
"   <!-- /menuMessage.jsp -->",
"  </div>",
"  <!-- header -->",
" </div>",
" <!-- topPanel -->",
" <div id=\"leftPanel\">",
"  <ul>",
"   <li>",
"    <a href=\"mobipreview.htm?3/45/3806\">",
"     Specialties",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"mobipreview.htm?18/22/18798\">",
"     Patient Information",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"mobipreview.htm?3/13/3294\">",
"     What's New",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"mobipreview.htm?0/37/606\">",
"     Calculators",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"mobipreview.htm?0/40/654\">",
"     Authors and Editors",
"    </a>",
"   </li>",
"  </ul>",
" </div>",
" <!-- leftPanel -->",
" <div id=\"rightPanel\">",
"  <noscript>",
"   <div id=\"javascriptDisabled\">",
"    It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"   </div>",
"  </noscript>",
"  <div id=\"printHeader\">",
"   <div id=\"printHeaderLogo\">",
"    <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"    </img>",
"   </div>",
"   <div id=\"printHeaderText\">",
"    Official reprint from UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"    <a href=\"file://www.uptodate.com\">",
"     www.uptodate.com",
"    </a>",
"    <br>",
"     &copy;2013 UpToDate",
"     <sup>",
"      &reg;",
"     </sup>",
"    </br>",
"   </div>",
"   <div id=\"printHeaderLinks\">",
"    <a href=\"#\" id=\"printHeaderPrint\" rel=\"\" title=\"Click here to print\">",
"     Print",
"    </a>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"     Back",
"    </a>",
"   </div>",
"  </div>",
"  <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" id=\"tocTable\" width=\"100%\">",
"   <trs>",
"    <tds>",
"     <h1>",
"      Contents:",
"			Pediatric surgical emergencies",
"     </h1>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds valign=\"top\">",
"     <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">",
"      <trs>",
"       <tds>",
"        <strong>",
"         Appendicitis",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?32/3/32826\">",
"           Acute appendicitis in children: Clinical manifestations and diagnosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?18/61/19416\">",
"           Acute appendicitis in children: Diagnostic imaging",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?31/2/31785\">",
"           Acute appendicitis in children: Management",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Ear nose and throat problems",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?25/58/26536\">",
"           Management of epistaxis in children",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Genitourinary problems",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?24/23/24953\">",
"           Balanoposthitis in children: Clinical manifestations, diagnosis, and treatment",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?32/55/33654\">",
"           Balanoposthitis in children: Epidemiology and pathogenesis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?28/39/29302\">",
"           Paraphimosis: Definition, pathophysiology, and clinical features",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Hernia",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?21/3/21561\">",
"           Overview of inguinal hernia in children",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Intestinal malrotation",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?19/48/20232\">",
"           Intestinal malrotation",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Intusussception",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?34/20/35145\">",
"           Intussusception in children",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Pyloric stenosis",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?3/29/3545\">",
"           Infantile hypertrophic pyloric stenosis",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Rectal prolapse",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?31/48/32519\">",
"           Overview of rectal prolapse in children",
"          </a>",
"         </li>",
"        </ul>",
"       </tds>",
"      </trs>",
"     </div>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"     <img height=\"10\" src=\"./../images/spacer.myextg\" width=\"1\"/>",
"    </tds>",
"   </trs>",
"  </div>",
"  <div id=\"footer\">",
"   <div id=\"footerNav\">",
"    <ul>",
"     <li>",
"      <a href=\"file://www.wolterskluwerhealth.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Wolters Kluwer Health",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.factsandcomparisons.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Facts &amp; Comparisons&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medispan.com\" rel=\"nofollow\" target=\"_blank\">",
"       Medi-Span&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationordersets.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Order Sets",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationmedical.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Medical",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://pharmacyonesource.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Pharmacy OneSource&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medicom.com.cn/\" rel=\"nofollow\" target=\"_blank\">",
"       Medicom",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.lexi.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Lexicomp",
"      </a>",
"     </li>",
"     <li class=\"last\">",
"      <a href=\"/home/privacy-policy\">",
"       Privacy Policy",
"      </a>",
"     </li>",
"    </ul>",
"   </div>",
"   <div id=\"footerLogo\">",
"    <a href=\"./toc\">",
"     Wolters Kluwer Health | UpToDate",
"    </a>",
"   </div>",
"   <div id=\"supportFooter\">",
"    <span class=\"sfInfo\">",
"     &copy; 2013 UpToDate, Inc. All rights reserved.",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Release: 21.3 - C21.34",
"    </span>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <span class=\"sfInfo\">",
"     <a href=\"/home/terms-use\">",
"      Terms of Use",
"     </a>",
"    </span>",
"    <br/>",
"    <span class=\"sfInfo\">",
"     Licensed to:",
"     <span class=\"emphasis\">",
"      UpToDate Marketing Professional",
"     </span>",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Support Tag: [0505-95.154.198.148-EFA918C7FA-14]",
"     <br/>",
"    </span>",
"   </div>",
"  </div>",
" </div>",
" <!-- rightPanel -->",
"</body>"].join("\n");
var script_f41_49_42781=[""].join("\n");
var outline_f41_49_42781=null;
var title_f41_49_42782="Measuring angulation of a metacarpal shaft fracture";
var content_f41_49_42782=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F67394&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F67394&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Measuring angulation of a metacarpal shaft fracture",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 281px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAEZAWgDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD5iOaQ804CjHNSMbRTiKQjjigBKKXFH86AEoozS4oAKTGaWigAopKKAFzRxQKPegANFFLQAgopRRigBAOKWiigAo70ClAoEJ1oHSlpKBhij2oo/nQAUlLR3oEGQKKKDQMB1pBS4oFACfWlpKKACiiloAMUlL9aT6UALSfSjNAoAO9B7UA0UAGaKKKACig/rRQA4Gl4zTfrQaYDjxSjmmg+tPGKBCFeKZip/SkxxQFyEiiptqmgxDHWgLkGKUipRGe1J5bdMUguRYxRipShHJpCp9KYXIxS/hTtpzRtPSkA2in7eKQg0ANpT0pQCacFoAZilwfSpljz2qeO2YjpTE5JFPZkUm2tQWnHNNayz0osLnRm4wKTFXJLZ07ZFQtGRSsO6ZDQeaeUPpSMuOtAxtJTselJQAlFLg0nWgYdRRR0ooAKPajFIBzQAtBoJooASloNFACUUpoNACflR2oNFABSUp5pDwKACiiigBRSijHNKBgUAFOA44oGKkRS2ABQK4sK5OG6GrCxx/xGo9hUetPVGYcA4qiG7lpLe1Zf9bhvpTv7NZwWiIce1Nt9OmmGUArWstCuwc+Zs/Gna5lKfL1MJoGRiGBBp8cO7oK9C0vQ7S4/d6kAzHpIOorat/BdvG4KhWUnginyGbrpnlTWR2ZIpPsQ6e3Jr21/CNs0KARoMNTofCFoWzIEAx6U+QPbM8TTRpZ1Jt/mPpUUmj3sfW2kP0FfQFr4XsYXDBQcegretLexiQIYEYD1UUOKEq0j5a+wXHQwuPbFTRaVcuflhc/hX1SdN0y4Tm0iBP8AsCqVz4MgnBa2VUz6Clyov2snsfNi6DdnH7lh9asJ4au8ZMZFe53HhWe0bi3LejYqsuis8qoYmDMe4pqJDrT7HjkXh+7DbRCSfWtK28OyuBvJB9AK95tPCym0ZRHkhc5x3qrp/h+R5TviAQccjvTSQnKbPI4PB0zru3DHXaeDUF34baDgghvzFfQlp4fjIJePkdsVXuvDUUkqgxjB6jFGgWn3Pmy40qdM5jJGO1Zc9lyQV2mvpjW/BUQVnso1JA+5XA6h4WSYslzEYpexxU8twU5R3PGJbRlzRZbLa8je4hEsY6of513+qeEb20BfyjJH2ZRmsKXSjj50wfpUOHMrM6KOKlRnGpHdO667eRT1jR4rq3F7pYG3HMa9D9B6+1cwUIrsrKOfTpT5YLwn7yD+YputaQlwhu7RfmIyyYxn3rhjOWHn7Kq7p7P9GfXYjC0s6oPH4GPLUj8cF/6VHy7r9d+OKmk296uPAQelQshB6cV2nyykQUlSFeaaV9qB3Gg8UlLikoAMUUDpR0oGHeg0cUZoEFAoo+poGBpMUtFACUUppDnOTQAUUUUAWBbyE/dp4tWHLHFTvJMegI+gqFy+fnzTM7tieWi9OTSoDnAoVWY8CrFvAWYZpoG+41htAzVmNgeO2KsvZjYDjuKetlgrgdadjPmJLMSYwma3bKKaYbnlYDOMCqFlFIXVIlLMx4UV3Wm2lnYwrJqpYOcHYvOK0SOapIpW1o+FwGI9a39PjuojtUv5Z6irtlq+ngAWtqcfStqy1BSwIgyPQ4pmKsZqC5WVcJIyd604bGcgFY5CevStmLXYIAN0Cgj6VNH4wiUHbaj9KNTRRjsUrG2vkkG9VRB2xXQ2v9m4C3EfzjvVBfFtrIuJbcgfUVYt9U0e5HJ8tj7VJaaXU2U06KTDW5Qp14qKSFoz0I5pLO2jf59Puhn0zWxaeaHWK/jBH94Cg0RXs7VrhGGM8d6fp2mW5uR58QZl74ro7KzRcvEcqe1VREEu247UrmnKTR2EBgfCYBBrIGnBAcLgE101suYsDn1NR/ZhnBOam5TiYAg2AjaQcY5pjWyhdxFbstkDn2qhcwEcDJzTvcTRksoVHIH4is+aytbxcXUQb/a7itl7diu0VELDDEM+PpRcho5+XwwYstaHzIz1Q8iuG+IGnaZpWnedPZMt3KxSMDgZ7k/nXs1rCI+N7YrzP4iaYurfFXQrM3UVvG0CSF5j8nysxxj1OMVhiqkoU7w3dl957OQ4HD4rFpYn4Ipya7qKvY81tvCGqTaat75BVJPmVcfMR64rEvLK5tJCs0TL7EV9aXOg2sjM8RKg/wAOOB7Vh6n4V064Ui5t1b3xWccDR5bSV336nTW4ozN1VUoVPZxW0YpcqXa1tfn8rHyTqmlLKxlhXDfxL6+9c9c2jIeVr6e8RfDeznif+z3EM3VCRwT6GvJb3ShFcS6fqcPkXSHaGI6H39ves4SeHl7Ko/dez/RnTi8NTzmjLHYGNqsdalNf+lQ7ruv138slgwelV2Qiu61Hw7LGzbVzt9K5u7sWQ4Iwa7eU+WhUTMUrTSKtyxEVXZMUjZO5HR1p2MfWjHFIpDTSUtJQAUUUcUCEpaKBQMDSZpTRQAlFFFAGsNVkHRE/KpI9QDkGSFCO/FZaDNWY0PpxVJszcYm1DPZzDBTy6nW1TcGj+Ye1UdPs/PyzcKK6DT1+yYIwe4GKtLuc83YItNurgARRNg9yOBXXaF4TWeNWuX+YDoKittYZYNixpuIxkDmlGqTqOJWX6GrtY5nNnUpo9jpcPmHyllH3emfrWJdy2aOWdt5zxWZJPNN8zMx9yahFrPcthI2J+lBN2yzNqkcIPkJzVb/hIrtCArAL6VNF4evZhym361YPhPGTNcoPX2pFJR6jYNca4I3NzWnFflgOfwrNj0Cyhfcb0Z+ta+nWOmq37+8A/GncnRPRjo7p5CQoz9K29PtnZRv6VoaVpelSEtBcJn61sJpKDHlyq30pXLjG5BpsbxN8jFD/ALJrrNH1a4Rgk5EqejVkWulTYyoFalnp7IwDsCc9hSNYpnY6NdRyljCSvH3TV+SNJpAwGH6YrnLC3eB1dCcCtQXgDxknGDzUs6E3bU1402DaKihIaVvrSrdxTRZjOXxz7U2EFBnoc0iy6kY25PJFVpIFyeOTVwOAnbJqMgsMgZpFaGc1jkkryT2qC5tNg+Yc1JqPiPRdLhuJb3U7OM26kyRiVS4x1G3Oc+1cPrnxp8NW0EZsI59SkZsMgQxbRjrlhzWU8RTp/FJHfhcnxmM/gUpS+Wn37HWpCQfWvK/jZo09td6Z4lhSSZLZkjlj2/KgVsgk+5OKlk+IvivV9Vgj8N+G/LtLnaITcwM2Sf4i/C496h/4Qr4ha/b3Nn4k1hraybDbZHEquQc4wvTHWuSvXjiIOFOLfn0ufRZVllTJ8THE4urCCW8XK8nF6NWV3f8Aruddo3xG8O6jp8N3calb2M8g/eQTMdyt3/D0NZ2q/Fvw5bNcwQpc3c0YIjaNR5cjduc5wT3xVHSPgvo6WiLqt/czXYJ3NAQiEduCM12cXgPwzBJHJDotmskZDK2DkEdD1rSLxco62RyVlw9Qqtw9pUWumiS7auzaPLE+IWueIDNbaH4dH2zZuDRs0hQZGTgjBrM1fwr4z8SWP27U7WBJYNwWNlEcz4HQADn2r30xxxsSQik91UA/pRGYnJUHNN4OVRWqzb/BEU+IqWEmp4DCwpvu7yfnq7aM+ZPCLpcagulX0R85yUjYjBB/utVXxp4Le1Z5oozs7ivX/iZ8Pxq6tq2iBYtWi+Z0XjzwO/s3+Fc/4N8Qw+IYzo+urs1VBtDSDHnY7H0b+dLD1JUJewqv0ffy9QzfA0c0pPNMuja38SC3i/5vOL8vXvb54vtM2k4GMdqxbmzZT0r6I8afD1o989imepKYryfU9IeF2SSMqw7EV3tXPkY1HHRnAPGV61Ew4ro73TsHgVkXFqUPSs2rHRGaZRNHfFSMhFMIpGiG0uKMd6SgAFFH1ooGJRS0g6UAFFFFAjQtoTI2AOB1PpW1b2Zmi+UcKKqCSKKPy4+nc+taNheRrCeuSMVorHNNy3RNYKFtQn1JqxDKWKqvashLwxyEY+gp0NxIrFgOPWnclxudJG0u4JEhLnjPrXTWOihLdJdRuEjBGcZFcFYa39hLzuNzr9wH1rK1DXLvUZmeeZyD/DngU3JEeylJnp82t6FpuUSQSsPfNZVx4+jjYi1gGOx6V5zuLHqasQx55YilzD9gludXdeN9SuRtjAQeuazZtV1G6JM1w2D2BqiiAdP0rQtLG4uMeXGxHqaV2HLGPQiWaU9ZH/OpYvNlcKpkYnjrW3a+Hig8y6kAGMkCrlnPZWMoCRhveqRnKouhZ0bStQ2KfNeFOpJNdtpWqXOngLHJ5pH8TVzzays0aiM/L6VasZw3JP1qjPzPRNM8UeYFEyMp9a6/TL6G5VTuB4zx1rx22uRvUevSuq8P3boxKnBFI0hOx6vaNG8JINZb3Cy3DKPurx9ap6ReNJCwJxj3pisY52zxuNT1OjmujXW4SzBndxHEilnY9AB1JrlG+M3h5JJI0tNRldSQpVFwxH45wa6KOYgLg+9VtP0DRLe9F9baXaR3iP5gmCfMG9axrRqyt7Npd7nqZdWwFNS+uU5TfSzsvn/XyOLHxN8Y+I7SaDw7oIhuI9rNNFlyoz0wwxzSXHhf4i+J0tLzVdXWyYAp5IlMLouepVBgmvT1lDuOB+AxV+KT5cd65/qbl/Em3+CPV/1ijRd8FhoU/Nrmltrq/wDI81sfhFolvqDXGp317qStktHINm5j/EWBzmux0Lwx4a0W3kgs9It2SRt589fOOcY4LZwOK1n5B75pFQ9a2hhqVP4Yo87E51j8UrVq0mu17L7lZGjFcxJGsaAIijaqqMAAdgPSp1eMryRisd2EQOevpVJ53LkljW1jzHI35UjcHb1rLuEuEb5WyPSq8N46ty2far0d2kg+YYNO1hXTM17jtKuCKAVPzRnBq9cQRzcgCs6S3eIkr0pid0XoZt3DcNXnnxP8BDV92r6Kpi1iIbiiHHn47j0f+ddlHdFGxIOlacUkdzEACM+lZ1qUa0eSWx2ZfmNbL66r0HZr7muz7o8s+H/jFNcUaRrmItXj+RGf5fOx2Pow/pU/i3wdbX6O4j2yeoFJ8TPA39pSNqujqIdXjO9wvHnY7j0YfrgCmfDvxyNXVdJ1w+Xq8Xyq7jHnY4wf9v8AnXNRqypS9jW36Pv/AME9jMctoY+g8xy5WS+OHWD7r+6/w+9LyvW/A08W77Owb2PBrhNW0K5tiRPA69s4r6z1rRrW/TfsAfPUV57rmgPAXGMr/dYZFdx8nrHY+abqzKEgg1nyQEdK9b8VeGPka5to9vdkHb6V53c2pVuRiocTWnUuYLIQeaStGWD2qq8OCSKlo3Urlc0lPZCCc03HFIq4lHaiigAooopjNAsTVi0l2gg9DTGtpAAShppR0HKkUzF2ZNM43AjqOhqSK9UR4K/NVFySORUIBJpXGop7k1zKZm9qjWM1NFEWICKSa1tP0G7vGG1Nq+pppXByUUZUYORtrX03Sry7ICoQp7kV1mnaBY2Kq1xh3HrzV99Sht1K20SjHcirUTlnXvpEoab4d+zgNMRuHdq05Lq3skwrBmHpWXdX09yR8xx6VRktbmXop59arYzUXLVhqmrPK5AY7fQGsyO5LS4qWay2SYlfFMtEhF2Ax4qTRRiloaljcPjaOldFaXIRV3ZU1RsktVGQAT3FaXm25GREPYVRzy11RcW8AZdp5Fdd4dvEfJB56GuBaS3I4Xac81a027aCUtHKy49fSi4lLU9x0aQZYE9RkU/Vpfs5hm52k4NcJoniZYkBknjOPU81e1HxbaXEIjdgPmGKLHQqisdpb3CuqlW4Iq5HcgnaDiuI03VUZV8pwyH9K37a4V1ypGDUtFRkmdNDKAy88VcMhOCprnra7IIBPStaC+jC5YjFBqpF9XZh0GacBL1AOKz21lFbEceR6mmtrT4+4AKRV0XpEc8nJqFoz6c1XTXAfvrgVai1GKQdR+NFgumV2Qg8imBmHFaXmRydcVG8Ct92mFitFcsnGatpOki4brVOS2YNgVXO6PvyKCdUW7qzEi5Xg1lvJPYyh+eD0q/FdFB89WSIbuMqwBz+lMNGOEsd/brNEfmA5HcGvMPiP4LOpE6npKmLVI/mZE487HcejfzrvkgmsLkGLLQtwRT9QTJDKODWVajGtHllsduX5hXy+ssRQdpL7muqa6pnmfgXxk2pAabq7eVqUfCl/l83HY+jf4V1kqreB0k6+9cz8QvBo1ItqmkqItTT52UHHnY7/wC9/PioPh94sGoSLpuqny9TjO1Swx5uOMH/AGv51z0a0qUvY1vk+/8AwT18xy6hjqDzLLVZL44dYPuv7r/D70rd9pC7mQr8pzn6V5tqXgRZ555IyQmeMDpXuGqRhWRwPvDBrOaxAtX2r15Ndx8o42eh81eJfCl1pOZNjSW56MB0rlJLc9cV9QX0MBhMN1GHibgg147418LPp960lkpe2bJAHapcSoVLbnm8kRGeM1A0YweOa27i2ZOHUiqckIx0qGjoUzKaPmmlavvD7VE0RFKxakU8UVYKdqKCrkkt1NKcs5qPzH7saZnApKQWXQkLE96lhXJUAcmq3erNs+JUz2NNEy2OgtbcQheOSK17W7liXCtgVkmf5QVPSpI7gbfmOK0RyNX3NRbuSSQgkkk8Ctm008yQh5UI46nisrTdSsdPtmuLlBLL0RT296xdY8W3d2xWJtidgKrmSRHI5vRHWzTWViGLyJu9KwdR8URoCtuM+9cZPcSzHdK5Y1FWbl2No4dfaZo3eqTXDlmPJqqbuUsCGIxUFFTc3UEtjVtL6fn96fzq0NRuR0lb86w4W2mrIk5FNMiUEayatdA/fz9auQa1JuBf+dc6XpfNp8xHsos60ayDg5x+NVLrV5pp94chV6DNc+Jcc04SZNPmEqSR3OjeIrm2UfOT75r0Lw340STYk7AH1zXiEF2ypt4qe3unjbKMR9Krm7mUqb3R9TWuopdRB4nDZ64NTG5cHBPFfPWheLL7TZVMUm9e6t0NeseFvFNrrkQGQk46oaPQLvZncQz5xk9atrICOuaxFJTBFWobjgCkWmX2wTmmk7TnNRh9x4pS+BigCVbuaM5RzVuDWmUgSjr3rKbkZFQSA5+XNMHJ9DsoNQjkXIYH8alkWObHTNcJ5jxt8pIrQstYlhIEvzCgan3N24jKH1qvHK8TblJGO1WrW+guo+opt1bgDcvSgb12LttepMoD8GruyOeMjjIrlhL5UqnPGea047hkZGRuDQOMrlm6sk2njntXnHj/AMBnU0bUtFBi1SIbmRPl87Hp6NXpLXiSLkHJHajzFIymMmsqtGNaPJM7svzCtl9dYjDuzX3Ndn3R5b4G8XrrKrpetfutUhG1Wf5fOx6g9GrtbqICz4GPUVxXxa8KyXckGsaLasb8P+/8o/M/91gvc5zk/Sur0VNSHhyyXXChvyn7zZ6fw5/2sdfescNKpGTpVNbbPuv8z0s5w+Dq0YZjg2oqbs6d9Yy62/u/5rvZclqymSR1XnHWsPxDbSS2CyRHDIOeOtdXeWonupFiGBmqf2B/MEL/ADLj5h612pnyzTPHtQsFukKyR7WP8QFc1NpDxy4YcZ44r2y/0VEDnZ0zXMajpq87U56/Sla5Kk4HAroaTIV6ORxWBe6fJbSlJVKn6V6P5BRtx+96CppraK6jIuY1cY49aTiVCs1ueTNB6UV1muaKtmRJCcxk9D2oqGjpjNSV0cBnj3pKCaQ1B0hnmpFY5zUQqRecUAaEMrMuCasRkjq3HvVW1RH4c496vGKEKPmLfjVmLtcoXkrORgnaKq1cnA3YHSqhHXFSWhMUdqSkPWkUhSaSgDP0pB05oAcDzUgbioSeKcrcUwsSg0ZqLdmlzigRMG9aUNUG7mlDEUCaLaPViKTH1rOD1KkmMUyWjWjmxWlpmoS2dwk0DlHBzwa51JcVPHMaaZnKFz3nwt42S8t40u/9YOM121vPHPGHiYMD6V8yaZfPbTK6n616P4b8UFNux/qpq9Gc0rweux69FKw61Y8zIFc/pOsQahEAGCydxWkJNuB2oNE00X93FJkEe9V1k685pd+KQXFfGeRUMi56damWUYORUTnuKYmRQzTWzF42Iro9J1lLkeXNw+K5t+lQFirhlO0jvQF7PQ7O7gBXcMYqO0mBHlvwR0qlpGqrOohnxntmpp4vKdnQ4PUUF3vqh00zRScZq1azljlic9hVOVGn2sOPWpoCsSlmOAOlAIuSPhlB/Sq+ozHGVJAx1p0IZ/nPU9KjukDAjBIBpgZxt9q5UfO3OamFqGtzwC543d6tsoEYJHFPgPyFiOOwFFxJHPXVp1VgefauY1HTf3L7Rnk9q9EkjBLkjOPXtWJeWwLMKETKJ5cbFnVgFwTxzV+Pw1eeQpjUdOhrb1S1NsVeFQWX5mreifzdPSSPrgEimZKJ5Z4h8Oaglm5kiB47c0V6BezFoGX2/Wince2x8h4oxS4ormPUE+lOX1puKcvWgC/bnA571K0oz8o5qtFzCPajnPWqRlYkkxsY5qoTzxU8/wAqDPeq5pMcQpD1pc80hpFhTSelKcdqbQAHrxQDzzSH2paBjiaCc02g0CHA0Z/Km5o/nQA8Madu9KizzxTgfWgCZGqxG+cVUBp6Ng0yJI0oX6VoWty0LBkY1jRvVqNz1pozlG+56H4d18q65chh716hoOtR3sKxyn95jr618828pQgg8+tdl4a1so6q7YYd60TucsouDuj21XIbA6VOJARWBpGppcwrlgT61pFiBkGixSlctFx1PWjfgfNVcSg8k0qyA9aAuiRm565qFjgYp5wORUbHNOwmNyykMpwRXR2N0LuyUMfnHytXNOcU+0uTbT7gTjoRQJOx1aBlYjtVhIzJgelZtteRuATIPbJrQtp0LDDBj7UGidy+qbF5HOOBSMihAHI31H9oVFLHlu1Z91JI2dxPPP0osU2X5VD4C4OKifCoR2FU1YxLtDH3NNkdjHtB+Y0E3JTMDJtB49KJoN2Wx7VnRCXztzfpVz7QfJYOenQ0BuZ93BHgrtDHoc0WyJHG0Y4HtSvMjtx2PSoIm3XBHPFBL3MXVo/LdsZIzkUVo6lFvkOAMEdKKdyGmfG/biig9aK5z0xKcKTNAoEXbQbo3Hcc0RjdIF96XT+ZGHYiprRM3aj3qjOXUh1Hifb/AHRVTpVm+O67kJ9arGpKjsITSZpT1ptBQdaKQUtAB2o7UnrS+lACCjFFAoAXtRRRQAUopKVaAHduacpphNOU5piLEZ4qzGeKpoT2qxGc0IzeheiPrVuB2UgqeaoRmrUJ461SZmzt/DOvvBIiSsceten6ZqSXUSjdyRXg0LY6HkV0mg63LZuqu2U9fStE7nM48ux7CzY96VJMnmsvSNTS8gBDKTjmrcjYJIPFML31RbMxGeaTcSKqh8jBqVXGPegLkjScc0xmB9KZ97PpSSBcHFAE1vPhtpPHatfTJT9oB3HA6mucjVjLtX7xrchiMMaKp56k+9AI62J0mUbDwOtK8Ixk9PSsWC4KKMcGrBmZ14Y5+tI1uWphyBRGigkkcY4NVoXkERJYMfSm+a4XDHr2oC/UfLGFBKnBqldTbYiuOSKW5nCgjPFY9zO2cHmmS2XIMYz1x1qe1Xa+5uvXFVLY5A28561pqDGAdoJbvSEiCRNxL4/D0oqeQrGozyMUUwaR8SUlLQK5z0RDS96MetA68UAW9POLgVfgG29rOszi4WtLOLskdapGM1qZt1/r3+tQ4qxeri4b3qDFSaIYRTaeaYePrQMDQKKUDNACUCijPQUAAoNFFAAOetH4UvpRyTQAlKKSl70AO9KUU3vSj6UASoanjNV1qVOopkSL0Z7Yq1EMAYqnGauw9KoykXIverCntVaHpVkdOapGNjW03Uriyz5bnB7V3uia6l9bqG4ccEV5khK/SrVlcyW8gkiJBH61VzOUeqPWBMByKes2D1rmNJ1dbqMBiBJ3FaYn6HNMm5riUDODU0ZaT5UUsfasqBzLIFU8muq0mOGzUOWLyHr6CgadzLsyUvE3DvgiujICAfWn3MEMrRzIgBJGcCnyxrk0tzRIgJPUc0qTSDgLSK208jn0qXcucngUCI5bqW3YkAEelQ/2kpGSDn0qW8YMvUCsa6K9R6cY7mncUnYfe6kchVX8TWd5zuCynnvmopcE4Ykt6UCVIxg8fXvTJudHokikIsrDJ6ZrafaBlsYrgZbxbfDF8FeetW9O8Tw3LeQJOfUmi3UakludFf3iqpWMZOOKKyzlmz3Y9aKQNNnyJmigc0prnPSE6UufSk7cUDGaBk1ucSqT61pO37/I6Vlp98H3q83YmqRnJXZFeDMmarGrU2GINVWwDSHEa3r2pp60800ikUJRR1ooAOKTFGRiloAMcUnUUpoxgUAJz3paPrRj0oAQUClpaAD0pwpgPJp4pgPXmpkHNRJ0qxGKDNssQDNXYhxVWEYFXIemcc1RnItRH0qwCcYNV4xVlMYxj8apGI/r7U9X/CmE0fWmtAaLtvOyOHQ4YV0mm6mJgFc4kH61x8b4PSt/w5aPcS/aXBEUff1NO5lKN9TvdMQxqXYfMw/KtiGYgKAc1g2FzuAEhwwrSjkXjD5piWh0tpcZhVTyARWhKO+eTXM2twVI9M1vvMCocnAx1oNIvQqXTeVls9KpyXTC3IJzzT9VlAtAT0Lc1jNdKwZAx56UIluxtG43ojE9R3rGu7gFmBbjPaoxfgQlcjKDHNYFzfNvOOSaZLkacs2W+Uj1qhquoRWkYd2O9ugrLOo7S1c1reo+ddbieAMDmgle9saF/q73JxnC/wA6rQ3ZR1ZWII5rBa8OelSLdZwSam5fsz0fRvFm0LFd8jsworz1LkZ5oqrktSWiPP8AFHaiiuY9UBR3o4pfWgABxV6JgyYJqgOamjboKaZLRckC7VVeW71VkQDpU6uFU+p4qF2zQSrkBpOnWnsuDTT0pFob/KkxS0lAw7UDNGKX0oASjNFFAB9aCOODR0FFACHmlHBpKMd6AFp69aQU9R0oQmSxip4hzUaDgetWYV55pozZYjWrMa9KjjXip4xVGUmToe361YWoF4XOKkU88daZmyQD3ppbmtXTdDvtQBaKMqg7mur03QrDR0E16VnufTsKonmSMXw54XnvnE97mC1HJ3cFq37+7ggj+zWKBYY+/r71W1PWJJvkUlY/7o4rHeRmJOaa0MpTvojTW8YEc4HWtOx1HDKGxgVzUe5+hNXYCyjCn65pkK9zuYLhWCkHIPNbtrcrLCEYjPavPYLlhCChPHWpINeeCTDnAHfPSgpSOp8SO6QRpz97Nc0Z3UE+/FZ+pePrYybDE0wAxnIrl9T8VmfcLdDED+dGxXK5dDZ1fWDFehFb2f2qKW+HYjpnNcRPeF2LFiTnnNMOqy+vPTNHMV7A6G9v9isCwGawLm7LsT6mqM920jZYkmq7S56mocjaFNIvedk8mlE2O9Zvmmk87BpXL5TZjm460VlC4460UcwuTsZtFHOaKzOoOKBzQaKAClFIDRQBIH4paiB/KnA80xWJPvKfWozTwcGkYZ5FJi2GGmninUmKChKPXNGO1GKAAc0mKXFLQA3pz1o607FHWgQmKDTjSelAx0YqVR6ClgjLsAOK0VsVABL4pmcpLqQWke5xkcVrC2V48qACKqCAwYY8qa2bGMsmccHpVpXMZvqUo4WArRt9LuZekZGfWt3RtLQt9onXMa9jWntBuCMjHUYppGMpmZaeE55QpllVF74rp9L8NafaRiSYiRh61BDPtGWO7b0HakuL15Btziny3M3Ns0rvVEixFbKEQelc/eXDSMdzbiTSSyMWPzCqshLZ/nT6ENjJPmHWkUbenejb8oxn6VbtbKSUggceppIFoMiA2470jMUIAOcdqu3b2WmRFrlg7f3fWuX1TxM8pKWsKRx9sjmnsUoORu/blhiIZtoA5NcvrWqifKQt8vc1lXN7NOcyyFqpPJwaTkbQo2d2PeXk81E8nHWoZH5qF5PWobOhR7kzye9RM57VCzmmFvypXLSJzJ2pu+oC2KbuJpXHy9ybzOetG/JqDNANBViYP60VFmikKw7HNLR2ooKENFKKQ0AFFLSEUAFGaD7UUAPU9qfio16YqRD2JpksaVwaCtPbBNIRx70g1IiKT6U7+KlApjG9cUdc0uKO3FIBvpS96WgZzQAhHNPVC3AHFSQxbhlhxUjYGMcUyW+w+2whxWjbkyTLxxWUnDVrWYw8bD8apMzkXr5NwtYlGC7c10dhHswFUY7cVgt817bE+ldDCrRgAgjI/Gr2Oao7JFyS+l3BFwEHYCpISQC3r61RKKFDE8/WommcSBAenUimY7msCwVjuwKhy7cfjmmg/us547e5qMmSQ85A/KgRJtLDgZqWGzeQhguF96ntVRByeMUk9zjMjvhF+6PShK4iYW0Fuu+dxgdhWJrPihYlMVmFyO4rD13VpZ3ZVl+XpxWA79cmk3y7G8KV9WWbu8luZC87lmPqaqvLUTtUTtU3OhRsSM5qFnpjNitjT7aP7A7Sr8z9Cancp6GFI/JqItkU+4XZIynjmoCelI1SF3Un8qQdaXtSKEPrS96KSgBT70mOaUUYoAUUUKPWigCTHFHaj8aWgBh60vejvR1oAT6UvUUH2ooATntS4paBmgAApQaSlxx70xNiipBjApAuOTTlHNBLEZR260bMDmpVGT70MM0CuyEpxkUoizTu9SocCiwbDFtSRknipVijTrzSbzzzSFumaYrtiSNnpwKiY05jk0n8qQxASfwrZ0tfMKDvmsgCtLSn2tzxgg1UdyJ7HRX0H2W4sJGGAWINdEQssPHXrms7xEoudHtbmP8A5Z8/nU2k3qyWYJI5ABHvVnFLVJizYWLJGAe9V227zgHnmrN7IqkAcjFUWY/KTxgUCSLfnM2VXqP0qRASRlt306VlNMTIFLfL35qtqWtCJDDa492pj5G9javdVgtMB2y/oO1ctqmry3btglY/QVlyztIxZ2JJqAyHFS5HRCio69SZpDzULPUZkqMvUGyRIXPao2fNMLUzOTxSuUkWrOPzpvm+6OTWhd3QC7V4UcYqkkggh2jlj1qq7l6a0JcbsLhvMNVyMVLSEUjRaaEXegUpGOtJSKCilHek46UAFOUUUqigBVFFX9I0661XUbexsYjNdTtsjRerGioc1HcEm9ilj2opaSrAO9J3pTTRQCFoAo9aUUCQYpcE0nen9jTBgE4pygDpzSj7tApEg3NOjXmmGpI+v4UCZKqgYanSIAM00f6sfWpJvu1RNyqRzT1UkHrTR1qZPuUihgXHFBQ4FSHrSnvTFciKe3FN2CpjTKQJht4qW1fY31qMdKWL74+tNbgzpodXK2JtmCMjDBBzWPb37Wtwyo/7snPNHf8ACs+X/Wn61beplGKTsdO2rqyAsy/XmoZNYjwQpQ/nWOf9SKr96bYlTRcudQkkyFwAfSqLSk56UhqM96i9zZRSQrSH2qMuaRu9MNJlJDt1NLUd6b3pDsGTUka4+aoh3qwn3BR1B7CiJ2R3wdq9T6UzHFXYf+PC6/4D/OqQ70kxDMUYp1IaYdRpXPFM24qWo260MaGke9L70h6/jS9qRQvtUigDJ7YqNepp0n+pND0A+vf2avhfb6Rp1v4o1WCUarOh8mOTaURD0ZcdyKK9Y+GX/IhaF/16R/8AoIopQXu3G9z/2Q==);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The amount of angulation of a metacarpal fracture is measured on a lateral radiograph. The angle (curved red line) between the axis of the proximal and distal fragments is measured. This mid-shaft 5th metacarpal fracture is angulated about 70 degrees and will need orthopedic referral for probable surgical reduction and fixation.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Kevin E Burroughs, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f41_49_42782=[""].join("\n");
var outline_f41_49_42782=null;
var title_f41_49_42783="B lines and lung sliding";
var content_f41_49_42783=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1040px;\">",
"  <div class=\"videoplayer\" h264=\"./images/PULM/64485/B_lines_lung_sliding_conv.mp4?title=B+lines+and+lung+sliding\" style=\"width:320px;height:256px\">",
"  </div>",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    B lines and lung sliding",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 442px; height: 364px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f41_49_42783=[""].join("\n");
var outline_f41_49_42783=null;
